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IAbstract
The majority of polypeptides in the mitochondrion are nuclear encoded 
and post-translationally transported to the mitochondrion from the cytosol.
These include the polypeptides which make up the pyruvate dehydrogenase 
complex (PDC), the largest multienzyme complex of the 2~oxoacid 
dehydrogenase complex family. This transportation is initiated by an N-terminal 
mitochondrial targeting signal. However, whereas standard mitochondrial 
matrix targeting signals are approx. 15-30 amino acids long in mammals, the N- 
terminal presequence of the PDC-E2 component is 73 amino acids in length.
Such long presequences usually carry additional information, such as a second 
targeting signal; however the presequence of PDC-E2 appears to have no such 
additional function.
Furthermore, mammalian PDC-E2 has the capacity to spontaneously self 
assemble into 60-meric dodecahedral cores, which form the superstructure for 
the complex itself. An integral part of mitochondrial targeting is prevention of 
such self assembly to allow translocation of the polypeptide from the cytosol to 
the matrix inside the mitochondrion.
This research details studies undertaken to examine the roles of the 
extended presequence of PDC-E2. A novel in vivo model was developed to 
monitor the natural behaviour of mitochondrial presequences with a reporter 
gene, utilising the reporter to measure both targeting and assembly. Sections of 
the PDC-E2 presequence were tested with this model system to discover their 
role within the translocation and folding of PDC-E2.
The regulation of PDC by PDC kinase was also investigated. PDC 
activity is strictly controlled by a variety of effector molecules, through the 
inactivation of PDC-El by PDC kinase. The kinase, by exerting control over the 
first, irreversible and rate limiting step, can block the entire reaction sequence.
I
Interestingly, phosphorylation of PDC-El can occur at 3 different sites, but 
previous research has demonstrated that not all sites must be phosphorylated to 
inactivate the complex.
To understand the behaviour of the kinase, and the circumstances under 
which the 3 phosphorylations take place, electrospray mass spectroscopy was 
employed to measure the number of phosphorylations on PDC-El made by 
PDC kinase, over time, under different circumstances.
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Chapter 1: Introduction
1.1 Targeting, assembly and regulation of pyruvate 
dehydrogenase complex
Pyruvate dehydrogenase eomplex (PDC) is the largest multienzyme 
complex of the 2-oxoacid dehydrogenase complex family, located within the 
mitochondrion of eukaryotic organisms and regulated by a wide range of 
metabolites and hormones. The polypeptides which make up PDC are all 
nuclear encoded and post-translationally transported to the mitochondrion 
from the cytosol. The targeting of these polypeptides to the mitochondrion, the 
assembly of this large multimeric array from its component polypeptides and 
the regulation of the mature multienzyme complex are all investigated within 
this thesis. This chapter firstly describes the basic structural and functional 
characteristics of the 2-oxoacid dehydrogenase complexes before exploring 
the current understanding in targeting, assembly and regulation of PDC.
1.2 The 2-oxoacid dehydrogenase complexes
The 2-oxoacid dehydrogenase complexes are a family of 3 related high 
molecular mass polypeptide assemblies; the pyruvate dehydrogenase complex 
(PDC), the 2-oxoglutarate dehydrogenase complex (OGDC) and the branched- 
chain 2-oxoacid dehydrogenase complex (BCDC). They are all located within 
the mitochondrial matrix of eukaryotes, in association with the inner 
mitochondrial membrane. PDC can also be found in the plastids of plant cells.
The complexes have been intensively studied from a variety of
organisms since they represent classic examples of multi-enzyme complexes; 
they have the capacity for spontaneous self assembly, the complexes are held 
together by non-covalent interactions between polypeptides and they catalyse 
a series of consecutive chemical reaction steps in metabolism.
Organising consecutive steps in a reaction pathway within multi-enzyme
2
I
........................................
Chapter 1: Introduction
complexes confers a number of advantages to the cell. Complexes can use 
‘substrate channelling’, where metabolic intermediates are passed from one 
active site to another, enhancing catalytic efficiency by increasing the 
concentration of intermediates within a defined microenvironment. 
Intermediates can also be protected from a harsh external environment whilst ;
in the complex; this is described as the ‘hot potato’ hypothesis, where a
■|particularly labile intermediate can be quickly passed between successive A
enzyme sites (Perham, 1991). 4
1.2.1 Role in metabolism
The 2“Oxoacid dehydrogenase complexes play key roles in intermediary
metabolism, catalysing the irreversible oxidative decarboxylation of 2-
I
oxoacids with the production of NADH, CO2  and an acyhCoA species (Fig. -K
1.1). PDC decarboxylates pyruvate to give acetyl-CoA, regulating the 
committed entry of 2 carbon units (acetate) from glycolysis into the TCA 
cycle. OGDC forms an important part of the TCA cycle, governing the flux of 
carbon units around the cycle, where it is involved in converting 2- |
oxoglutarate to succinyl-CoA. OGDC is also vital for providing succinyl-CoA 
for the synthesis of porphyrins, lysine and methionine. BCDC has a broad 
range of substrates, promoting the irreversible step in the degradation of 
branched-chain amino acids (leucine, isoleucine, valine), and as such regulates 
the breakdown of these compounds for entry of their carbon units into the 
TCA cycle. BCDC is also involved in the degradation of methionine and ?■
threonine, and is therefore integral to the control of branched-chain amino acid
Chapter 1: Introduction I
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Figure 1.1 Diagram showing position of the 2-oxoacid dehydrogenase 
complexes in metabolism
As seen in the diagram, key positions in metabolism are occupied by 
these complexes, each of which catalyses a committed and irreversible step in 
carbohydrate or amino acid breakdown.
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Chapter 1: Introduction
levels in mammals, converting excesses into acyl-CoA derivatives for 
recycling back into catabolism (see Perham, 1991, for a review).
All 3 complexes are regulated by the end-products of their reactions; 
PDC and BCDC are additionally regulated by complex-specific kinases and 
phosphatases. These kinases and phosphatases are controlled by various 
metabolites, such as end products, a variety of hormones and other effector 
molecules (see section 1.4).
1.2.2 Reaction sequence
ÎThe complexes are composed of multiple copies of 3 distinct enzymes: 
E l, a substrate-specific 2-oxoacid dehydrogenase, E2, a complex-specific 
dihydrolipoamide acyltransferase and E3, a dihydrolipoamide dehydrogenase.
Although the E l and E2 components are complex-specific, the E3 
component was previously thought to be common to all the complexes. 
However, evidence exists for E3 isoforms in certain cases. In rat liver 
mitochondria (Carothers et a l ,  1987), bacteria (M^Cully et al, 1986; Sokatch 
et a l ,  1983), potato tuber mitochondria (R. Fullerton, Ph.D. thesis, Glasgow 
University, 1995) and pea leaf chloroplasts (Conner et a l ,  1996), distinct E3 
isoforms have been detected.
E l catalyses the first, rate limiting step in the overall reaction sequence 
of each complex (Walsh et a l ,  1986), the irreversible decarboxylation of its 
specific 2-oxoacid substrate. During the reaction, the cofactor of E l, thiamine 
diphosphate (ThDP), forms a 2-(l-hydroxyacyl)-ThDP intermediate, with the 
concomitant production of CO2  (Fig. 1.2). E l then catalyses the reductive 
acylation of the lipoyl prosthetic group of E2. This lipoamide moiety is found 
within a conserved motif located in the N-terminal region, covalently linked to 
a specific lysine via its e-amino group. Acylation of the lipoamide moiety
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2-oxoadd + CoA + NAD+ ► N m u  + Acyl CoA + GQz
R-C-S-CoATHDP
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s
Figure 1.2 Reaction mechanism of the 2-oxoacid dehydrogenase 
complexes highlighting the specific reactions catalysed by the component 
enzymes
E l, 2-oxoacid dehydrogenase; E2, dihydrolipoamide acyltransferase; E3, 
dihydrolipoamide dehydrogenase; ThDP, thiamine diphosphate; Lip, lipoic 
acid; R=CHs for PDC; COOHCH 2 C H2 for OGDC; (CH 3 )2 CH, 
(CH3 )2 CHCH2  and (CH3 )2 (C2 H5 )CH for BCDC.
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forms an S^-acyldihydrolipoamide intermediate; E2 then transfers the acyl 
group to its coenzyme A (CoA) acceptor, leaving the lipoamide prosthetic 
group in a reduced state. E3, using an FAD cofactor, reoxidises the reduced 
lipoamide prosthetic group. The FAD component is in turn reoxidised by 
NAD+, which is the final electron acceptor. This leaves the complex in its
original state, ready for the next reaction cycle. Each part of the complex will 
be discussed in more detail shortly.
1.2.3 Structure of the 2-oxoacid dehydrogenase complexes
Electron microscopy studies have shown the 2-oxoacid dehydrogenase 
complexes to be 30-50 nm in diameter, comparable in size to ribosomes 
(Henderson et a i ,  1979). Negative stain electron microscopy of PDC (Oliver 
and Reed, 1982) and low resolution X-ray crystallography of E2/F3 
subcomplexes (Fuller et al, 1979) led to a model where F2 formed a core 
around which E l and F3 bound on the vertices and faces, respectively. The 
core of the complex, an oligomer of E2 subunits, has been determined at a
higher resolution by X-ray crystallography of recombinant F2 C-terminal 
catalytic domains (the N-terminal lipoyl domains, being highly flexible 
[section 1.3.2] appear to prevent such determinations). This, along with 
various reconstitution studies, have demonstrated that the E l and F3 
components are arranged around the surface of an E2 core. In OGDC and 
BCDC, this core forms a cube of 24 E2 subunits (octahedral 432 symmetry).
PDC-E2 also exists as an octahedron in Gram negative bacteria, but in Gram 
positive bacteria, yeast, mammals, birds and fungi, PDC-E2 is present as a 
pentagonal dodecahedron of 60 subunits exhibiting icosahedral (532)
symmetry (Fig. 1.3, Wagenknecht er a/., 1991).
I -i
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Figure 1.3 Proposed 3-D structure of PDC-E2 and native PDC
(a) Model of the cubic core of 24 E2 subunits arranged in groups of three as 
the eight vertices of a cube. E2 is represented by orange eliptoids.
(b) Proposed model of mammalian PDC core with 60 E2 subunits in groups of 
three forming the 20 vertices of an icosahedron. E2 is represented by orange 
elipses.
(c) Model of the cubic core form of PDC with 12 El dimers bound along the 
edges of the E2 core and 6 E3 dimers on the faces of the cube. The E3 dimers 
are represented by blue spheres, whilst the El dimers are represented as 4 
smaller red spheres, to highlight the similarities to the model in (d).
(d) Model of the pentagonal dodecahedral PDC core with 20-30 El tetramers 
bound to the 30 edges and 12 E3 dimers bound to the 12 faces of the 
pentagonal dodecahedral core. The E3 dimers are represented by blue spheres, 
whilst the El tetramers are represented as 4 smaller yellow spheres
%
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It has long been observed that PDC from mammalian sources, fungi, 
birds and Bacillus species have bOmeric, icosahedral E2 cores. One 
reservation had previously been that these complexes could not be visualised 
using EM techniques such as negative staining, the complex dissociating 
during the various procedures of staining. Other EM methods have since been 
used to detect the complexes, and this 60meric structure has been confirmed in 
a number of more recent studies (Roche et a l ,  1993; Wagenknecht et aL,
1991).
E l is thought to bind the edges of such cores (20-30 in icosahedral PDC, 
12 in cubic forms of the complexes, as seen in Table 1.1). E l in OGDC is a 
homodimer, but in PDC and BCDC, it exists as a heterotetramer (a 2 P2 ). E3 
slots into the faces of cubic E2 (6 dimers, 1 dimer per face). In PDC it was 
previously thought that only 6 B3 dimers bound to the PDC dodecahedral E2 
core (1 monomer per face), but recent evidence suggests that 12 dimers bind 
instead, with 1 dimer per face (Wu and Reed, 1984; Sanderson et a l ,  1996). 
PDC from mammalian and yeast sources also possess protein X, a tightly 
associated subunit which exhibits strong similarities to E2. The polypeptide 
appears to have a function in binding E3 to the E2 core (Gopalkrishnan et al, 
1989). Recent evidence has increased the number of protein X subunits per 
complex from 6 to 12 monomers, possibly as 6 dimers (Maeng et al, 1994; 
Sanderson et a l ,  1996), which corresponds well with the stoichiometry 
expected for E3.
PDC and BCDC also posses specific kinase and phosphatase enzymes. 
In PDC, there are 1-3 tightly associated kinase and 5 loosely associated 
phosphatase molecules (see Table 1.1). These will be discussed in detail in a
later section.
The subunit composition and mass of PDC is summarised in Table 1.1 
below.
§
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Table 1.1
1 Number of of ^ ubumt # #
Subunit OGDC BCDC PDC OGDC BCDC PDC
E l(a )  12 12 60 96,000 46,000 42,000
El(p)^^ 12 60 37,000 36,000
, E2 - 24 24 60 48,000 50,000 70,000
6 12/24 55,000 55,000 55,000
Protein X - 12 - 51,000
Kinase 1 N/D 1-3 43,280* 49,244*
Kinase 2 - 1-3 - 46,181*
Kinase 3 - 1-3 - 46,938*
Kinase 4#  ^ : -fitter# - 1-3 - 46,466*
Phosphatase a - N/D N/D 38,000 50,000
Phosphatase b - - N/D - 97,000
(Values taken from bovine hearts or pig kidney, Lindsay, 1989, ^except: 
Kinase 1-3 masses from human cDNA, Popov et a i ,  1995; Kinase 4 mass 
from cDNA clone, Rowles et al, 1996; BCDC Kinase from rat cDNA clone, 
Popov et a l,  1992. N/D- Not determined.)
1.2.4 Diseases associated with the 2-oxoacid dehydrogenase 
complexes
A number of genetic defects, causing a variety of metabolic acidoses 
where substrates accumulate to toxic levels, have been characterised which 
involve deficiencies in the activities of the 2-oxoacid dehydrogenase 
complexes. The majority of these diseases are in the El components of the 
complexes. One such example is ‘Maple Syrup Urine Disease’, an autosomal
10
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recessive inborn condition where BCDC has deficient activity, arising from 
various genetic errors in the E l and E2 subunits. The loss of activity can cause 
severe mental retardation, and leads to accumulation of branched-chain amino iacids and derived metabolites in the urine of sufferers.
Another interesting case was a genetic error present in the protein X 
subunit of two brothers (Marsac et al., 1993). These patients rapidly developed
'neurologic disorders in conjunction with chronic lactic acidaemia. PDC 
activity was reduced to 12% and 22%, demonstrating the necessity for this 
component (see McConnell et al, 1997, for a recent study).
Of importance to the research described in this thesis is another disease 
associated with the 2-oxoacid dehydrogenase complexes. Primary biliary 
cirrhosis (PBC), a chronic autoimmune disease found predominantly in 
middle-aged women (average age at diagnosis is 51), is Britain’s most 
common non-alcohol related cause of liver cirrhosis (O’Donohue and 
Williams, 1996). The disease is characterised by inflammation of septal and 
interlobular bile ducts arising from the immune reaction against bile duct 
epithelia. This progresses to cirrhosis of the liver, and often liver failure.
:Patients with PBC usually have antibodies to mitochondrial antigens present 
within their sera; the major autoantigens associated with this disease include 
the E2 components of PDC, OGDC and BCDC, component X of PDC and the 
PDC E la  and E lp  subunits (Yeaman et a l ,  1988; Fussey et a l ,  1988; Surh et 
a l,  1989a, 1989b; Fregeau et a l,  1989). Approximately 95% of patients with 
PBC have antibodies directed at the inner lipoyl domain of PDC-E2: the most 
immunoreactive part of the lipoyl domain is the site of attachment of the lipoic 
acid. Previous research demonstrated that the lipoic acid itself plays a major 
part in the immunoreactivity of PDC-E2 (Fussey et a l ,  1990). Recent 
evidence, however, suggests that it may be the lipoic acid of protein X which 
is implicated in the disease (Joplin et al, 1997).
The major autoantigen involved in this condition is found on the surface
11
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of the plasma membrane in the bile duct epithelial cells; additionally, 
antibodies are unable to enter the cells to react to mitochondrial antigens 
(Joplin et al., 1995), It follows that a mistargeting or processing defect causing
yrelocation of PDC-E2 or protein X epitopes to the cell surface could lead to an 
autoimmune reaction, and may be involved in promoting the onset of this 
disease.
1.3 Composition of the 2-oxoacid dehydrogenase complexes
1.3.1 2-oxoacid dehydrogenase
1 2
f.
The 2-oxoacid dehydrogenases are ThDP-requiring enzymes, and 
catalyse both the initial irreversible decarboxylation of the 2-oxoacid and the 
reductive transfer of the resultant acyl group to the lipoyl prosthetic group on 
the lipoyl domains of the appropriate E2. As the rate limiting stage within each 
complex, it is these enzyme components which are regulated by
phosphorylation in PDC and BCDC (Linn e ta l ,  1972).
E ls from many sources have been characterised both at the protein and
cDNA level, and 3 families have been described based on the gene sequences.
These groups were E ls from OGDC, E ls from PDC found in Gram negative 
bacteria, and E ls from all other PDC sources and BCDC. Between groups of 
E ls  there is minimal homology, suggesting early evolutionary divergence
'(Darlinson et a l ,  1984). In OGDC and PDC from Gram negative bacteria, El 
is a homodimer, with each subunit approximately 100,000 Da. In eukaryotic 
PDC and BCDC, E l exists as a hetero-tetrameric enzyme (a2p2)» with a  
subunits of 41-46,000 Da and B subunits of 35-38,000 Da.
The cofactor, thiamine diphosphate (ThDP) is bound by the two a  
subunits. ThDP is bound by 2 domains: one which binds the pyrimidine ring, 
and one which binds the diphosphate. Although eaeh a  subunit in the tetramer 
has both domains to bind ThDP, the cofactor is located in the cleft between the
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a  and p subunits, so that one subunit binds the diphosphate whilst the other 
holds the pyrimidine ring (Stepp et a l ,  1985).
Within the a  subunit is also a p subunit binding domain, whilst the P 
subunit is responsible for binding the tetramer to the E2 core. It has been 
proposed that E ip  is involved in the reductive acylation of the lipoyl group of 
E2, but this has yet to be proven (Yeaman, 1989; Patel and Roche, 1990).
1.3.2 Dihydrolipoamide acyltransferase
The E2 component forms the structural and functional framework of all 
the complexes. Not only do the other components bind to this oligomer in a 
non-covalent fashion to form the complex, but E2 also links the components 
functionally, coupling the activities of the various enzymes by providing 
flexible lipoyl domains which are able to visit the various active sites. E2, an 
acyltransferase, also catalyses the second step in the reaetion sequence, by 
transferring the acyl group from its lipoyl domain(s) to CoA.
1.3.2.1 The domains of the dihydrolipoamide acyltransferases
Proteolytic cleavage of E2 has revealed a highly segmented structure 
consisting of a number of functional domains, between which are 
proteolytically sensitive linker regions (Fig. 1.4). All E2s have 3 main regions; 
the N-terminal lipoyl domain or domains, the E l and/or E3 binding domain, 
and the C-terminal core forming domain, which also contains the catalytic part 
of the polypeptide. The E2s from all the complexes also share structural 
similarities with the ‘H ’ protein of the glycine decarboxylase complex (GDC) 
(Fujiwara e ta l ,  1986; Fujiwara et a l ,  1991).
At the N-terminal region the E2 polypeptide has 1-3 highly homologous 
lipoyl domains (Fig. 1.4). Each domain is approx. 80 amino acids long, joined
13
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by linker regions of 25-30 amino acids which are rich in alanine, proline and 
various charged residues to allow conformational flexibility (Dardel et al.,
1991). These provide the flexibility required for interaction of the lipoyl 
domain(s) with the active sites of E l and E3. Each of these domains is post- 
translationally modified by a ligase which covalently attaches the lipoic acid 
to a specific lysine on the domain via an amide linkage (Brookfield et a l ,
1991). No conformational change is caused by attachment of the lipoic acid, 
which supports the concept that the domain is a free-swinging arm in solution 
(Perham, 1991). The flexibility of these domains is essential to the proper 
functioning of E2, providing a means of linking the various enzymatic 
activities.
The peripheral subunit binding domain is C-terminal to the lipoyl 
domain. This domain, 30-50 amino acids long, has the function of binding E l 
and/or E3 to the core. In BCDC and Bacillus species, E l and E3 appear to 
compete for binding to this domain which is unable to bind both 
simultaneously. In OGDC and octahedral PDC (e.g. in E. coli), the domain is 
largely associated with E3 binding, however the octahedral core of PDC in A. 
vinelandi binds E l, as does PDC-E2 in mammalian cells. E3 in mammalian 
cells is instead bound by protein X in PDC, and by E l in OGDC, where the 
binding domain appears to be located in the gene for OGDC-El (Rice et a l ,
1992).
The C-terminal domain of E2 acts as both the catalytic and the core­
forming domain, with a compact structure. This domain also possesses E2 
binding sites, allowing it to interact with other E2 polypeptides to form the 
high Mr core assembly. It is believed that the PDC-E2 core is generated via a 
trimeric intermediate (McCartney et a l ,  1997), which then polymerises to 
make either the cubic or icosahedral structures.
4■î:
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E2
X
N— Lipoate Lipoate A/N Lipoate AA E3 AA E l CAT
N -  Lipoate AA Lipoate AA AA CAT
Lipoate AA Lipoate AA E l AA CAT
N -  Lipoate AA AA CAT
■C E.co/t PDC
•C A. vinelandii PDC
. Q Mammalian PDC 
S.faecalisPDC
■C B. stearolherniophilusVDC
N-jLipoate|AA| E l |/V'
N'
CAT
Lipoate AA E j [ ^  AA
Lipoate AA E3 E l
CAT
CAT
—C S. cerevisiae PDC 
C Mammalian BCDCs, OGDCs 
C E. coll OGDC
Lipoate /V ' E3 AA S. cerevisiae PDC Mammalian PDC
Figure 1.4 Diagram of the domain structure of the E2 and protein X 
components
Legend:
E3/E1- E3 and/or E l binding domain 
CAT- catalytic core domain 
Zigzags- flexible linker regions
The domain structure of protein X is shown for comparison. Note that 
mammalian OGDC has been shown to lack the E3 binding domain. E3 
binding sequences are found on E l and the E l binding sites on E2 are 
unknown as yet (Rice et al., 1992).
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1.3,2.2 Structure of dihydrolipoamide acetyl transferase
The entire structure of E2 from PDC has yet to be determined at the 
molecular level since the N-terminal domains of E2 are highly flexible and 
prevent crystal formation for X-ray crystallography. Whilst NMR is able to 
resolve the structure of the lipoyl domain, it cannot determine the structure of y
the whole molecule due to the size of PDC-E2. However, the structure of 
individual domains and the structure of the assembled core is known in detail, 
at least from prokaryotic sources.
In terms of the entire E2 polypeptide it is the C-terminal domain, 
forming the inner core of the complex, which has the most conserved amino 
acids between species. The active site histidine is especially conserved, 
surrounded by the motif HXXXDG, a region which is shared with the active 
site of chloramphenicol acetyltransferase (CAT). Indeed, throughout the C- 
terminal domain of E2 there is remote but significant sequence similarity 
between the two polypeptides. X-ray crystallography of this domain of PDC- 
E2 from Azotobacter vinelandii also reveals a structural similarity to CAT 
(Fig. 1.5). These comparisons may be a reflection of the similarities in 
catalytic mechanisms between E2 and CAT ; E2 transfers acetyl groups from 
its lipoyl domain to CoA, whereas CAT transfers acetyl groups from acetyl- 
CoA to chloramphenicol to inactivate it. There is considerable variety between 
species in the active site residues of E2; however, a mechanism based on that 
demonstrated for CAT has been made and substantiated for a number of PDC- 
E2s (reviewed in Russell and Guest, 1991). In brief, protons are abstracted 
from the thiol of CoA, which then undergoes nucleophilic attack on the 8-acyl 
lipoamide thioester (Fig. 1.6).
The structure of the E3 binding domain has been solved by NMR studies 
on E. coli OGDC (Robein et al, 1992) and PDC from B. stearothermophilus 
(Kalia et a l ,  1993). The structure of the lipoyl domains has also been
16
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determ ined by NMR studies on the purified segments from B . 
stearothermophilus (Dardel et a i,  1993) and E. coli (Green et al., 1995). NMR 
has revealed that the lipoyl domain folds into a flattened barrel formed from 
two p-sheets, with the lipoic acid group attached to the tip of a P-turn.
I
1.3.3 Dihydrolipoamide dehydrogenase
IDihydrolipoamide dehydrogenase is a member of the flavoprotein disulphide 4
oxidoreductases (Carothers et al., 1989), found in the 2-oxoacid 
dehydrogenase complexes, the distantly related GDC (where it is called L- g
protein) and the bacterial acetoin dehydrogenase system. In all these |
complexes, it is responsible for the NAD"** dependent reoxidation of the 
dihydrolipoamide prosthetic groups of the E2 components in 2-oxoacid
dehydrogenase complexes, and hydrogen carrier protein (H-protein) in GDC. {
I-
This allows the acyltransferase component to re-enter the catalytic cycle 
(Kikuchi andHiraga, 1982; Carothers etal., 1989).
A single E3 was previously thought to be common to all three 2-oxoacid 4
dehydrogenase complexes. However, evidence for complex specific isoforms 4
of E3 is accumulating for a number of species, namely Pseudomonas putida i
(Palmer et al., 1991a, b). Pseudomonas aeruginosa (McCully et al., 1986), E. |
coli (Richarme, 1989) and rat liver (Carothers et al., 1987).
E3 exists as a dimer of identical subunits of approx. 50,000 Da 
containing a molecule of non-covalently bound FAD. The sequence of E3 is 
highly conserved between species (e.g. porcine E3 has 96% identity with 
human E3, and 44% identity with E. coli E3). Structural similarity, as shown 
by X-ray crystallography, has been demonstrated between E3 and other 
pyridine nucieotide-disulphide oxidoreductases, such as glutathione reductase 
(Karpins and Schulz, 1987), mercuric reductase (Schiering et a l ,  1991),
NADH peroxidase (Stehle et al., 1991), trypanothione reductase (Kuriyan et r
17
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Chloramphenicol Acetyltransferase- CAT
Subunit
core
H I
Subunit
core
Subunit
core
Dihydrolipoamide Acetyltransferase- PDC E2
Subunit
core
Subunit
core
Subunit
core
HI
Figure 1.5 Comparison of CAT and PDC-E2 (Core domain)
This diagram from Mattevi et al. (1992) shows in two dimensions 
similarities between the domain structures of CAT and dihydrolipoamide 
dehydrogenase (PDC-E2), including their abilities to form trimers through 
similar interactions between the subunits. The shaded boxes represent 
important regions of
18
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Figure 1.5 cont’d
secondary structure common to both polypeptides. The N-terminal region is 
the ‘A’ strand, which is involved in formation of an important p-sheet, the 
other is the H i a-helix, which is involved in the 3-fold symmetry.
19
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Figure 1.6 Catalytic mechanism of the acetyltransferase reaction
Two subunits of E2 participate in the reaction; residues provided by one 
subunit of E2 are represented by a prime (‘), the other E2 residues are 
unlabelled. (A) In the ground state, the side chain of Asn 614' forms a 
hydrogen bond with Asp 508 (not shown), blocking the CoA-binding channel 
at the pantethiene moiety of CoA. (B) During binding of reduced CoA 
(CoASH), a reorientation of the Asn 614' side chain allows the formation of a 
new hydrogen bond with the reactive sulphydryl group of CoA. The sulphur 
atom  su b seq u en tly  a ttack s  the carbony l in the ace ty l
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Figure 1.6 couFd
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group of acetyl-dihydrolipoamide. (C) This intermediate is stabilised by a
"’I -hydrogen bond to Ser 558. Rearrangement of the acetyl carbonyl group results f
in the simultaneous release of dihydrolipoamide and acetyl-CoA. (D) The 
reaction is completed when acetyl CoA and dihydrolipoamide are released 
from the active site, and Asn 614' has rearranged to go back to the original 
state (reproduced from Hendle et al, 1995).
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al., 1991a) and thioredoxin reductase (Kuriyan et al., 1991b).
1.3.4 Protein X
Protein X was discovered as a polypeptide tightly associated with the 
complex in yeast and mammalian PDC (De Marcucci and Lindsay, 1985). 
Protein X has an M^ - of 50,000, and was originally thought to be a proteolytic 
fragment of E2. Protein X has since been cloned (Harris et a l,  1997); it 
possesses a lipoyl domain and a structure similar to E2 (Fig. 1.4). Protein X, or 
E3 binding protein as it has been recently called (E3BP), binds strongly to the
complex through an unknown interaction with the E2 core. It was originally 
suggested that the 12 subunits integrated into the E2 core; however, protein X 
appears to have a post E2-assembly interaction in mammals, and is not a 
requirement for assembly of the core in yeast. Additionally, the presence of 60 
PDC-E2 monomers per core would prevent any integration of protein X 
(Sanderson e ta l ,  1996; McCartney e ta l ,  1997).
Although no catalytic activity has been ascribed to protein X, a number 
of functions have already become apparent. The lipoyl domains of protein X 
are able to participate in the overall reaction since they are capable of being 
reductively acetylated, they also form a network of lipoyl domains over the 
PDC-E2 core which can sustain approx 15% of overall PDC activity after loss 
of all E2 lipoyl domains (Sanderson et a l, 1996). It has also been established 
that protein X is involved in positioning and binding E3 around the core to
facilitate its role in electron transfer. Recent work has demonstrated that
protein X binds the E3 domain to the PDC-E2 core; PDC without protein X 
has only 10-20% residual activity, which can be enhanced by the presence of 
excess exogenous E3 (McCartney et a l,  1997).
2 2
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1.4 Regulation of complexes
The complexes are strictly controlled by short and long term regulation. 
In both bacteria and mammals the complexes are regulated in the short term 
by end-product inhibition (i.e. acyl CoA and NADH) when product 
concentrations increase in relation to the substrates. Such inhibition is 
competitively reversed by the substrates CoA and NAD+ respectively.
Both short and long term regulation is achieved by phosphorylation from 
kinases and dephosphorylation by phosphatases in PDC from mammals, birds 
and Neurospora crassa, as well as mammalian BCDC. The kinases and 
phosphatases are modulated by a variety of hormones and other effector 
molecules. It is interesting to note that the complexes which have such 
regulation also have a a 2 P2  tetrameric form of E l, whereas other complexes 
have only an a 2  form.
1.4.1 Kinases of PDC and BCDC
Inactivation of E l is caused by phosphorylation of 1 of 3 possible sites in 
PDC E l, or 1 of 2 in BCDC EL It is known from empirical studies that 1
phosphorylation per tetramer is sufficient for complete inhibition of an E l
(Korotchkina et al., 1996). Both the kinase and phosphatase require Mg "^*".
The kinase is inhibited by CoA, NAD+, pyruvate, ThDP and is activated by
2+acetyl CoA and NADH. The phosphatase is activated by Ca and inhibited
2 Iby NADH. Ca binds at 2 sites, one site involved in binding to the E2 core, 
and the other site involved in catalysis (Reed and Yeaman, 1987). The kinase 
and phosphatase, by exerting control over the El component (which catalyses 
the first, irreversible, rate limiting step) can block the entire reaction sequence.
In rat heart PDC two kinases, p45 and p48, have been identified by N- 
terminal protein sequencing and subsequent cDNA cloning, whilst four
23
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distinct isoforms have recently been cloned from the human genome (Rowles 
et al., 1996). These all have sequences related to the prokaryotic protein 2,
histidine kinase fam ily, quite dissim ilar to regular cytoplasm ic 
serine/threonine kinases (Popov et al., 1993). The functions of each kinase 
would appear to be important to the metabolism of different tissues, since the
isoenzymes are found in varying quantities in each tissue and are subject to 1
%differential allosteric regulation by metabolic effectors.
Liu et al. (1995b) proposed that the kinase dimer is able to move over 
the complex by swinging ‘hand over hand’, alternating between states where 
the kinase is bound specifically to 1 and 2 of the inner E2 lipoyl domains. This
concept arose after demonstrating that the kinase repeatedly releases and binds |
'Ithese domains. An active kinase molecule would then be able to move over the 
surface of the E2 core, deactivating all the E l components.
1.4.2 Phosphatases of PDC and BCDC
The phosphatases of PDC and BCDC are more loosely associated with 
their respective complexes, and are often lost during the purification of PDC :ç.
and BCDC. In PDC the phosphatase is composed of two subunits, a catalytic
subunit with an of 50,000 and a subunit with an of 97,000 which 1
possesses an FAD cofactor. The function of this larger subunit is unknown to |
date (Teague et a l,  1982; Pratt et al., 1982). PDC phosphatase requires Mg^”^
2+for activity and Ca promotes binding of the phosphatase to the E2 core of
2+.  4PDC, stimulating activity. Ca is thought to elicit this behaviour by lowering |
the Kjxi for Mg^ "*". This can also be achieved by spermine; by contrast, NADH
inhibits the enzyme.
The corresponding phosphatase from BCDC is not as well characterised.
The native enzyme has an Mj- of 460,000 but its subunit composition and
general properties remain unclear; only one catalytic subunit has been
24 4
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identified with an Mr of 33,000 (Daumuni et a l,  1984; Daumuni and Reed, 
1987).
1.5 Mitochondrial targeting
1.5.1 The requirement for protein import
The mitochondrion is an organelle containing several hundred 
polypeptides at a high concentration. Since only 13 of the polypeptides 
required by human mitochondria are encoded ‘on site’ by the genome present 
within the organelle, the rest must be imported from their site of synthesis in 
the cytoplasm (reviewed in Glover and Lindsay, 1992). All the other 
mitochondrial polypeptides, including those of the 2-oxoacid dehydrogenase 
complexes, are encoded by nuclear genes. These genes are transcribed into 
mRNA, which are then translated on free cytosolic ribosomes. Subsequently, 
the polypeptide which is synthesised is also cytosolic, but is required inside 
the mitochondrion. Such polypeptides must therefore be imported from the 
cytosol into the mitochondrion. Although co-translational transport of proteins 
into the mitochondrion has been observed (see Lithgow et a l ,  1997, for a 
review), the majority of translocation occurs post-translationally; this is 
achieved through a variety of routes. One post-translation route appears to be 
used by more mitochondrial proteins than any other, and it is this route by 
which the polypeptides of the 2-oxoacid dehydrogenase complexes probably 
enter the mitochondrial matrix.
1.5.2 The method of protein import
Opinions vary on the details of how translocation of newly synthesised 
polypeptides into the mitochondrion is achieved, but most researchers agree 
that the following events take place: there is first an antifolding-unfolding step
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where the emerging polypeptide or newly emerged polypeptide is kept from 
folding, i.e. is maintained in a translocation competent state. Evidence exists 
to suggest this is initiated by recruitment of chaperones as a direct result of the 
polypeptide possessing a specific N-terminal presequence. There is then a 
targeting event, which is facilitated by one or more presequence binding 
proteins, aiding the interaction of the polypeptide with the surface of the 
mitochondrion. This in turn leads to localisation of the polypeptide to the site 
of translocation. Following this is the translocation event itself, where the 
polypeptide is transported across the outer membrane, and then most 
frequently across the inner membrane, at a point where the 2 membranes of 
the mitochondrion are in close juxtaposition, called the ‘translocation contact 
site’. Once across, the polypeptide is usually processed to remove the 
presequence, and is folded into its mature form, or retargeted to a sub- 
mitochondrial location.
In the mitochondrion, there are 4 sub-locations; the outer membrane, the 
inner membrane, the intermembrane space and the matrix. Polypeptides bound 
for the mitochondrion carry the ‘default’ matrix targeting signal, but often 
have additional information to divert the polypeptide to its final destination, 
sometimes, as in the case of outer membrane proteins, before reaching the 
matrix.
To complicate the picture further, there are a number of exceptions to the 
various steps; some polypeptides are able to insert themselves directly into the 
mitochondrion in a passive manner, some enter the intermembrane space yet 
do not pass through the inner membrane, and yet others possess a non- 
cleavable presequence. Such exceptions will be mentioned occasionally, but 
since they form the minority of cases, the focus will be on the route adopted 
by the majority of polypeptides, the ‘default pathway’ for mitochondria] 
targeting.
I
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1.5.2.1 Antifolding :s.
Early research in yeast noted that mitochondrial import m vitro was 
enhanced by the presence of some cytosolic fractions. Two proteins were 
purified subsequently which enhanced activity, one which was termed 
presequence binding factor (PBF), and one which was later shown to be a 
chaperone, Hsp70 (Fig. 1.7). Both proteins are critical in yeast for uptake of 
mitochondrial precursors.
Chaperones such as the cytosolic Hsp70 family appear to be involved at 
several steps in the import process in keeping the polypeptide unfolded. 
Chaperones also have a pivotal role in the unidirectional translocation of the 
polypeptide through the membranes of the mitochondrion, and are then 
responsible for folding the polypeptide correctly in the protein-dense
mitochondrial matrix (Stuart et a l,  1994).
The polypeptide must usually be unfolded before entry into the 
mitochondrion, as shown by precursors which could not be imported when 
bound to antibody fragments, or presequence-dihydrofolate reductase (DHFR) 
constructs which would not import in the presence of its tightly-bound 
inhibitor, methotrexate (reviewed in Stuart et a l ,  1986). In support of this 
view are the observations that preproteins are held in an open conformation 
before import, since precursors are often sensitive to digestion. Furthermore, 
import of preeursors is accelerated by their unfolding; in experiments where 
precursors could not be imported into mitochondria due to mutations affecting 
the antifolding activity, polypeptides could still be imported if they were 
unfolded in 8 M urea beforehand (reviewed in Ryan and Jensen, 1995).
It has been proposed that cytosolic Hsp70 is one of the chaperones 
helping to keep the precursor in an unfolded state and prevent non-specific 
aggregation of these ‘loosely folded’ intermediates. Yeast mutant studies have 
demonstrated that when cytosolic Hsp70 is depleted, import of polypeptides
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Figure 1.7. Illustration of the steps in antifolding
After translation of the mRNA to the polypeptide, the factors in antifolding 
bind the precursor as a result of a recognition event. Cytosolic Hsp70 is known 
to be involved in keeping many such polypeptides in a translocation- 
competent state. PBF (presequence binding factor) may bind along with 
Hsp70, or just bind the presequence. Mitochondrial import stimulating factor 
(MSF) may bind precursors without Hsp70 present.
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into the mitochondrion is inhibited (reviewed in Glick and Schatz, 1991).
Since active unfolding by an ‘unfoldase’ has not been demonstrated thus 
far, it is believed that the chaperones are recruited to the emerging peptide as it 
exits the ribosome, preventing rather than reversing folding. The experiments 
of Endo et al. (1996) are especially relevant in this context, demonstrating that 
the chaperone HspVO in yeast is bound by mitochondrial presequences 
depending on the degree of amphiphilicity. With amphiphilicity being a 
defining characteristic of mitochondrial presequences, it follows that an 
important function of these sequences is to recruit chaperones to the emerging 
polypeptide.
PBF was characterised as a 50 kDa protein which could bind the 
immature form (pOTH) but not the mature form (OTH) of rat ornithine 
carbamoyltransferase. In experiments by Murakami and Mori (1990), the role 
of PBF was elucidated. When PBF was used in a mitochondrial import 
experiment with pOTH, it was found that it could stimulate import, and 
furthermore, could be further enhanced by the addition of Hsp70. The authors 
of this work also noted that Hsp70 alone could not stimulate uptake of pOTH.
M itochondrial import stimulating factor (MSF) is another such 
antifolder/import enhancer. MSF is a chaperone, binding precursors in a 
partially folded conformation (especially aggregated mitochondrial precursors) 
and hydrolysing ATP. It differs from other chaperones in that it recognises 
mitochondrial signals, can direct precursors to mitochondrial receptors and has 
shown the ability to actively disperse protein aggregates (Ryan and Jensen, 
1995). The mechanism by which MSF aids the fidelity of mitochondrial
targeting is only partially understood; it is believed to work independently 
from Hsp70, possibly recognising presequences in conjunction with PBF.
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1.5.2.2 Targeting
The unfolded polypeptide is then taken from the cytosol into the 
mitochondrion. This requires that the unfolded precursor be recognised by the 
mitochondrion, and bound by a receptor on the surface of the organelle, before 
being guided toward the translocation contact site (Fig. 1.8). Several receptors 
were first discovered during protease and antibody experiments, where the
action of various mitochondrial membrane proteins was affected, causing 
different import behaviours in a number of precursors. On this basis, 
mitochondria were predicted to have a range of precursor receptors, and a 
number of putative receptors have since been identified, although not all have
i
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been characterised. These receptors have been found using a variety of 
methods, from simply using antibodies to mitochondrial membranes to the use 
of an anti-idiotypic antibody against a mitochondrial presequence peptide.
:Inhibition of a receptor can prevent uptake of several precursors into isolated 
mitochondria, but can be non-lethal; entire deletion of a receptor can also be 
non-lethal. Many of these receptors are therefore multiply redundant, with 
some precursors showing specificity for only one receptor, and others 
demonstrating a less particular nature, able to use one of a number of receptors 
(Glick and Schatz, 1991). A more complete analysis of the receptors MOM 
20, 22, 37 and 70 can be found in Kubrich et a l  (1995). The putative receptors 
MOM 19 ad MOM 40 have less defined roles, and are discussed in Seki et al 
(1995) and Rapaport et al (1997), respectively.
Such receptors are usually membrane bound with the receptor segment 
on the cytosolic side, recognising either the signal sequence (e.g. MOM 20 or 
MOM 22) or a cytosolic factor bound to the presequence, such as PBF.
Differences between the receptors are manifold. For example, one receptor in 
S. cerevisiae binds the amphiphilic presequence directly without the 
requirement for any accessory proteins; by contrast, others, such as MOM 70
30
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Figure 1.8 Schematic diagram of targeting by mitochondrial receptors
Mitochondrion outer membrane proteins (MOMs) and their possible 
mechanisms for targeting are shown. Receptors such as MOM 20 and 22 are 
expected to bind the presequences of precursor polypeptides directly. In the 
diagram, the peptide is held in an open conformation by Hsp70, and aided in 
targeting by PBF; this may not always be the case.
Other receptors, such as MOM 37 and 70 bind the mature part of the 
precursor, with bound chaperone, such as MSF.
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and MOM 37, are proposed to bind only mitochondrial precursors which are 
held in an open conformation by chaperones such as MSF (Haucke et a l ,
1995). It is also thought that receptors may work co-operatively, some binding 
the presequence, others binding mature regions of the same polypeptide; this 
may have important consequences for the differential kinetics of protein 
import (Shore et a l,  1995).
During recognition of the peptide and subsequent translocation, 
chaperones such as Hsp70 are removed or lost from the unfolded precursor.
This may well involve another chaperone, known in S. cerevisiae as Ydjpl, a 
member of the DnaJ family and sometimes known in eukaryotes as Hsp40 
(Fig. 1.9). This is required for efficient import although its precise role is not 
fully defined; it is postulated that it accelerates the ATPase activity of Hsp70 
and subsequent dissociation of the chaperone from the precursor (reviewed in 
Martinus et a l ,  1995). In yeast, Hsp40 is thought to bind the newly 
synthesised polypeptide along with Hsp70 to form a ternary complex; this then 
stimulates the ATPase activity of Hsp70 (Hendrick and Hartl, 1995). Thus, for 
efficient translocation, it is obvious that the chaperones, receptors and 
translocation apparatus must be able to function in a co-ordinated fashion.
Undoubtedly one function of these receptor proteins is to anchor the
,u.presequence to the membrane of the mitochondrion, limiting diffusion towards 
the translocation contact site to two-dimensions. A further implied role of the 
receptor is in aiding and co-ordinating insertion of the peptide into the 
mitochondrion and corresponding release of the peptide by the various 
chaperones.
It is of some interest that targeting may not be solely achieved through 
signals from the presequence. In yeast mutants incapable of targeting a non- 
mitochondrial protein with a mitochondrial presequence, one mutant was 
found which could distinguish between genuine and fusion mitochondrial 
polypeptides, transporting normal mitochondrial proteins to their correct
32
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location, and leaving the ‘synthetic’ mitochondrial polypeptides in the cytosol 
(reviewed in Schatz and Dobberstein, 1996). It has been suggested therefore 
that further targeting information, at least in yeast, may be held within the 
mature part of the protein. Further investigation has also revealed that a large 
proportion of the mRNA coding for mitochondrial proteins is localised to the 
mitochondrial surface, and may be involved in co-translational translocation 
(Lithgow et al, 1997). A number of mRNA binding proteins have been found 
which aid import of mitochondrial precursors in yeast, and microscopy studies 
have demonstrated a bias for mRNA encoding mitochondrial precursors to be 
in the vicinity of mitochondria, possibly mediated by an RNA signal in the 3’ 
untranslated region. It is concluded therefore that both co-translational and 
post translational import of precursors can take place in vivo.
Translocation is achieved by the combined efforts of a large number of 
proteins, some which form a pore in the membrane through which the 
polypeptide can travel, and some of which aid unidirectional movement of the 
amino acid chain through this proteinaceous pore (Fig. 1.9).
Despite the tremendous amount of research that has been invested into :
understanding the translocation systems of mitochondria, chloroplasts, 
endoplasmic reticula, peroxisomes and bacteria, the precise mechanisms 
remain the subject of considerable debate. Partly due to the difficulty in 
obtaining sufficient structural data on membrane proteins, a number of 
questions remain unanswered with regards to the translocation contact site, 
and indeed, the translocation apparatus of all membranes. A simple pore is not 
sufficient, since the translocation contact site is able to accommodate all 
amino acids, from glycine to tryptophan, without letting through any ions.
Whilst the pore may not allow protons through from the intermembrane space
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Figure 1.9 Diagram demonstrating the various contributing factors 
required for translocation into the mitochondrion
As shown, a number of factors are known to be required for efficient 
import in the majority of cases. Initial insertion of the presequence into the 
outer membrane translocation complex may be co-ordinated by one of the 
receptors, but the precise mechanism for insertion is poorly understood. It is 
thought, however, that insertion
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Figure 1.9 cont’d
of the presequence into the inner mitochondrial membrane translocation pore
*
is through an electrostatic interaction with the membrane potential (AT).
For release of the cytosolic chaperones during subsequent translocation,
ATP is required, probably aided or coordinated by Ydjpl (Hsp40). This allows 
movement of further sections of the polypeptide to be taken through the
mitochondrial membranes. It is likely that the polypeptide is then pulled 
through the pore as proposed in the Brownian ratchet model, requiring ATP
for the mitochondrial Hsp70.
'ÿ
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to the matrix, it must, however, permit the transfer of bulky charged amino 
acids. Of interest is a protein called BSCl, a mitochondrial inner membrane 
protein which possesses an internal, unprocessed targeting signal. Since this 
polypeptide’s signal is deep within the mature part of BSCl, it is expected to 
form a tight hairpin with a neighbouring transmembrane domain, and would 
be translocated through the pore as a loop. Import of such a loop would be 
analogous to the import of membrane spanning polypeptides into the 
endoplasmic reticulum (Folsch et a l,  1996)
Many proteins of the translocation contact site have been identified by 
biochemical and genetic methods in yeast. Without structural data, there is 
only anecdotal evidence for the function of individual polypeptides within the 
complexes of the inner and outer translocation machinery (Kiebler et al,  
1993).
After being bound by a receptor, the polypeptide is then inserted into the 
outer membrane pore, termed the ‘general insertion pore’ since it is noted that 
a number of polypeptides are able to use the same site. Precursors for the 
matrix, inner membrane and some for the intermembrane space then cross the 
inner membrane through a second, separate pore. To do this, the 
mitochondrion must have a membrane potential (A\|/) and a supply of ATP.
The proton gradient is required only for initial insertion of the 
presequence into the inner membrane translocation apparatus. It has been 
proposed that the positive charge on the presequence interacts with the 
gradient to allow it to overcome any kinetic barrier in inserting into the pore. 
Once inserted into the pore, the potential difference is no longer required, only 
the presence of ATP is necessary to complete translocation, as demonstrated 
by uncoupling and ATP depletion experiments (reviewed in Kiebler et al,
1993).
Matrix ATP has been shown to be required for the reversible binding of 
mitochondrial HspVO to the incoming polypeptide. Studies by Stuart et a l
36
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(1994) used ATP-depleted mitochondria to reveal the ability of mt HspVO to
■
‘unfold’ a polypeptide located on the cytosolic side of the mitochondrion and 
initiate its translocation from the mitochondrial matrix. This is in support of 
the ‘Brownian ratchet’ theory, where chaperones on the matrix side of the 
translocation contact site bind the polypeptide as it enters this compartment.
As the polypeptide comes though by Brownian motion- either as a result of the 
folded polypeptide spontaneously unfolding a short section, or as the unfolded 
polypeptide is released from chaperones- the mt HspVO binds the precursor 
and makes any such tr ans location one way.
1.5.2.4 Processing and folding
ISubsequent to this translocation, the polypeptide usually has the 
presequence removed and is then folded into the mature form (Fig. 1.10). The 
presequence is removed by a mitochondrial processing peptidase (called 
MPP), an unusual peptidase requiring zinc and cleaving peptides based not on 
primary sequence, but on a 3-dimensional motif. This peptidase has been 
classified with the pitrilysin family on the basis of the motifs it uses to bind its 
zinc cofactor. MPP is a heterodimer; the a  subunit recognises the cleavage site 
according to an uncharacterised motif which may not be wholly contained 
within the presequence. Once recognised, the a  subunit presents the 
polypeptide to the |3 subunit, which then cleaves the presequence from the rest 
of the polypeptide. Recognition of the peptide is tolerant of a large number of 
mutations (Luciano and Geli, 1996). As ever, there are exceptions to the rule. 
There are a few polypeptides in which the presequence is not processed (e.g. 
the N-terminal sequence of rhodanese) or is held within the mature part of the 
protein, such as BCSl, or many of the mitochondrial ‘carrier proteins’ which 
appear to translocate through the outer membrane by the default pathway, but 
then integrate into the inner membrane by a separate mechanism (Sirrenberg et
Î
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peptide
Figure 1.10 Diagram of the processing and folding of precursors in the 
mitochondrion
During translocation the presequence is cleaved by MPP. In the case of 
matrix bound polypeptides, mt Hsp70 is removed with hydrolysis of ATP, 
possibly during translocation. The mature-sized, partially folded peptide is 
then bound by Hsp60, along with CpnlO (Hsp 10). After release of these 
chaperones (with ATP hydrolysis), the peptide is fully folded.
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al,  1998).
After processing, the polypeptide may be either re-targeted or folded. A 
matrix protein starts being folded shortly after entering the matrix; it is
.currently held that folding takes place after processing. Previously, however, 
opinion has been divided over when processing took place, it is possible that 
the two events may take place simultaneously. Those proteins which are 
bound for other compartments may be re-targeted. It is often the case that a 
polypeptide bound for either the intermembrane space or the inner membrane 
will posses a ‘bipartite signal’, that is, the presequence will be made up from 
one N-terminal signal that targets the polypeptide to the matrix, then a second 
signal is revealed when the first is cleaved off. This second N-terminal signal 
will redirect the polypeptide to its final destination; this re-addressing is called 
‘conservative sorting’. The second part of the signal shares similarities to 
bacterial secretory presequences, which supports the endosymbiotic theory of 
mitochondrial origins.
The re-addressing of polypeptides has been another area of some 
controversy, with the focus of debate being on the ‘stop-transfer’ theory or the 
contrasting ‘conservative sorting’ hypothesis. Both concepts are illustrated in 
Fig. 1.11. The question has often been one of whether a re-targeted protein 
uses matrix proteins for translocation or not. Experiments by Gruhler et a l  
(1996) provide some insight; in this research cytochrome 6 2  presequences 
attached to DHFR were imported into mitochondria, but could not be fully 
imported due to the presence of methotrexate. Methotrexate binds DHFR, and
■ ;
can hold it in a closed, translocation-incompetent state, and if added before 
translocation, can halt iinport of the DHFR portion of the peptide. Such 
arrested polypeptides could be isolated which had already been re-addressed 
by their second targeting signal whilst still bound to mtHspVO, having lost 
their original mitochondrial targeting sequence. This demonstrates the 
polypeptide’s contact with the matrix before re-targeting. Polypeptides
J
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Figure 1.11 Stop-transfer and conservative sorting models
4 1
Bipartite signal sequences are thought to be sorted using either a ‘stop- 
transfer’ (a) or a ‘conservative sorting’ (b) method. In stop-transfer, the second 
part of the signal prevents further translocation; the inner membrane 
translocation machinery then dissociates from the outer membrane, allowing 
the polypeptide to enter the intermembrane space without passing through the 
matrix. The signal is then cleaved off by an inner membrane space processing 
peptidase.
In conservative sorting, the second part of the presequence acts as an
export signal would in a bacterial cell, re-addressing the polypeptide to the 
inner mitochondrial membrane. The polypeptide is therefore fed through a 
new translocation pore as a hairpin loop, leaving the targeting signal in the 
matrix.
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targeted to the intermembrane space are subsequently folded by chaperones 
present within this compartment.
Matrix polypeptides are folded in the presence of an unusually high 
concentration of proteins. It is not surprising that chaperones are present to 
prevent non-productive interactions and misfolding. Mitochondrial HspVO was 
identified from ATP-depletion studies, and as discussed, appears to have a role 
in translocation. It is likely that HspVO keeps incoming polypeptides in a 
loosely folded state before being folded by other chaperones. Another such 
chaperone is Hsp60; mitochondrial Hsp60 was identified from screens of 
temperature-sensitive yeast mutants able to import human ornithine 
transcarbamoylase into the mitochondrial matrix, but unable to assemble them 
at the non-permissive temperature (reviewed in Glick and Schatz, 1991). Other 
chaperones have also been implicated in the folding of mitochondrial proteins; 
these include mitchondrial GrpE and CpnlO (also called Hsp 10). These 2 
chaperones have been discovered to be essential to the cell for survival and are 
not only implicated in protein import but also in regular protein maintenance;
'refolding damaged polypeptides (Martinus et al, 1995).
1.5,3 Mitochondrial targeting sequences
Mitochondrially targeted polypeptides most usually posses a cleavable 
presequence of between 19 and 40 amino acids, although shorter and longer 
sequences have been found. These sequences exhibit no sequence homology, 
but have a high content of serine, threonine and basic amino acids. When the 
sequence is displayed as an a-helix, it will frequently reveal an amphiphilic 
nature, hydrophobic on one side, basic and hydrophilic on the other. Many 
studies have been carried out to detect patterns in all known presequences; no 
observed motif appears to be obligatory though some motifs are prominent, 
such as the amphiphilic helix, a lack of acidic residues and absence of proline
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(Heijne et a i ,  1989). Of all randomly generated synthetic presequences, 25% 
are able to target polypeptides to either the translocation apparatus of the 
endoplasmic reticulum, bacterial plasma membrane or the mitochondrion. 
However, these synthesised targeting sequences are much less effective than 
genuine presequences (Schatz and Dobberstein, 1996). It is therefore clear that 
whilst no consensus exists between the primary sequences of the 
mitochondrial targeting presequences, there are distinct signals located within 
these sequences which have yet to be completely deciphered.
1.6 The targeting and position of the components of 2-oxoacid 
dehydrogenase complexes
The components of the 2-oxoacid dehydrogenase complexes are all 
found in the matrix, in association with the inner membrane. Targeting to the 
mitochondrion is expected to proceed via the normal route through the 
translocation contact site.
1.6.1 The extended presequences of E2
The presequences of the components of the 2-oxoacid dehydrogenase 
complexes are all typical of mitochondrial targeting signals with the exception 
of the E2 components of each complex. These polypeptides possess highly 
extended presequences, PDC-E2 having the longest at 73 amino acids. 
Extended presequences often contain additional information, such as the 
bipartite signals of conservatively sorted inner membrane and intermembrane 
space proteins. However, they could also aid in maintaining the solubility of 
highly hydrophobic polypeptides, possibly through the recruitment of extra 
chaperones, or by acting directly as an intramolecular chaperone (Hajek et al., 
1997). Since E2s are known to be highly hydrophobic and easily form
43
Si:.
%4 :
■Chapter 1 : Introduction
aggregates, this is one possible reason for them having extended presequences.
Antibodies raised to the mature form of E2 are unable to recognise any 
epitopes in precursor E2 (Hunter and Lindsay, 1986), consistent with the 
theory that PDC-E2 is kept in an especially unfolded state to avoid 
aggregation of the precursor.
I
1.7 Aims of research
Having discussed what is known about the targeting of PDC-E2 to the 
mitochondrion and the behaviour of PDC kinase, we are able to pin-point two 
areas which require some investigation.
1.7.1 The role of the extended presequence of PDC-E2
The first aim of this research was to uncover the properties held by the 
extended presequence of PDC-E2. Why is it so long- are there a number of 
signals held within the signal, and what are their functions? Is there a shorter 
portion of the sequence which is sufficient for targeting? If so, what is the 
function of the rest of the presequence? Finally, one could ask if this 
presequence was capable of mistargeting to the rough endoplasmic reticulum, 
and therefore a possible cause of the abnormal expression of E2 epitopes on 
the surface of bile duct epithelia in PBC.
Some answers to these questions may be obtained by testing parts of the 
presequence for their ability to target polypeptides to the mitochondrion. The 
main part of the research detailed in this thesis describes the strategy used to 
answer these questions, which involved initial construction of a new plasmid 
vector designed for such experiments, made not only for this research, but for 
more general studies on mitochondrial targeting in vivo. Secondly, this thesis 
describes the methods used to clone the presequence and, based on a
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computer-aided analysis of the polypeptide sequence, the selection and 
synthesis of various presequence segments for testing in the new plasmid.
Finally, this work reports on the in-vivo  expression of the plasmid- 
presequence constructs and analysis of the results. y
1.7.2 The behaviour of PDC kinase
It is known that PDC kinase phosphorylates three sites on El when both 
the El and the kinase are attached to the E2 core, but only acts upon one site 
when the El is freed from the core. However, it is unknown what takes place 
when E l is bound to the core but the kinase is freed from the complex. If this 
was determined, it would help in understanding which interactions permit the |
phosphorylation of all three sites.
As an adjunct to the main research described in this thesis, further 
experiments were performed which were designed to answer this question, 
utilising electro spray mass spectroscopy to measure by mass the number of |
phosphorylations on E l made by bound and free kinase.
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2.1 Materials
2.1.1 Kits
Sequenase™ Version 2.0 DNA Sequencing Kit and ECL Western 
blotting detection reagents were purchased from USB through Amersham 
International pic., Aylesbury, Bucks, UK.
Tag D y e D e o x y T M  Term inator Cycle Sequencing kits and 
sequencing-grade phenol/chloroform/H2 0  (68:18:14) were obtained from 
Applied Biosystems Inc. (ABI), Warrington, Cheshire, UK.
The MERmaid® kit was bought from BIO-101, 1070 Joshua Way, 
Vista, CA 92083, USA.
Micro BCA Protein Assay Reagent Kit was obtained from Pierce 
Laboratories, Rockford, Illinois, U.S.A.
W i z a r d ™  plus Mini Preps and Maxi Preps DNA purification system 
and the W izard^ ^  PCR preps were purchased from Promega, 
Southampton, UK.
Qiaex gel extraction kit and Qiagen midi and maxi kits were bought 
from Qiagen Ltd., Boundary Court, Gatwick Rd., Crawley, East Sussex, 
England.
PC R -Scrip t™  Amp SK(+) Cloning Kit was obtained from 
Stratagene, Cambridge, UK.
2.1.2 Enzymes
Chloramphenicol acetyltransferase was a kind gift from Dr. Ann 
Lewendon and Prof. William Shaw, University of Leicester.
T4 DNA ligase with lOx buffer, and Tag DNA polymerase with lOx 
buffer and 25 mM MgCQ was supplied by Promega, Southampton, UK. 
VentR® (exo-) DNA polymerase and lOx buffer was supplied by
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New England Biolabs, Hitchen, Herts, UK.
‘Native’ and ‘Cloned’ Pfu DNA polymerase and supplied lOx 
buffers were obtained from Stratagene, Cambridge, UK.
EcoRl, Hindlll, Kpnl, Nhel, Pstl, calf intestinal alkaline phosphatase 
(CIP), and T4 DNA ligase, all with supplied lOx buffers, were obtained 
from Boehringer Mannheim Gmbh., Lewes, East Sussex, UK.
Cpol and Bj/MI were purchased from Amersham International pic., 
Aylesbury, Bucks, UK.
2.1.3 Chemicals
Agarose (electrophoresis grade) was supplied by Appligene®- 
Oncor®, Parc d’Innovation, 67402, Illkirch, France.
Isopropylthio-(3 -D -galactoside, X-Gal and DTT were from i
Boehringer Mannheim Gmbh., Lewes, East Sussex, UK.
Acrylamide, A,A’-Methylenebisacrylamide, Poly(ethylene glycol)
6000 grade and Triton X-100 were obtained from Fisons, Loughborough,
England. ;
Tris and caesium chloride were purchased from Gibco BRL Life 
Technologies, Inchinnan Business Park, Paisley.
Leupeptin was from the Marketing Association, Herts, England
Substrates and coenzymes for enzyme assays, PMSF, benzamidine- 
HCl, MOPS, Tween-20, antifoam A concentrate, Coomassie brilliant blue, |
ampicillin, tetracycline and collagenase were supplied by Sigma Chemical 
Company, Poole, Dorset, UK.
HPLC grade water and acetonitrile were from Rathburn Chemicals ^
Ltd. Walkerburn, Scotland.
Methanol, propan-l-ol, propanol-2-ol and glycerol were from Fisher 
Scientific UK Ltd., Bishop Meadow Rd, Loughborough, Leicestershire,
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UK.
Tris equilibrated phenol (Tris-phenol) was purchased from Fisons 
Scientific, Bishop Meadow Rd, Loughborough, Leicestershire, UK.
All other chemicals were bought from BDH Chemicals Ltd., Poole,
U.K.
2.1.4 Electrophoresis markers
Low molecular weight (‘Low Mj-’) marker proteins were from Pharmacia 
Biotech UK, St. Albans, Herts.
‘100 bp ladder’ DNA markers were from Gibco BRL Life 
Technologies, Inchinnan Business Park, Paisley.
‘(j)X-174 RF DNA-HocIII ‘digest DNA markers were purchased from 
Promega, Southampton, UK.
‘DRIgest IIP (k  DNA-HWIII/())X-174 RF DNA-Haelll digest) DNA 
markers were supplied by Pharmacia Biotech UK, St. Albans, Herts.
2.1.5 Media
Bacto®-tryptone, Bacto®-agar and Bacto®-yeast extract were 
supplied by Difco, East Molesey, Surrey, UK.
All cell culture materials were supplied by Gibco BRL Life 
Technologies, Inchinnan Business Park, Paisley.
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2.1.6 Bacterial Strains
Escherichia coli XL 1-Blue MRF’ (Stratagene Ltd., Cambridge): a 
restriction and recombination deficient host strain for propagating plasmid 
DNA, plating Lambda ZAP II cDNA libraries and double-stranded 
sequencing.
Genotype: A(mcr/l) 183, A(mcrCB-hsdSMR-mrr) 173, endAl, supE44, thi-l 
recAl, gyrA96, relAl, Lac [F’ proAB,  /tzc/IZAMlS, TnIO(tetO] (Bullock, 
1987)
Escherichia coli DH5a (Stratagene Ltd., Cambridge): a recombination 
deficient, suppressing strain for the propagation of plasmid DNA.
Genotype: siipE44 AlacU\69  (f80 lacZAMlS) hsdR ll recAX endAX gyrA96 
thi-X relAl (Hanahan, 1983)
2.1.7 Plastics
2.1.8 Miscellaneous
Alconox™  detergent was supplied by Aldrich Chemical Company 
Ltd., Gillingham, Dorset, UK.
Sterile Acrodisc® 0.2 (tm filters were supplied by Gelman Sciences
Ltd., Northampton, UK.
Gel-Mix® 6  was from Gibco BRL Life Technologies, Innchinan
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Centricon 3, 10 and 30 concentrators were bought from Amicon Ltd., 
Stonehouse, Gloucestershire.
Quickseal polyallomer ultracentrifuge tubes (3.9 ml) were from 
Beckman Instruments (UK) Ltd., Sands Industrial Estate, High Wycombe, 
Bucks., England.
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Business Park, Paisley.
Permacel™  tape was obtained from Genetic Research Instruments, 
Dunmow, Essex, UK.
Dialysis tubing (Visking size 1-8/32’) was supplied by Medicell 
International Ltd, London, UK.
X-Omat S film was obtained from Kodak Ltd., Dallimore Road, 
Manchester, England.
Hybond-C extra nitrocellulose sheets. High performance Hyperfilm- 
ECL and the ECL Western blotting kit were supplied by Amersham 
International pic., Aylesbury, Bucks, UK.
Non-immune donkey serum was supplied by the Scottish Antibody 
Production Unit (SAPU), Lanarkshire, Scotland.
Bovine hearts were obtained from Paisley Abbatoir, Sandy ford Road, 
Paisley, Scotland.
2.1.9 Equipment
The automated sequencer was from Applied Biosystems Inc. (ABI), 
Warrington, Cheshire, UK.
The X-Omat-100 processor was purchased from Kodak Ltd., which 
was manufactured for Kodak Ltd. by L ’accessori radio grafico, Burago, 
Molgora, Italy.
The Fast Protein Liquid Chromatograph (FPLC) , FPLC columns and all 
gel chromatography materials were purchased from Pharmacia Biotech UK, 
St. Albans, Herts.
The High pressure liquid chromatograph (HPLC) was from Hewlett 
Packard, Eskdale Rd., Wokingham, Berks.
The C4 reverse phase column was a Delta-Pak™  HPI C4, 2.0 x 150 
mm, from Waters, Watford, Herts.
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The Electrospray mass spectrometer (ESMS) was produced by VG 
Biotech Ltd., Altrichara, Cheshire.
The centrifuges and the refrigerated benchtop centrifuge were bought 
from Beckman Instruments (UK) Ltd., Sands Industrial Estate, High 
Wycombe, Bucks., England.
The benchtop centrifuges (MSE Microcentaurs) were from Scotlab,
Coatbridge, Scotland.
The PCR machines were purchased from Techne (Cambridge) Ltd.,
Duxford, Cambridge and from Genetic Research Instruments Ltd., Gene 
Plouse, Dunmow Rd., Felsted, Dunmow, Essex, England.
2.2 General cell culture
Except where described, all following cell culture methods were carried 
out under sterile conditions. Mammalian cell culture procedures were 
performed inside sterile flow hoods with bottle necks flamed before sterile 
disposable pipettes were introduced to add or withdraw fluids. All media were 
preincubated to test for the presence of bacteria or yeast. Prokaryotic cell 
culture procedures could be carried out on the open bench. Bottle necks were 
still flamed before taking or adding fluid, again, using sterile pipettes.
Platinum wire loops, used for taking isolated colonies of cells, or taking up 
small amounts of broth, were held in the flame of a bunsen until glowing red 
to sterilise between uses. Similarly, glass spreaders were dipped in 70% (v/v) 
ethanol and lit in a bunsen to obtain sterility. Platinum wires and glass 
spreaders were allowed to cool before use.
Most plasticware, such as flasks, graduated pipettes, syringes, filters, 
uni versais and polypropylene centrifuge tubes were purchased in pre-sterilised *
packs. Pipette tips for the auto-pipettors were placed in sealable racks and 
autoclaved (126°C, 15 psi, 15 min); eppendorfs were bottled in jars and
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autoclaved.
Media were supplied as sterile for eukaryotic cell culture. For bacterial 
cell culture, media were either autoclaved or filter sterilised into sterile 
containers.
2.3 Eukaryotic cell culture
2.3.1 Starting cultures from frozen stocks
Cells which had been previously frozen (as described below) were 
revived by removing an aliquot of cells from liquid nitrogen and placing in a 
water bath at 37°C. Once defrosted, medium containing the cells was 
transferred to a medium sized flask (75 cm^). Dulbecco’s minimum essential 
medium (‘DMEM’, 450 ml dH20, 50 ml 10 x Dulbecco’s minimum essential 
medium, 50 ml new born calf serum, 5 ml 200 mM ‘ lOOx’ L-glutamate, 5 ml 
‘lOOx’ MEM non essential amino acids, 35 ml 7.5% (w/v) sodium 
bicarbonate), preincubated at 37°C, was added (20 ml), and the flask was 
incubated at 37°C in 10%(v/v) CO2 , with the lid screwed on loosely to allow 
transfer of gases.
2.3.2 Passaging
Once cells had grown to confluence, they could be split into 3-7 new 
flasks of the same size, or put into new vessels, such as transfection dishes. To 
do this, the medium was taken off, and replaced with 5-20 ml of Versene (140 
mM NaCl, 2.5 mM KCl, 8 mM Na2HP0 4 , 1.5 mM KH2 PO4 , 0.5 mM EDTA, 
3 |iM Phenol Red) depending on the size of the flask. The cell monolayer was 
gently washed with this, then the Versene was replaced with 1-2 ml of 1:4 
trypsin/Versene (0.25% (v/v) trypsin). The flask was incubated with the 
trypsin until the cells started to appear round or detached from the flask, by
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checking under a microscope. A gentle tap on the side of the dish could also 
help to dislodge the cells from the flask. Once the cells had all become 
dislodged, a small amount of DMEM was added to stop the tryptic digestion, 
and the medium was distributed among the new flasks. A volume of medium, 
appropriate to the size of flask, was added to each flask, and each flask 
incubated at 37°C in 10% (v/v) CO2 , with the lid screwed on loosely.
2.3.3 Freezing down cells
As before, cells were removed from the flask by use of a wash with 
Versene, then trypsin/Versene. For a large (162 mm^) flask, 10-20 ml medium 
was added, and the cells spun down at 4°C at 2000 rpm (in a Beckman GS- 
15R benchtop centrifuge) for 5 min. The cells were gently taken back up in 9 
ml medium, and 1 ml DMSO. The solution was then aliquoted into 1.8 ml 
sterile Nunc™  Cryotubes, and kept on ice until freezing. The aliquots (1.5 ml) 
were frozen in a -80°C freezer and placed in liquid nitrogen for long term 
storage 16-24 h later.
2.3.4 Transfection of DNA
2.3.4.1 Transfection by Lipofection
Cells were grown to 50% confluence in 60 mm transfection dishes, by 
seeding at low densities and culturing cells until they reached the desired 
numbers. The original growth medium was removed, and the cells were 
washed with OPTIMEM 1 medium. Meanwhile, 2-5 |lg of DNA solution was 
added to 200 jal OPTIMEM 1 medium, and 4-40 |xl of lipofectin reagent was 
diluted into another 200 fxl OPTIMEM 1. The two solutions were then gently 
mixed together and allowed to stand for 15 min at room temperature. After 
this incubation, the medium was removed from the cells, and the
I :
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lipofectin/DNA mixture put in place. The cells were incubated in the presence 
of the DNA for 5-24 h (usually overnight) under normal growth conditions. 
The lipofectin/DNA mixture was removed, and the cells again grown in 
normal growth medium for 48 h before being harvested.
2 3.4.2 Transfection by DEAE dextran
The protocol employed was based on that devised by Sambrook et a l  
(1989). Cells were grown to 50% confluence in 60 mm transfection dishes, by 
seeding at low densities and culturing cells until they reached the desired 
numbers. The growth medium was removed, and the cells washed with 
OPTIMEM 1 medium, A DNA solution (250 pi 1 M Tris (pH 7.3), 200 pi 0.5 
M HEPES (pH 7.2), 4.475 ml OPTIMEM 1,75 pi DEAE-dextran solution (50 
mg/ml) and 5 pg DNA) was put over the cells and incubated in normal growth 
conditions for 4 h. This solution was removed from the cells, and the cells 
were incubated for 1 min at room temperature in OPTIMEM 1 containing 25% 
(v/v) glycerol. After removal of the glycerol solution, the cells were again 
washed with OPTIMEM 1, and 5 ml normal growth medium was added to the 
cells. The cells were then allowed to grow in normal conditions for 48 h 
before harvesting.
2.3.4.3 Transfection by calcium chloride
The protocol employed was based on that devised by Sambrook et al. 
(1989). Cells were grown to 50% confluence in 60 mm transfection dishes, by 
seeding at low densities and culturing until they reached the desired numbers. 
A DNA solution was prepared to add to the growth mediumas follows; 5 pg 
DNA was added to 437.5 pi water and 62.5 pi 2 M CaCl2 - This was added to 
500 pi HBS buffer (Hepes buffered saline; 280 mM NaCl, 1.5 mM Na2 HP0 4 ,
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10 mM KCl, 12 mM dextrose, 50 mM HEPES (pH 7.05 with NaOH), all filter 
sterilised), and left to stand for 1 h, before being added to the cells in the 
growth medium. The cells were incubated with the CaCl^/DNA precipitate for 
20 h, under normal growth conditions, before the medium was removed from 
the cells and replaced with fresh growth medium. The cells were then grown 
for a further 48 h before being harvested.
2.4 Prokaryotic cell culture
Bacteria were grown either on agar plates or in broth cultures. Agar 
plates were made with a broth medium containing 1.5% (w/v) agar. Molten, 
sterilised agar medium could be poured out into Petri dishes in approx. 30 ml 
measurements. Once set and dried in a 37°C incubator for 1 h, bacteria could 
be streaked or spread onto the plate, and incubated upside down. This would 
produce isolated colonies of bacteria derived from a single cell, with any 
condensation from metabolism collected on the lid. Bacteria could also be 
grown as a suspension, or liquid culture, where the cells were grown in a 
suitable volume of medium, and incubated. Such cultures were usually grown 
aerobically, which entailed vigorous shaking of the culture at approx. 150-200 
rpm. For this reason, a defined volume of medium was shaken in a vessel, 
often a conical flask, which had a greater capacity (at least 5 times the volume 
of the culture), as this allowed efficient aeration of the contents.
Bacteria were usually grown in Luria broth (10 g Bacto-tryptone, 10 g 
NaCl, 5 g yeast extract per litre H^O, pH 7.4) which had been sterilised by 
autoclaving, or on Luria broth-agar (10 g Bacto-tryptone, 10 g NaCl, 5 g yeast 
extract, 15 g agar per litre H2 O, pH 7.4) which had been sterilised by 
autoclaving.
Bacteria were supplied in stabs, on plates, and in frozen cultures.
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2.4.1 Starting cultures from frozen stocks
When the starting culture was a broth or a frozen liquid culture a small 
volume could be taken and spread out on a fresh agar plate using a sterile glass 
spreader. Alternatively, a sterile wire loop could be used to take a small 
volume of culture to be streaked out on a plate. The plate would then be
A
incubated overnight at 37°C upside down.
2.4.2 Starting cultures from agar plates
When starting a culture from bacteria on a streaked-out plate, a single 
colony could be taken from the plate using a sterile wire loop, re-streaked on a 
fresh plate of a similar medium agar and incubated overnight at 37°C.
2.4.3 Growing and subculturing bacterial cultures
Subculturing bacterial cells could be performed by picking a single 
colony off an agar plate and re-streaking as above.
To grow larger numbers of cells, a single colony could be taken from the 
plate, using either a sterile pipette tip or a sterile wire loop, and dispersing the 
colony into 5 ml broth in a sterile universal. After an 8 h or overnight 
incubation, at 37°C with shaking, a small amount of the broth could be taken 
out with a sterile pipette, and diluted 100 fold into fresh broth. This broth 
could then be grown overnight again at 37°C with shaking.
2.4.4 Freezing down cells
Cells could be stored for 1-2 weeks as colonies on agar plates at 4°C. For 
longer term storage, up to a number of months, an 8 h or overnight broth
57
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culture could be mixed with an equal volume of glycerol and kept at -20°C in
i.
Sterile eppendorfs. The same culture/glycerol stock, stored at -SQoC, could be 
kept for even longer term storage (a number of years).
2.4.5 Transformation with DNA
2.4.5.1 Competent cell preparation
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'1
Bacteria were regularly used for cloning and growing plasmids by 
transforming them with a small amount of plasmid DNA. A suitable strain was 
selected (e.g. E. coli XLl Blue MRF’) and streaked out onto a sterile LB agar 
plate and grown overnight at 37®C. Isolated colonies (4-5) were then taken 
from the plate with a sterile wire loop and dispersed into 15 ml LB broth 
(supplemented with 20 mM sterile MgSO^) in a 50 ml polypropylene tube.
Another 4-5 colonies were treated likewise so that, in total, a 30 ml culture 
was made. The two tubes were incubated with shaking at approx. 200 rpm at 
37°C for 4.5 h, then spun at 4000 rpm in a JA17 rotor in a Beckman J2-21 
centrifuge at 4°C for 10 min. The supernate was poured off and the pelleted 
cells gently resuspended in 10 ml modified ‘TFB’ (10 mM MES pH 6.3 with 
KOH, 50 mM CaCIi, 100 mM KCl, filter sterilised and stored at 4°C). The 
cells were left on ice for 30 min with occasional swirling. At this stage, the 
cells were pelleted as previously, and resuspended in 4 ml modified T F B ’, 1
and left for 15 min on ice. ‘DnD’ solution (140 p,l) was added (1.53 g DTT, 9 
ml DMSO, 100 ]Lll 1 M potassium acetate (pH 7.5), made to 10 ml with H2 O, 
filter sterilised). These cells, competent for efficient transformation, remained 
viable for up to two weeks at 4°C using this method.
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2.4.5 2 T ransfo rm ing  com petent cells
I
Competent cells (400 jil) were pipetted into a sterile eppendorf for each 
transformation. Plasmid (10-50 ng), in a maximum of 20 |ll1, was added to the 
cells and gently mixed by pipetting up and down. This was incubated for 45 
min on ice, then warmed to 42°C in a water bath for 90 sec. The 
transformation mix was then rapidly cooled on ice, and left for 2  min, before 
adding 800 p.1 SOC medium (20 g bacto-tryptone, 5 g yeast extract, 0.5 g 
NaCl, 10 ml 250 mM KCl, pH 7.0 with NaOH, volume made to 1 L, and 
sterilised by autoclaving; before use, 5 ml of filter sterilised 2 M MgCl^ and 
20 ml filter sterilised 1 M glucose were added), pre-warmed to 37°C, to the 
transformation mix. This was then incubated, with shaking, at 37°C, for 1 h.
After the 1 h incubation, the cells were pelleted by centrifugation for 1 
min at 6500 rpm in a bench top centrifuge. The supernate was removed, and 
the cells gently resuspended in 100-200 p.1 of SOC medium. This was pipetted 
onto a suitable selective media agar plate, spread out on the plate using a 
sterile glass spreader and incubated overnight at 37°C.
I
2.4.5.3 Selective m edia
Plasmids most often contain a gene which when expressed in the host /
bacterium, confers a selectable advantage over other bacteria not carrying the 
plasmid. The ‘marker’ gene used throughout this work was the ampicillin 
resistance gene. Media which were selective for the bacteria carrying this
■■
plasmid contained 25 \xg ampicillin per ml of broth, or 50 |Lig/ml of agar. The 
ampicillin was added as a filter sterilised 50 mg/ml solution after media had 
been autoclaved and cooled to below 50°C. Ampicillin was added to agar
:
before it set, at approx. 45°C.
Agar plates could also have blue/white selection, to test for the
59 y:•
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insertional inactivation of the P-galactosidase gene. Plasmids which had been 
used for cloning short pieces of DNA (see section 2.10.4.2) sometimes utilised 
this system. In addition to selecting for bacteria carrying the plasmid 
ampicillin resistance gene, it was possible to detect if the DNA had been 
inserted into the plasmid depending on whether or not the P-galactosidase 
gene had been inactivated by the presence of a DNA insert. To test for an 
active p-galactosidase gene, expression of the gene was induced by the 
presence of IPTG, and the gene product hydrolysed the X-Gal substrate, which 
then turned blue. LB-ampicillin plates were first coated with X-Gal (10% 
(w/v) X-Gal in DMSO) by spreading 20 p.1 solution into a plate until the 
solution had dried into the plate, followed by 20 p,l IPTG (0.2 M IPTG 
solution, filter sterilised), spread on in the same way.
2.5 Protein methods
No protein methods required sterility. However, care was taken to ensure 
all plastic ware and glassware was clean.
2.6 Protein purification
2.6.1 Protein extraction from cells
2.6.1.1 Obtaining cell suspensions
Cells grown in 60 mm culture dishes were washed by first discarding the 
culture medium, and then gently rinsing the cells with ice-cold PBS (140 mM 
NaCl, 2.5 mM KCl, 8  mM Na2HP0 4 , 1.5 mM KH2 PO 4 , sterilised by 
autoclaving). Rinsing with PBS was performed twice, and the cells were 
scraped off the surface of the dish with a sterile cell scraper, resuspended in 1 - 
1.5 ml ice-cold PBS and pipetted into a sterile eppendorf. The suspension was 
centrifuged at 2000 rpm for 5 min at 4°C, and the supernate removed with a
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pipette before resiispending in 100 |li1 ice cold PBS. Cells were stored at 4°C 
until fractionated.
2.6.1.2 Fractionating cells
Cells could be broken open to release the contents of both the 
mitochondrial matrix and the cytoplasm by simply adding 1 % (v/v) Triton X- 
100 to the cell suspension in PBS, and then vortexing momentarily. Debris, 
such as membranes and nuclei, could be pelleted by centrifugation at high 
speed in a benchtop centrifuge at 4°C and the supernate retained for further 
analysis. Alternatively, a freeze-thaw process, where the cells were frozen to 
-70°C, thawed and vortexed, could also achieve cell lysis in the absence of 
detergents.
Fractionation of the cells into cytoplasmic and cytoplasm + 
mitochondrial matrix fractions was carried out using digitonin. Digitonin is a 
detergent which crystallises cholesterol, causing lipid membranes to rupture. 
Since more cholesterol is found in plasma membranes than in mitochondrial 
membranes, less digitonin is required to permeabilise the plasma membrane. A 
cellular suspension in PBS was fractionated with 0.05 mg digitonin per million 
cells to Img digitonin per million cells. Digitonin was made as 10 and 1 mg/ml 
standard solutions in Hepes-buffered saline (0.8 g NaCl, 0.037 g KCl, 0.027 g 
Na2 HP0 4 .2 H 2 0 , 0.2 g dextrose, 1 g HEPES in 100 ml H2 O, pH 7.05 with 
NaOH, and filter sterilised). Cells were incubated on ice for 2 min, and 
membranes and unbroken organelles pelleted by centrifugation at high speed 
in a benchtop centrifuge at 4°C, with the supernate retained for further 
experimental work.
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2.6.2 Pyruvate dehydrogenase complex (PDC) purification
This method was adapted from Stanley and Perham (1980). PDC was 
isolated from bovine hearts which had been stored at -80°C and were 
subsequently defrosted overnight at 4°C. Prior to freezing, the fat and 
connective tissue was removed, and the rest of the heart diced into cubes 
approx. 1 cm x 2 cm. Bovine heart (300 g) was used in a single PDC 
preparation. The heart muscle was homogenised in a blender for 5 min, 
maximum speed, in an equal volume of 3% (v/v) Triton X-100 buffer (2.7 mM 
EDTA, 0.1 mM DTT, 3% (v/v) Triton X-100, 1 mM PMSF, 1 mM 
benzamidine-HCl, silicone antifoam (0.5 ml/1), 50 mM MOPS, pH 7.0). More 
3% (v/v) Triton X-100 buffer was added to bring the total volume to approx. 
1.51. The homogenate was then spun at 10000 rpm in a JA-14 rotor in a 
Beckman J2-21 centrifuge for 20 min, and the pellets discarded.
The pH of the supernate was adjusted to pH 6.45 with 10% (v/v) acetic 
acid, and 0.12 vol of 35% (w/v) PEG 6000 added with stirring which was 
continued, on ice, for a further 30 min. The preparation was centrifuged at 
14000 rpm in a JA-14 rotor in a Beckman J2-21 centrifuge for 15 min. The 
pellet was retained, resuspended and homogenised using a Teflon/glass 
homogeniser into a total volume of 200 ml using 1% (v/v) Triton X-100 buffer 
(2.7 mM EDTA, 0.1 mM DTT, 1% (v/v)Triton X-100, 1 mM PMSF, 0.15 gM 
leupeptin, 1 mM benzamidine-HCl, 50 mM MOPS, pH 6 .8 ). The homogenate 
was centrifuged in a JA-17 rotor at 17000 rpm in a Beckman J2-21 centrifuge 
for 40 min, and the supernate retained. The solution was filtered through 
muslin to remove fat particles; 0.013 vol 1 M MgCl^ was added to the 
solution, followed by 0.05 vol 1 M sodium phosphate buffer (pH 6.3), which 
was added whilst the solution was stirring. During the addition of the 
phosphate buffer, 0.5 M NaOH was used to prevent the pH of the solution 
falling below pH 6.5.
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After adjusting the pH of the solution to 6.45 with 10% (v/v) acetic acid, 
0.12 vol 35% (v/v) PEG 6000 was added with stirring, and retained for 30 min 
on ice. The solution was centrifuged as previously, in a JA-17 rotor at 16000 
rpm for 10 min, and the supernate discarded. This pellet was then left 
overnight in 80 ml 1% (v/v) Triton X-100 buffer at 4°C, and allowed to 
solubilise in the buffer. Resuspension of the pellet was performed using the 
homogeniser, and then centrifuged at 17000 rpm in a JA-17 rotor for 60 min.
All subsequent steps were monitored for PDC and OGDC activity 
(enzyme assays 2.7.1.4 and 2.7.1.5). To the supernate was added 0.04 vol 35% 
(v/v) PEG 6000; this was stirred for 30 min on ice. An aliquot (1 ml) of the 
solution was then taken and centrifuged at high speed in a benchtop centrifuge 
to ascertain if the OGDC had been precipitated and pelleted whilst the PDC 
was left in solution. This was analysed by assaying the supernate for PDC and 
OGDC activity. If the OGDC had not been reduced to 5% of the initial 
activity, then another 0.01 vol 35% (v/v) PEG 6000 was added to the solution, 
and stirred for 30 min on ice. Another aliquot was taken to assay for PDC and 
OGDC activity as before, to determine if the OGDC was pelleting whilst the 
PDC remained in solution. Additional 0.01 vol 35% (w/v) PEG 6000 were 
added until this was achieved, after which the solution was centrifuged at 
17000 rpm in a JA-17 rotor for 10 min.
The supernate was centrifuged in a Ti70 rotor at 45000 rpm for 2.5 h at 
4°C prior to leaving the pellet overnight at 4°C in a minimal amount of 1 % 
(v/v) Triton X-100 buffer. The softened pellet was subsequently resuspended 
in more 1% (v/v) Triton X-100 buffer, to obtain a concentration of 10-50 
mg/ml. The purity of the PDC could then be checked by assays for OGDC and 
PDC activity, or by SDS-PAGE (section 2.7.3). A Lowry or Micro BCA 
protein assay was employed to measure PDC concentration (section 2.7.5.1. 
and 2.7.5.2., respectively).
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2.6.3 E1/E3 purification
PDC solutions were mixed 1:1 with ice cold dissociation buffer (4 M 
NaCl, 50 mM imidazole, pH 7.0) and incubated on ice for 1 h. The PDC was 
subsequently spun in a benchtop microfuge at 13500 rpm for 15 min at 4°C to 
remove any insoluble material. Gel permeation chromatography of the 
supernate was performed on a Pharmacia FPLC Superose 12 column (16 mm 
X 500 mm, 100 ml bed volume). The column was pre-equilibrated with 200 ml 
running buffer (filtered and degassed 1 M NaCl, 50 mM imidazole, pH 7.0) at 
a flow rate of 0.1 ml mimh Dissociation buffer (2 ml) was injected onto the 
column at a flow rate of 0.5 ml minH, then 2 ml dissociated PDC sample was 
injected onto the column at the same flow rate. All the injected material was 
then eluted from the column in running buffer flowing at 1 ml m in 'F An 
absorbance trace at 280 nm recorded the elution profile, and 2  ml fractions 
were collected using a Pharmacia Frac-100 fraction collector.
The fractions containing the E1/E3 polypeptides were diluted in HPLC 
grade H2 O, and concentrated by spinning in centricon 10 tubes at 7000 rpm 
for 4 h or until concentrated. Again, HPLC grade H2 O (10 ml) was added to 
each sample to dilute out the salt, and reconcentrated as before. This was 
repeated 4 times in total to remove the majority of the salts, and leave the 
E1/E3 in HPLC grade H2 O.
2.6.4 HPLC of E l and E3
The E1/E3 fraction was subsequently spun in a benchtop microfuge at 
13500 rpm for 5 min at 4°C. The supernate was carefully removed and placed 
on ice in preparation for HPLC isolation of the polypeptides. HPLC was 
carried out on a Hewlett-Packard HPLC using a Delta-pak HPI C4 reverse 
phase column (2 ml). The column was first equilibrated in solution A (filtered
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and degassed 98:2 H20:acetonitrile with 0.1% (v/v) trifiuoroacetic acid) at a 
flow rate of 0.3 ml m iirF  The sample was injected onto the column at the 
same flow rate. The various proteins in the sample were eluted from the 
column by changing the running solution over a period of 60 min from 
solution A to solution B (filtered and degassed 10:90 H20:acetonitrile with 
0.1% (v/v) trifiuoroacetic acid). Fractions were collected from the column 
with on-line monitoring at 214 nm to detect eluted polypeptides.
2.6.5 U ltra filtra tio n
Amicon Centricon-10 concentrators were used, since these had a filter 
cut-off point at 10,000 Mj-, therefore retaining Bloc, El(3 and E3. The solution 
was pipetted into the concentrator, and was centrifuged in a JA-17 rotor in a 
Beckman J2-21 centrifuge at 5,000 xg for 1 h at a time, until the desired 
volume was reached.
To dialyse into a different buffer, the same procedure was followed to 
concentrate the proteins into a minimal amount of buffer. The new buffer was 
then added, and the proteins reconcentrated. This concentration/wash cycle 
was repeated 3 or 4 times to ensure complete replacement of the original 
buffer.
2.7 P ro te in  detection  an d  charac terisa tion
2.7.1 E nzym e assays
2.7.1.1 C itra te  synthase
This method was based on that of Srere (1969). Into a 1 ml glass or 
plastic cuvette was pipetted 200 p,l 0,5 M Tris/HCl pH 8.0, 200 pi 0.5 mM 
DTNB (which was freshly prepared), 100 pi 3 mM acetyl CoA (also freshly 
prepared) and sample added, with dH20 to give a final volume of 0.9 ml. 
Once oxaloacetate was added, the solution had final concentrations of approx.
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0.1 M Tris/HCl, 0.1 mM DTNB, 0.3 mM acetyl CoA, and 0.5 mM 
oxaloacetate. The assay mix was pre-warmed to 25°C, and the reaction started 
by adding 100 pi 5 mM oxaloacetate. Enzyme activity was measured by 
monitoring the increasing absorbance at 412 nm as the product, Co ASH, 
generated a mercaptide with DTNB.
2.7.I.2. L ac ta te  dehydrogenase
This method was adapted from Pesce et al. (1964). Into a 1 ml glass or 
plastic cuvette was pipetted 943 pi phosphate buffer (0.1 M potassium 
phosphate buffer, pH 7.5), 330 pi sodium pyruvate solution (23 mM sodium 
pyruvate in phosphate buffer), and 16.7 pi NADH solution (12 mM sodium 
salt of NADH in phosphate buffer). The solution had final concentrations of 
approx. 94 mM phosphate buffer, 7.6 mM sodium pyruvate and 0.2 mM 
NADH. The assay solution was mixed and pre-warmed to 25°C, sample was 
added, and the enzyme activity measured by loss of absorbance at 340 nm, on 
conversion of NADH to NAD+.
2 .7 .13  M alate  dehydrogenase
This method was adapted from Kun et al. (1967). Into a 1 ml glass or 
plastic cuvette was pipetted 943 pi phosphate buffer (0.1 M potassium 
phosphate buffer, pH 7.5), 330 pi oxaloactetate solution (15 mM oxaloacetate 
in phosphate buffer), and 16.7 pi NADH solution (12 mM sodium salt of 
NADH in phosphate buffer). The solution had final concentrations of approx. 
94 mM phosphate buffer, 0.5 mM oxaloactetate and 0.2 mM NADH. This was 
mixed and pre-warmed to 25°C, sample was added, and the enzyme activity 
measured by loss of absorbance at 340 nm, on conversion of NADH to NAD+.
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2.7.1.4 P y ruvate  dehydrogenase complex
This method is one based on the procedure of Brown and Perham (1978). 
Into a 1 ml glass or plastic cuvette was added 670 pi solution A (50 mM 
potassium phosphate buffer, pH 7.6, containing 3 mM NAD+, 2 mM MgCl%, 
0.2 mM ThDP), 14 pi solution B (0.13 M cysteine HCl, 0.13 mM Li2 CoASH), 
and 14 pi solution C (100 mM pyruvic acid). This was mixed and 
preincubated at 30°C, then sample was added, and the overall complex activity 
measured by increasing absorbance at 340 nm, as the reaction generates 
NADH.
2.7.1.5 2-Oxoglutarate dehydrogenase complex
This method is one based on the method of Brown and Perham (1978). 
Into a 1 ml glass or plastic cuvette was added 670 pi solution A (50 mM 
potassium phosphate buffer, pH 7.6, containing 3 mM NAD+, 2 mM M gC^, 
0.2 mM ThDP), 14 pi solution B (0.13 M cysteine HCl, 0.13 mM Li2 CoASH), 
and 14 pi solution C (100 mM 2-oxoglutarate). This was mixed and 
preincubated at 30°C, sample was added, and the overall complex activity 
measured by increasing absorbance at 340 nm, as the reaction generates 
NADH.
2.7.1.6 C hloram phenicol ace ty ltransferase
This method was adapted from that of Seed and Sheen (1988). Cell 
extracts could be measured for CAT activity using a radioactive assay where 
radiolabeled chloramphenicol was linked by CAT to butyrate, causing the 
chloramphenicol to partition into an organic phase.
To a 1.5 ml eppendorf was added 10 pi 1 M Tris/HCl, pH 7.8, 32 pi
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(IH2 O, 40 pi cell extract, 8 pi 0.446 mM D-threo-[dichloroacetyl-l-^4(p] 
chloramphenicol and 10 pi 2.5 mM butyryl CoA. This was mixed and 
incubated for 1 h at 37°C, and the reaction stopped by adding 210 pi 
TMPDiXylene (2:1). The eppendorf was vortexed for 15 sec, and then spun in 
a bench top centrifuge at 13000 rpm for 2 min. The upper, organic, phase ( 180 
pi) was removed with a pipette, and put in a scintillation vial. To this was
Fractions collected from the HPLC were injected onto the electrospray 
mass spectrometer (ESMS) at 0.02 ml min" F The ESMS was operated by Dr. 
Tino Krell. Data were collected by a computer and processed using the VG 
Mass Lynx software.
2.7.3 SD S-Polyacrylam ide gel electrophoresis (SDS-PAGE)
Proteins could be resolved by the use of SDS-PAGE, with the 
discontinous Tris/glycine buffered system of Laemmli (1970). Prior to 
electrophoresis, an equal volume of Laemmli sample buffer (62.5 mM 
Tris/HCl, pH 6.8, containing 2% (w/v) SDS, 10% (w/v) sucrose and 2% (w/v) 
pyronin Y) was added to the samples. DTT was included to give a final 
concentration of 10 mM. Samples were then boiled for 3-5 min.
Gels with dimensions of 170 mm x 145 mm x 1.5 mm were made from 
the following stock solutions to give a stacking gel of 4.4% acrylamide (with 
0.12 M Tris/HCl, pH 6.8, 0.1% (w/v) SDS, 0.1% (w/v) ammonium 
persulphate and 0.08% (v/v) TEMED), and a resolving gel beneath of 7-15%
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added 3 ml of Ecoscint scintillation fluid, the vial was vortexed to mix the 7
solutions, and the amount of incorporation into product was measured in a 
scintillation counter.
2.7.2 Elot and  phosphory la ted  E l  a  detection by ESM S
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acrylamide (with 0.375 M Tris/HCl pH 8.8, 0.1% (w/v) SDS, 0.1% (w/v) 
ammonium persulphate and 0.08% (v/v) TEMED). The stock solutions were: 
acrylamide (29.2% (w/v) acrylamide, 0.8% (w/v) N ,N ’-m ethlene 
bisacrylamide), stacking gel buffer (0.17M Tris/HCl, pH 6.8, 0.14% (w/v) 
SDS), resolving gel buffer (0.75M Tris/HCl, pH 8.8, 0.2% (w/v) SDS) and 
ammonium persulphate solution (10% (w/v) ammonium persulphate). 
Polymerisation of the acrylamide solution was initiated by the addition of 
TEMED.
Gels were placed in vertical gel electrophoresis kits (Gibco BRL), and 
electrode buffer (24 mM Tris/192 mM glycine buffer, pH 8.3, containing 0.1 % 
(w/v) SDS) added. The samples could then be applied to wells formed in the 
stacking gel, and a current of 40-70 mA applied. Electrophoresis was stopped 
as the Pyronin Y reached the end of the gel and entered the lower buffer 
reservoir.
Peptide subunits could either then be visualised immunologically by 
Western blotting, or by staining the gel for proteins. Gels were stained by 
using 0.04% (w/v) Coomassie Brilliant Blue R in 10% (v/v) acetic acid and 
25% (v/v) methanol, and gently shaking overnight, followed by destaining 
with 20% (v/v) methanol and 10% (v/v) acetic acid.
The sizes of particular proteins could be estimated by using low M, protein 
markers to construct a calibration curve relating relative mobility (Rf, as 
described below), to log(Mr) for each protein standard. In this way, the relative 
molecular mass of sample proteins on the same gel could be determined. The 
standards were: phosphorylase b (94000); bovine serum albumin (67000); 
ovalbumin (43000); carbonic anhydrase (30000); soybean trypsin inhibitor 
(20000); and a-lactalbumin (14000). Relative mobility was calculated by the 
equation :-
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distance migrated by protein
R f  ~   ^ "distance migrated by tracking dye
Where the determination of relative molecular mass of a protein was 
required from a Western blot analysis, prestained Mr protein standards with 
extra protein, myosin (H-chain; 200000), were used for easy identification on 
nitrocellulose.
2.7.4 W estern  blotting
Proteins which had been resolved by SDS-PAGE were transferred to 
nitrocellulose membranes for subsequent immunological detection following 
the method of Towbin et al. (1979).
Gels were overlaid with pre-wetted Hybond-C extra transfer membrane 
and placed into cassettes, between pre-wetted W hatman 3 MM 
chromatography paper. Cassettes were then placed into a Bio-Rad 
Transblot™ tank filled with transfer buffer (25 mM Tris, 0.19 M glycine, 
0.02% (w/v) SDS, 20% (v/v) methanol) and a current of 40 mA applied 
overnight. A non-fixative stain. Ponceau S, was used to check that proteins 
had transferred successfully onto the nitrocellulose. This was then rinsed off 
the membrane with wash buffer or dH2 0 .
Enhanced chem ilum inesence (ECL) was employed to detect 
polypeptides which were of interest. This utilises anti-rabbit antibody linked 
horseradish peroxidase (HRP), which catalyses a chemiluminescent reaction 
(the oxidation of luminol in alkaline conditions) whilst bound to the rabbit 
antisera, which in turn is bound to the antigen of interest. The protocol 
followed is a modified version of the protocol supplied with the reagents.
After blotting of the proteins onto the nitrocellulose, the nitrocellulose 
sheet was placed in a plastic tray, and gently shaken with blocking solution
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(20 mM Tris/HCl pH 7.2, 15 mM NaCl, 5% (w/v) non fat dried milk, 5% heat 
inactivated donkey serum, 0.2% (v/v) Tween 20) for 2 h at 37°C or 4 h at 
room temperature. The nitrocellulose was then incubated overnight, with 
gentle shaking, at 4°C with primary antibody solution (20 mM Tris/HCl pH 
7.2, 1% (w/v) non fat dried milk, 1% (v/v) heat inactivated donkey serum, 
0.1% (v/v) Tween 20, 1:500 - 1:5000 dilution of primary antibody). The 
primary antibody solution was removed, and replaced with wash solution (20 
mM Tris/HCl pH 7.2, 15 mM NaCl, 1% (w/v) non fat dried milk, 1% (v/v) 
heat inactivated donkey serum) and incubated at room temperature with 
agitation for 30 min. This washing procedure was repeated four times, before 
replacing the solution with a secondary antibody solution (20 mM Tris/HCl 
pH 7.2, 150 mM NaCl, 1% (w/v) non fat dried milk, 1% (v/v) heat inactivated 
donkey serum plus 1:1000 dilution of anti-rabbit HRP antibody) and incubated 
at room temperature, with shaking, for 2 h. The nitrocellulose sheet was then 
washed as previously, for 3 washes. It was finally washed in a solution of 20 
mM Tris/HCl pH 7.2 with 150 mM NaCl for 30 min at room temperature, with 
shaking.
To detect the HRP, equal volumes of Amers ham’s ECL detection 
reagents 1 and 2 were mixed, so that there was 0.125 ml of the detection 
mixture for every 1 cm^ of nitrocellulose sheet. The detection mix was poured 
onto the nitrocellulose, on the side where the proteins were bound, and 
incubated for 1 min. The blot was drained and dabbed dry with tissue, 
wrapped in SaranWrap™, and placed, protein side up, in a film cassette. A 
sheet of autoradiographic film (ECL Hyperfilm) was placed on top of the 
nitrocellulose in the dark, and the cassette closed. The film could be exposed 
for a few seconds to half an hour, depending on the strength of signal. The 
film was then developed in a Kodak X-Omat automatic film processor.
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2.7.5 P ro te in  q u an tita tio n
2.7.5.1 L ow ry p ro te in  assay
This method was based upon that of Maxwell et al. (1978) derived from 
Lowry (1951), Solution A (2% (w/v) NaiCOs, 0.4% (w/v) NaOH, 0.16% 
(w/v) sodium tartate and 1% (w/v) SDS in water), solution B (4% (w/v) cupric 
sulphate pentahydrate in water), solution D (equal volumes of Foiin- 
Ciocalteau reagent and dH2 Ü) were required. A standard curve was 
constructed, using BSA at 1 mg/ml, from 0 mg to 150 mg, with each standard 
made up to 1 ml with water. The unknown protein samples to be assayed were 
also made to a final volume of 1 ml. To each assay in the standard curve and 
unknown samples 3 ml solution C (1 ml solution B added to 100 ml solution 
A, prepared freshly) was added, mixed and left for 15 min. Solution D (0.3 ml) 
was then added and mixed, and left for a further 30 min. All the assays were 
then measured for absorbance at 660 nm, the unknown samples being 
compared to the standards for quantitation of protein content.
2.7.5.2 M icro  BCA p ro te in  assay reagen t k it
To measure protein concentrations between 20 |ag/ml and 1.0 |.lg/ml, the 
Micro BCA protein assay reagent kit was used. The kit utilises bicinchoninic 
acid, a molecule which reacts with Cu^"'' to form a purple reaction product 
with a peak absorbance at 562 nm. This allows the quantitation of C1H+ which 
is generated by the reaction of peptide bonds and individual amino acid side 
chains with Cu^+.
Three reagents were supplied; Micro reagent A (MA), containing sodium 
bicarbonate and sodium tartrate in 0.2 M NaOH, Micro reagent B (MB), 
containing 4% (w/v) BCA in water, and Micro reagent C (MC), containing 4% 
(w/v) cupric sulphate pentahydrate in water.
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To assay protein, a working reagent was made. This consisted of 2 vol 
solution MC and 48 vol solution MB mixed together before 50 vol solution 
MA were added and mixed.
A set of protein standards, ranging from 20 pg/ml to 1.0 pg/ml of BSA 
were made, and 1 ml added to 1 ml of the working reagent. Likewise, the 
unknown protein samples were diluted to give a range of concentrations which 
would lie within the standard curve, and 1 ml each dilution added to 1 ml 
working reagent. All the reactions were incubated at 60°C for 1 h, and then the 
absorbance at 562 nm measured. The unknown protein concentrations could 
then be deduced from the standard curve.
2.7.6 T rea ting  PD C w ith A T P
This method was adapted from that used by Hucho et al. (1972). PDC 
was diluted with 2 vol kinase buffer (20 mM potassium phosphate buffer, pH 
7.5, 2 mM MgCl], 2 mM DTT). To start the treatment, 4 mM ATP was added. 
Loss of activity was followed using consecutive assays for PDC activity, 
noting the percentage loss of activity with time. Activity was expected to drop 
to below 5% after 20 min.
2.7.7 T rea tin g  PDC with collagenase
This method was adapted from that used by Rahmatullah et al. (1990). 
PDC was diluted with 2 vol of collagenase buffer (50 mM Tris/HCl pH 7.5, 2 
mM CaCl2 , 3 mM NAD+, 0.2 mM ThDP). Collagenase was added, Img 
collagenase for every lOmg PDC. Loss of activity was followed using 
consecutive assays for PDC activity, and noting the percentage loss of activity. 
Activity was expected to drop to 10-20% after 40 min.
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2.8 DNA m ethods
Except where described, all the following methods were carried out 
under sterile conditions to reduce contamination with DNA from micro­
organisms. Procedures could be carried out on the open bench using sterile I
plasticware, glassware and media. Most plasticware, such as flasks, graduated 
pipettes, syringes, filters, uni versais and polypropylene centrifuge tubes were 
purchased in pre-sterilised packs. Pipette tips for the auto-pipettors were 
placed in sealable racks and autoclaved; eppendorfs were bottled in jars and 
also autoclaved.
2,9 DNA purification
2.9.1 P lasm id  purification
Plasmids were purified in a number of different ways over the course of 
this research. It was found that some methods were more reliable than others, 
and it was advantageous to vary the preparation method depending on how f
much DNA, what purity of DNA and how quickly the DNA was needed.
For small amounts of DNA (up to 5 |lg) required relatively quickly, but 
at a higher expense. W izard™  Mini Preps were routinely employed; for small 
amounts of DNA, but without using expensive kits (e.g. for screening a large 
number of clones by restriction analysis), a standard ‘Mini Prep’ protocol was 
used. For medium to large amounts of DNA (up to 0.5 mg) with only 
reasonable purity (e.g. for restriction digests to obtain segments of plasmids), a 
‘Maxi Prep’ was used. Again, using a Maxi Prep kit could improve yield and 
quality, but at higher expense. Finally, for a large amount (up to 5 mg) of 
highly purified DNA (e.g. for transfection of eukaryotic cells or for permanent 
stocks of DNA) a ‘caesium chloride density centrifugation’ method was 
employed.
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For all these DNA preparations, a culture of bacterial cells, carrying the 
plasmid of interest, was grown as described, in a medium selective for the 
plasmid.
Alkaline lysis forms the basis of all these plasmid preparations, 
commercial and non-commercial, as the means of releasing the DNA from the 
bacterial cells whilst precipitating and pelleting all the protein and 
carbohydrate as well as the genomic DNA.
When not using commercial kits, 3 solutions were used; solution 1 was a 
resuspension buffer, containing 50 mM glucose, 25 mM Tris/HCl pH 8.0 and 
10 mM EDTA, sterilised by filtering. Solution 2 was a lysis buffer, best made 
freshly, which was a 0.2 M NaOH solution with 2% (w/v) SDS. Solution 3 
was a precipitation buffer, made up from 60 ml of 5M K-acetate, 11.5 ml 
glacial acetic acid and 28.5 ml H 2 O.
The ways in which the cells were incubated with each of these solutions 
in turn varied according to each protocol, and are described below.
2.9.2 Sm all p rep a ra tio n s  of plasm ids- M ini P re p s ’
2.9.2.2 P rep a rin g  plasm id DNA using a ‘M ini P re p ’ pro tocol
This method was adapted from Sambrook et al. (1989). Only 1.5 ml of 
an overnight cell culture were needed for this method. The required volume of 
culture was pipetted into an eppendorf and centrifuged at 5000 rpm for 5 min.
The bacteria were resuspended in 100 ql solution 1 and left for 5 min at 
room temperature. Solution 2 (200 jxl) was added and mixed by pipetting the 
solutions up and down gently with a sterile, wide nozzle tip. It was then left on 
ice for 5 min, before 150 jiil solution 3 was added and mixed as before. After 5 
min on ice, the precipitate was pelleted by centrifugation at 12000 rpm in a 
bench top centrifuge, for 10 min.
Equal amounts of phenol and chloroform (230 jll) were added to the
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supernate in a new eppendorf tube. The phases were mixed by inverting the 
tube a few times, and then separated again by centrifuging at 12000 rpm for 10 
min (see phenol extraction, 2.9.6.2). The aqueous phase was pipetted into 
another sterile eppendorf, and 1 ml 100% ethanol was added and mixed. This 
was then incubated at -70°C for 15 min before pelleting the precipitated DNA 
by centrifugation in a benchtop centrifuge at 12000 rpm for 10 min. The 
supernate was removed with a pipette, and the pellet gently washed with 70% 
(v/v) ethanol. If the pellet was dislodged at this stage, the tube could be 
recentrifuged; otherwise, the 70% ethanol could be removed without re- 
pelleting the DNA. The pellet was dried, either by air drying or in vacuo, and 
resuspended in 40 pi TE buffer (pH 7.4- 8.0).
2.9 .2,1 P rep a rin g  plasm id  DNA using a ‘M ini P re p ’ k it
The preferred kit was the W izard™  Plus Mini Preps DNA purification 
system. A bacterial culture (1-3 ml), taken from 5 ml overnight culture, was 
used for each preparation. The cells were pelleted at high speed in a benchtop 
centrifuge for 2 min, the supernate was discarded, and the pellet resuspended 
into 200 pi Cell Resuspension Solution. After lysis with 200 pi Cell Lysis 
Solution, the proteins and genomic DNA were precipitated with 200 pi 
Neutralisation Solution. The lysate was centrifuged for 5 min in a benchtop 
centrifuge at high speed. The supernate was carefully removed, placed in a 
fresh eppendorf tube, and 1 ml resin was added to the cleared lysate. This 
solution was then pipetted into a syringe barrel, which was attached to a 
minicolumn. The solution was filtered through the minicolumn by either 
applying a vacuum to the column to draw the solution through, or by pushing 
the solution through with a syringe plunger. Resin was washed by pushing 
through 2 ml Column Wash Solution in the same manner. The resin was dried 
by centrifuging the column placed in a microfuge tube in a benchtop
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centrifuge for 2 min at high speed. The DNA was finally eluted from the resin 
by applying 50 pi dH20 or TE buffer to the column, allowing the DNA 1 min 
for solubilisation, then centrifuging the column in a fresh eppendorf to recover 
the DNA in the water or TE buffer.
2.9.3 L arge  preparations of plasmids- ‘Maxi Preps’
2.9.3.1 P rep a rin g  plasm id DNA using a ‘Maxi Prep’ protocol
This method was adapted from Sambrook et al. (1989). Overnight 
bacterial culture (200 to 500 ml) was centrifuged at 6000 rpm in a JA-14 rotor 
in a Beckman J2-21 centrifuge at 4°C, for 15 min. The pellet was resuspended 
in 10 ml solution 1, lysed with a further 10 ml solution 2 and then neutralised 
by addition of 7.5 ml solution 3. The lysate was then centrifuged at lOOOOrpm 
in a JA-14 rotor, for 15 min at 4°C.
The supernate was carefully removed, the DNA and RNA was 
precipitated with 1 vol isopropanol, incubated for 15 min, and then pelleted by 
centrifuging for 15 min at 13000 rpm at 4°C in a JA-14 rotor. The DNA pellet 
was dried and redissolved in 2 ml TE buffer, and 2 ml solution 4 (5 M LiCl, 
50 mM Tris-HCl, pH 8.0) added. This was incubated on ice for 10 min to 
precipitate the RNA only, which was pelleted at 13000 rpm in a Corex tube in 
a JA-17 rotor, in the Beckman J2-21 centrifuge for 15 min at 4°C. The DNA 
was precipitated from the supernate by addition of 2 vol absolute ethanol, 
incubated for 15 min on ice, then centrifuged again at 13000 rpm for 15 min as 
previously. The ethanol was removed, the pellet dried, and the DNA then 
resuspended in 500 p.1 TE buffer, and pipetted into an eppendorf tube. To this 
was added 30 )il RNase (lOmg/ml filter sterilised solution of RNase), prior to 
incubation at 37°C for 1 h.
To remove the RNase, a phenol:chloroform extraction was carried out 
(see 2.9.6.2), using 2 washes of phenol:chloroform, and a final wash with
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chloroform. The DNA was precipitated with 0.5 vol 3 M sodium acetate (pH 
5.4) and 2 vol 100% ethanol. This was incubated at -70°C for 10 min before 
being centrifuged at high speed in a benchtop centrifuge at 4°C. The supernate 
was carefully removed, and the pellet washed with 70% (v/v) ethanol. DNA 
was repelleted by centrifuging for 10 min at high speed as before, the 
supernate was removed, and the pellet dried for 5-10 min in vacuo to remove 
all traces of ethanol. The DNA was redissolved in 100-500 \il TE buffer, 
depending on expected yields and preferred coneentration.
2 .93 .2  P re p a rin g  p lasm id DNA using a ^Maxi Prep' Idt
The preferred kit was the W izard™  plus Maxi Prep DNA purification 
system. Cells from an overnight bacterial culture (500 ml), were pelleted at 
5000 xg for 10 min in a centrifuge at 22°C; the supernate was discarded, and 
the pellet resuspended in 15 ml Cell Resuspension Solution and lysed with 15 
ml Cell Lysis Solution. Cell lysis was monitored by ensuring that the solution 
became clear and viscous before proceeding. Proteins and genomic DNA were 
then precipitated with 15 ml Neutralization Solution. The lysate was 
centrifuged for 15 min at 14000 xg at 22°C. The supernate was carefully 
removed, and filtered through a sheet of muslin, 0.5 vol isopropanol added, 
and the DNA pelleted at 14000 xg at 22*^ C in a JA-14 rotor in a Beckman J2- 
21 centrifuge. The supernate was carefully discarded and the pellet 
resuspended in 2 ml TE buffer. Resin (10 ml) was added to the DNA, and the 
solution was pipetted into a maxicolumn. The solution was filtered through the 
maxicolumn by applying a vacuum to the base of the column. The resin was 
then washed with 25 ml Column Wash Solution in the same manner. The resin 
was dried by maintaining the vacuum for 1 min, centrifuging the column in a 
50 mi microfuge tube in a benchtop centrifuge for 5 min at 1300 xg, and 
finally drying by replacing the vacuum for another 5 min. The DNA was
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eluted from the resin and the column by applying 1.5 ml dH20 or TE buffer 
(at 65°C) to the column, allowing the DNA I min to solubilise, and then 
centrifuging the column in a fresh 50 ml tube to recover the DNA in dH20 or 7
TE buffer. To ensure that resin fines were not present, the DNA was filtered 
through a sterile Nalgene filter, included with the kit.
The other kits used were the Qiagen Midi and Maxi Prep kits, expected 
to yield 100 |ug and 500 p-g DNA respectively. The kits were not used 
frequently since they were found to be variable and unreliable. The protocol f
was as follows for both kits;
The bacterial pellet from a 50 ml (500 ml for Maxi) culture was 
resuspended in 4 ml (10 ml for Maxi) buffer PI, then lysed with 4 ml (10 ml) 
buffer P2, and precipitated with 4 ml (10 ml) buffer P3, and kept on ice for 15 
min (20 min). The precipitated material was pelleted at 3000 xg and the 
supernatant retained. The supernate was poured down a pre-equilibrated 
Qiagen column containing a resin which bound the DNA. The column was 
washed with 2x10 ml (or 2x30 ml for Maxi) of buffer QC, and the DNA then 
eluted with buffer QF (5 ml for Midi Prep, 15 ml for Maxi). The DNA was 
precipitated by adding 0.7 ml of isopropanol to the elute, and centrifuged at 
15000 xg for 30 min at 4°C. The DNA pellet was washed with 70% (v/v) 
ethanol, dried, and then redissolved in TE buffer.
2.9.33 P re p a rin g  p lasm id  DNA using caesium  chloride  density  
centrifugation
This method was adapted from Sambrook et a l  (1989). Cultures of cells 
were grown overnight and lysed by the Alkaline Lysis Method as described 
above in the ‘Maxi Prep’ protocol. After centrifugation of the lysate to pellet 
the precipitated carbohydrate and protein, the supernate was taken and all 
polynucleotides precipitated by adding 2.5 vol of isopropanol and incubating
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on ice for 1 h. The various polynucleotides were then pelleted by centrifuging 
at 14000 xg (as described above) for 30 min at room temperature. The 
supernate was discarded, and the pellet air dried.
This pellet was then resuspended gently in 2 ml TE buffer at pH 7.8. Into 
this was dissolved 2 g caesium chloride, and then 200 jil ethidium bromide (10 
mg/ml) added. This was carefully pipetted into a puncturable ultracentrifuge 
tube (Beckman Polyallomer Q u i c k s e a l ™  tubes) by means of a syringe and 
needle, and the tube filled with mineral oil before balancing tubes to within 50 
mg of each other, and sealing. Tubes were then spun at 45000 rpm for 24 h in 
a TEN 100 rotor in a Beckman benchtop ultracentrifuge. The tubes were 
carefully removed, and the tube then clamped to a retort stand. A needle 
punctured the top of the tube to allow air into the vessel, and then the plasmid 
was taken out by means of a syringe and needle puncturing the side of the tube 
to remove the relevant band (Fig. 2.1) .
The ethidium bromide and caesium chloride were both removed from the 
DNA. To extract the ethidium bromide, washes with a butanol solution were 
carried out. The butanol solution was made by saturating butan-l-ol with 
sterile distilled water first, and then saturating the water with caesium 
chloride. An equal volume of the top, butanol, layer was added to the DNA to 
wash out the ethidium bromide. The solutions were gently mixed, and the 
bottom, aqueous phase, was retained. This was repeated until the pink colour 
could no longer be seen in the butanol layer, and then a final wash was 
performed.
Ice cold ethanol (2.5 vol) was added, the sample was incubated on iee for 
a further Ih, and then centrifuged at 12500 rpm for 30 min to obtain the DNA 
pellet. The DNA pellet was resuspended in 20 ml of ice cold 70% (v/v) 
ethanol, and recentrifuged as before. This procedure was repeated until the 
pellet turned from a hard, salty pellet, into a fluffier, salt-free pellet (usually 2 
or 3 ethanol washes). After this, the DNA was air or vacuum dried,
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C o llec t  plasmic  
u sin g  need le
Protein
■ G e n o m ic  and linear p lasm id  D N A  
•Circular plasmid D N A
R N A
Figure 2.1 Collecting plasmid DNA from CsCl/ethidium bromide 
centrifugation
Needles are used to puncture the polyallomer tube containing the DNA 
at two points, the first needle allows air to enter from the top. The second 
needle allows the DNA to flow out, where it is collected for the next stage in 
the purification.
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resuspended in I ml TE buffer pH 7.8, and the spectrum and absorbance 
readings taken for the solution for determining purity and quantity of DNA, as 
described below.
2.9.4 E x trac tion  of linear DNA from  agarose gels
Four different methods for the extraction of DNA from gels were used. j
The original method to extract DNA from gels was the Qiaex DNA Gel 
Extraction kit. Later, however, 3 methods were adopted for individual 
applications. To isolate small fragments of DNA (90 bp or less), the 
MERmaid® kit was used, to extract larger fragments, the W izard™  PCR prep 
was used. The last method, electroelution, was used to isolate a large amount 
of DNA from a large piece of agarose. In all applications, the band of interest 
was located in the gel by UV light and working as quickly as possible. To 
minimise damage to the DNA, the band was excised using a scalpel.
2.9.4.1 Iso lation  of DNA from  agarose gels w ith the  Q iaex k it
The Qiaex kit is similar in methodology to the other two kits, utilising a 
bead technology to bind DNA whilst solubilising the agarose. The beads could 
then be pelleted with the DNA, leaving the agarose and other contaminants in 
solution.
After excising the DNA fragment from the rest of the gel, 300 {il buffer 7
QXl was added for every 100 mg of gel, followed by 10 p.1 Qiaex. The 
solution was incubated for 10 min at 50°C, then centrifuged in a benchtop 
centrifuge at high speed for 30 s to pellet the DNA/Qiaex. The pellet was 
washed twice in 500 |Lil buffer QX2, repelleting the DNA by centrifuging as 
before each time. In the same manner, the pellet was washed twice with 500 [ll 
buffer QX3. The pellet was air dried to remove all traces of ethanol, and
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finally eluted from the Qiaex in 20 fxl TE by resuspending the Qiaex in the TE, 
pelleting the Qiaex as before and removing the supernate, which contained the 
DNA.
2.9.4.2 Iso lation  of sm all DNA fragm en ts w ith the M E R m aid®  
kit
The MERmaid® kit is optimised for the isolation of 10-200 bp of single 
or double stranded DNA fragments from gels, using a silica bead technology 
to bind the DNA in solution and pellet it by centrifugation.
Using the agarose and running buffer included with the kit, a 3% (w/v) 
gel was used to separate fragments, electrophoresing at high voltage (16 
volts/em) for 15 min to minimise diffusion of DNA. The DNA was visualised 
under UV, and the band of interest excised. High Salt Binding Solution (3 vol) 
was added to the gel slice, and 8 p,l Glassfog (DNA binding solution) added 
for every Ifxg DNA expected to be present. The solution was vortexed 
continuously for 10 min and DNA was pelleted at high speed in a benchtop 
centrifuge for 1 or 2 sec. The supernate was discarded and the pellet 
resuspended in 300 jil Ethanol Wash by vortexing for a few seconds. The 
DNA was repelleted by centrifuging as previously, and the ethanol wash 
repeated two more times. The last time the DNA was pelleted, care was taken 
to remove all the ethanol, and the pellet was dried under vacuum for 5 min.
The DNA was then eluted from the Glassfog by resuspending the pellet 
in 2 vol dH20, and heating to 45°C for 5 min. The Glassfog was pelleted by 
centrifuging at high speed for 1 min, and the DNA, now in solution, was 
removed from the Glassfog pellet with the supernate, and transferred to a new 
tube. The elution step was repeated, and the two elutions combined.
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2 .9.43  Isolation of large DNA fragments w ith the W izard ^ M  
PCR prep kit
The W izard™  kit is optimised for the isolation of 200-3000bp of double 
stranded DNA from gels, using a resin to bind the DNA in solution. The resin 
beads are designed to be too large to pass through a filter included with the kit, 
whereas the DNA being eluted is not.
Using standard protocols, either a normal or a low melting point agarose 
gel, in TAB buffer, was used to separate fragments. The DNA was visualised 
under UV, and the band of interest excised. The gel was estimated for volume, 
and for every 300 p,l of gel, a separate preparation was carried out. The gel 
slice was incubated at 65°C until melted (approx. 5 min), and 1 ml resin was 
added. The mixture was gently pushed, using a syringe, or sucked, using a 
vacuum, into a W izard™  minicolumn and 80% (v/v) isopropanol (2 ml) was 
pushed through the column to wash the DNA. The minicolumn was 
centrifuged for 20 sec at high speed in an benchtop centrifuge to remove all 
traces of the isopropanol. The DNA was then eluted from the column and the 
resin by adding 50 jil dH20 or TE buffer to the column, and leaving for 1 min 
before centrifuging the column in a fresh eppendorf tube, as previously. The 
column was disposed of, and the DNA solution in the tube retained and 
checked for purity and concentration.
2.9.4.4 Isolation of DNA from gels using electroelution
This method was taken from Sambrook et al. (1989). DNA was 
electrophoresed through a TAE-agarose gel, as described in 2.11.2.1. The 
DNA was visualised by using 0.5fxg ethidium bromide per ml of agarose in the 
gel. The band of interest was located and the band was excised. The gel slice 
was then placed in a dialysis bag filled with IxTAE buffer (the dialysis tubing
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was previously pre-treated by boiling for Ih in 2%(w/v) NaHCOg, I mM 
EDTA. Dialysis tubing was stored in ethanol and rinsed in dHiO before use). 
Most of the buffer was removed, leaving just enough to surround the gel slice. 
The bag was sealed and placed in an electrophoresis tank filled with TAB 
buffer. The dialysis bag was then elecrophoresed for 2-3h at 4-5volts/cm. 
After this, the current was reversed for 1 min to force the DNA back from the 
wall of the dialysis bag and into the buffer. After opening the bag, the buffer 
was carefully removed, leaving the agarose behind. The DNA was isolated by 
extracting several times with butan-2-ol, another 2 times with 
phenol [chloroform (see 2.9.6.2), and then precipitated with 0.2 vol lOM 
ammonium acetate and 2 vol absolute ethanol at 4^C. The DNA was incubated 
10 min at room temperature, and centrifuged at high speed for 20 min in a 
benchtop centrifuge. The pellet of DNA was then resuspended in 200 jil TE 
buffer, and reprecipitated with 25 |il 3M sodium acetate and 2 vol absolute 
ethanol at 4°C, and centrifuged as previously. This pellet was retained and 
dried under vacuum before resuspending in a small amount of TE buffer.
2.9.5 XgtlO cDNA purification
These methods are taken from Sambrook et al. (1989).
2.9.5.1 Ig tlO  cDNA lib ra ry  am plification
An overnight culture of E. coli C600 (1 ml), grown in LB broth, was 
added to 500 ml LB medium, pre-warmed to 37°C, and incubated, with 
shaking at 37°C for 3-4h. To this, lOdO plaque forming units of XgtlO phage 
were added, and incubated further for 3-5h, or until bacteria appeared to be 
lysed (overnight if necessary).
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2.9.5 2 IgtlO phage purification
Chloroform (10 ml) was added to the culture described in the previous
completely. The pellet was then gently resuspended in 8 ml SM medium (5.8g 
NaCl, 2g MgS0 4 .7 H2 0 , 50 ml IM Tris/HCl, pH 7.5, 5 ml 2% gelatin solution, 
H2 O to 11, sterilised by autoclaving), and mixed with an equal volume of 
chloroform. This was centrifuged in glass Corex tubes at 3000 xg for 15 min 
at 4°C in a JA-17 rotor using a Beckman J2-21 centrifuge. The aqueous phase 
was removed with a pipette and retained.
2.9 5.3 Purifying DNA from IgtlO phage
0.5M EDTA (320 pi) and 400pg of proteinase K were added to the 
aqueous phase obtained in section 2.9.5.2, and mixed; 400 jil 10% (w/v) SDS 
was then added, and mixed. After incubation at 56°C for Ih, the solution was 
cooled to room temperature. An equal volume of Tris-phenol was added, 
mixed by inverting the tube and allowed to settle. The aqueous phase was 
removed, and an equal volume of phenol/chloroform was added, mixed in, and 
allowed to separate as before. The aqueous phase was dialysed overnight in 
1000 vol TE buffer at a pH between 7.4 and 8.0. The dialysed DNA was 
stored at -20°C until required.
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section and incubated a further 10 min. The lysed culture was then cooled to 
room temperature and left for 30 min after adding 500pg RNase and DNase. 7:
NaCl was added to give a final concentration of IM. The solution was slowly 
stirred for Ih on ice, before centrifuging at 11000 xg for 10 min at 4°C, using 
a JA-14 rotor in a Beckman J2-21 centrifuge. The supernate was retained, and 
PEG 8000 was added as a solid to a final concentration of 10% (w/v). This 
solution was slowly stirred on ice for 1 h, and again centrifuged at 11000 xg 
for 10 min at 4°C. The pellet was retained, and the fluid drained from it
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2.9.6.1 Decontamination of DNA
centrifuged for 1 min at 14000 rpm in a bench top centrifuge, and the aqueous 
phase retained for DNA precipitation.
An alternative method was to use one or two phenol/chloroform washes 
(phenol[chloroform:isoamyl alcohol, 24:24:1) as above, followed by a final 
chloroform:isoamyl alcohol wash, as above.
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DNA which was found, through spectrophotom etry or gel 
electrophoresis, to be contaminated by solvents, salts or protein, could be 
purified by precipitating the DNA. If the DNA was in an inappropriate buffer, 
containing too much salt from a previous precipitation, or contaminated with 
ethanol from a precipitation, then the DNA could be re-precipitated, as 
described below. If, however, the DNA was contaminated with protein from 
either a plasmid preparation, a DNA modifying enzyme, or if an oil overlay 
from a PCR reaction was present, it was necessary to include a 
phenol/chloroform extraction before proceeding to the DNA precipitation.
a
2.9.6.2 Phenol/chloroform extraction
This protocol was adapted from Sambrook et al. (1989). The DNA 
solution was mixed with an equal volume of Tris-phenol, and then spun in 
eppendorf tubes at 14000 rpm for 1 min in a bench top centrifuge. The 
aqueous phase was kept and pipetted into a new eppendorf tube, and this 
phenol extraction step was repeated. A final extraction with an equal volume 
of chloroform:isoamyl alcohol (24:1) followed, the solutions were mixed,
;,r
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2.9.63  DNA precipitation
0,1 vol 3 M sodium acetate (pH 5.4) was added, and then 2.5 vol ice cold 
absolute ethanol prior to mixing by pipetting the solution up and down. The 
DNA solution was then ineubated either at -70^C for 15 min or -20^C for I h. 
After the incubation, the solution was centrifuged at 14000 rpm for 30 min at 
4°C in a refrigerated benchtop centrifuge. The supernate was carefully 
removed and replaced with half the original volume of cold 70% (v/v) ethanol. 
Unless the pellet was very small, and unlikely to contain much salt, the pellet 
was resuspended in the ethanol. In either case, this was then re-centrifuged as 
before. The supernate was removed and the pellet dried in air or in vacuo, and 
finally redissolved in TE buffer.
Occasionally 4 M ammonium acetate was used in place of sodium 
acetate, such as in the pCRScript protocol (2.10.4.2), to precipitate large DNA 
fragments, leaving very small DNA molecules and dNTPs in the supernate 
following centrifugation.
2.10 DNA manipulation
2.10,1 Polymerase chain reaction
The polymerase chain reaction is a powerful technique which allows the 
in vitro amplification of DNA, and can be used to detect the presence of 
specific sequences, to clone genes from a population of DNA molecules and to 
create mutated DNA (Arnheim and Erlich, 1992).
During the course of the research all the above uses of PCR were 
employed. It was found that different PCR reactions required different reaction 
conditions, so for each of the desired products the necessary reaction 
conditions had to be optimised and modified from the more general protocol 
below.
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‘Primers’, oligonucleotides based on a known DNA sequence, were 
synthesised either by Pharmacia, by Dr. Veer Math at the Division of 
Biochemistry and Molecular Biology (IBLS), Glasgow University, or latterly 
by Gibco BRL, Inchinnan Business Park, Paisley. In order to amplify DNA, 
two primers were required- one which would anneal to one 3’ end of the DNA 
sequence of interest, and another to bind to the other end of the sequence on 
the other strand of DNA. Primers also frequently incorporated restriction sites 
at their 5’ ends, so that the subsequent reaction product, as well as having the 
DNA sequence of the original DNA, carried extra DNA at either end that 
allowed easy cloning of the DNA into restriction sites present in other DNA 
sequences, such as plasmids.
To carry out a reaction, the following components were added to a 0.5 
ml eppendorf tube: 0.1-1 pg each primer, 10-500 ng template DNA, 5 fil lOx 
reaction buffer, 1 |il nucleotide mix (‘dNTPs’- 25 mM dATP, 25 niM dCTP, 
25 mM dGTP, 25 mM dTTP) and 0.5 p,l Taq DNA polymerase or 1 jul VentR® 
(exo-) DNA polymerase.
If Taq polymerase was used then 3 jll of 25 mM MgCl2  was added, but if 
VentR® (exo-) was used then no MgCl2  was added. The volume was made up 
to 50 \x\ with sterile distilled water. The contents were mixed by tapping the 
tube and centrifuging momentarily in a bench top microfuge. If required, 40 |il 
mineral oil was layered over the reaction.
The tubes were then placed in a Techne PHC-3 Thermal Cycler or a 
Genetic Research Instruments PTC 100 Thermal Cycler, where they were 
heated and cooled to allow dénaturation of all the double stranded DNA, 
annealing of primers to the DNA and then extension of the primers by the 
polymerase to give the required DNA sequence.
Since different methodologies were used, different cycling conditions 
were employed. However, cycling conditions were usually based on the 
following scheme:
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Initial dénaturation 
95°C
4 min
30 cycles of the following with a 1°C per second ramp rate 
1 ) Dénaturation 95°C
1 min
2) Reannealing dO-ôO^C 1
min
3) Extension 72°C
1 min
This was followed by a final extension step:
1) Final extension 72°C
5 min
2) Cooling 4°C
Products were then taken out and kept either at 4°C or -20°C until further use.
2.10.2 Restriction digestion of DNA
Restriction enzymes could be used to cut DNA so that it could be ligated 
to a different piece of DNA. It could also be used in diagnostic procedure; 
detecting changes in the DNA by examining the pattern of DNA digestion 
before and after a manipulation.
Restriction digestion of DNA was performed by diluting or dissolving 
DNA in an appropriate buffer which optimised salt concentration and pH for 
the enzyme being used. If DNA was pure and dissolved in TE buffer, then 
simple addition of a 1 Ox buffer, usually included with the enzyme by the 
supplier, would provide the correct conditions. A final volume of 10 p,l per 1 
|Llg DNA was usually needed, and to this, 1-10 units of enzyme per 1 p.g of
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DNA were added. This was incubated for 1 h at a temperature that depended 
on the enzyme used (usually 37°C). These conditions were occasionally varied 
depending on circumstances.
To digest DNA with more than one enzyme, all enzymes could be used 
at the same time if they required similar conditions. However, if enzymes 
required different conditions, the DNA would be incubated with one according 
to its requirements, the DNA would be precipitated and redissolved in the new 
buffer, as described above, and digested with the second enzyme in its 
required buffer.
2.10.3 Déphosphorylation of DNA
This protocol was based on Sambrook et al. (1989). Purified cut DNA, in 
either water or TE buffer, was dephosphorylated at 5’ protruding termini by 
incubating with calf intestinal phosphatase (CIP). For every 100 pmol of DNA 
(approx. 1.4 p,g of a 5 kb plasmid) 1 unit of enzyme was added, along with an 
appropriate volume of the supplied CIP lOx buffer. This was incubated at 
37°C for 30 min.
CIP was inactivated by adding EDTA solution (pH 8.0) to 5 mM and 
heating the solution to 74°C for 10 min.
2.10.4 Ligation of DNA
Fragments of DNA which were of interest could be ligated into a 
plasmid; once in the plasmid the fragment could be amplified, sequenced and 
manipulated more easily.
DNA could either be ligated into a plasmid ‘sticky ended’ or ‘blunt 
ended’. Sticky ended ligation involved the ligation of a piece DNA, cut at both 
ends using restriction enzymes, to a plasmid which has also been cut with the
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same enzymes. The choice of enzymes used previously dictated how this 
ligation was performed. Typically, the plasmids were cut so that they 
presented two cohesive termini cut by separate enzymes. Ligated into this 
would be a DNA fragment which also had cohesive termini, generated by the 
same enzymes, so that ligation of the DNA fragment into the plasmid could 
only take place in one direction, that is, when the correct cohesive termini 
lined up with each other (Fig. 2.2a).
Alternatively, blunt ended ligation could be used, where the fragment to 
be cloned and the vector into which the fragment was being ligated were both 
blunt ended, with no cohesive termini (Fig. 2.2b). Ligation of one to the other 
could still occur, but proceeds at a slower rate, and with a higher background 
of self ligations of the original vector. A kit used to clone PCR products 
utilised blunt end ligation combined with a restriction enzyme which would 
re-cut non-recombinants.
2.10.4,1 Sticky end ligation
This protocol was adapted from Sambrook et a l (1989). Vector DNA, 
cut with the appropriate enzymes, was mixed with similarly treated foreign 
DNA in equimolar quantities. Greater amounts of foreign DNA could be used 
if necessary. Typically 0.1 jag vector DNA was employed, and 1 gl 5 mM 
ATP, 1 |al T4 DNA ligase and 1 jll lOx buffer was added. The total volume 
was made to 10 jll with dH2 0 , and left for L12 h, then used to transform 
bacteria.
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(a)
Ligate
Sticky ended fragment,  
m ad e  using a restriction  
en zy m e ,  or a pair o f  
e n z y m e s  to achieve  
directional ligation
Sticky ended plasmid,  
made using the sam e  
restriction 
en zy m e /en z y m  es
Plasmid containing  
insert
Blunt end fragment, e.g. 
m ade by PCR
Blunt ended plasmid,  
made using a restriction  
e n zy m e
Ligate
Plasm id containing  
insert
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Figure 2.2 Blunt and sticky end ligation
The diagram at the top (Fig. 2.2a) represents the situation where a piece 
of DNA has "sticky ends" or "cohesive termini", i.e. a restriction enzyme has 
cut each strand at a different position, leaving a small 2-4 base overhang. This 
overhang can interact, through base-pairing, with another sticky end which has 
the complementary sequence. A plasmid cut with the same restriction 
enzymes, for instance, would bind in this way. The ligation proceeds quickly, 
since the interaction is specific.
The diagram below it (Fig. 2.2b) represents the situation where a piece 
of DNA with "blunt ends", i.e. 5’ and 3’ termini which end at the same point 
ligates to a plasmid with similar termini. Such is the case when a PCR product 
ligates into a plasmid eut with an enzyme that leaves blunt ends. This ligation 
proceeds slowly since it is non-specific.
I
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2.10.4.2 The p C R S c r i p t ™  cloning protocol (blunt end ligation)
The pCRScript™  cloning protocol was a kit and methodology devised 
and supplied by Stratagene. This procedure allows relatively easy cloning of 
PCR products into a pBluescript based vector, and subsequent transformation 7
into E. coli XLl Blue MRP’ Kan. The protocol below was a slightly modified 
version of that given by Stratagene®, to give more transformants per plate, and 
optimised for the particular PCR reactions.
A PCR product could either be isolated and purified through agarose gel 
electrophoresis followed by a gel extraction, as described above, or, if the 
PCR product was pure enough, a selective precipitation was used to remove 
excess PCR primers. STE buffer (0.1 vol) was added to the PCR product, plus 
an equal volume of 4 M ammonium acetate. To this new solution was added 
2.5 vol (approx. 5 vol original PCR product) of absolute ethanol, at room 
temperature, was added, mixed, and immediately centrifuged at 14000 rpm for 
20 min in a bench top centrifuge. The pelleted DNA was then washed with i
200 jll 70% (v/v) ethanol, and centrifuged at 14000 rpm for 10 min as before.
After drying the DNA pellet in vacuo, it was finally resuspended in TE buffer.
Though the protocol advised resuspending the pellet in the original volume 
(50-100 jll), it was found to be more helpful if the DNA was concentrated 
during this step by resuspending in 10-50 jtil of TE buffer, since PCRs were 
often found to yield less DNA than was supposed by the manufacturers of the 
kit. The DNA was then stored at 4°C until further use.
If the PCR product was generated using Taq, then a ‘polishing’ step was 
required, since Taq polymerase can leave ends which are not blunt-ended, but 
have 3’ overhangs (Hu, 1993). To a 0.5 ml eppendorf tube, 10 jtil purified 
DNA was added, and then the following supplied reagents; 1 jll 10 mM dNTP 
mix (2.5 mM eaeh), 1.3 jtil 10 x polishing buffer, 1 fil cloned Pfu DNA
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polymerase (0.5 units). This was mixed by pipetting up and down, a 20 [il 
overlay of mineral oil was added, and the reaction mix incubated at 12^C for 
30 min. The DNA product was stored at 4°C until further use.
The amount of PCR product used in the cloning protocol was optimised 
to give insert end to vector end ratios of between 40:1 and 100:1. This was 
deduced using the calculation:
( 2 x  10(^)
Since 10 ng of vector was used in the cloning reaction, this entails using 36-90 
ng of a 300 bp insert.
The following components which, with the exception of the insert DNA 
and distilled water, were supplied by the manufacturer, were added in order to 
a sterile 0.5 ml eppendorf tube; 1 [il pre-digested pCRScript vector (10 ng), 1 
[tl lOx reaction buffer, 0.5 [il 10 mM rATP, 2-4 fil PCR reaction/polishing 
reaction, 1 [il of SrfJ restriction enzyme, 1 fil T4 DNA ligase and dH2 0  to 
make the volume up to 10 [il. This was mixed by pipetting the solutions up 
and down, and then incubated for 1 h at room temperature. The reaction was 
stopped and enzymes inactivated by heating the reaction mixture to 65 ®C for 
10 min; this was stored at 4°C until it was required for transforming the E. coli 
XLl Blue MRF’ Kan.
E. coli XLl Blue MRF’ Kan were supplied by the manufacturer of the 
kit as frozen ‘supercompetent’ cells, stored at -80°C. The cells were thawed on 
ice, and then aliquoted into 40 [il amounts in sterile 1.5 ml eppendorfs. To 
each aliquot was added and mixed 0.7 [il (3 -mercaptoethanol (a final 
concentration of 25 mM). Cell suspensions were incubated on ice for 10 min, 
with oecasional swirling, until addition of 2  [il of the previous cloning 
reaction. This was then mixed by gently swirling the eppendorf, and left on ice 
for 30 min. The cells were heat pulsed for 45 sec at 42°C, put on ice for 2 min,
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and 0.45 ml of SOC medium, preheated to 42°C, was pipetted into the cells. 
The transformation mix was incubated, with shaking, at 37°C for 1 h, before 
spinning down the cells at 6500 rpm for 1 min, resuspended in 100 jil SOC 
medium, and then plated onto LB ampicillin/X-gal/IPTG plates. These were 
incubated overnight at 37°C, and white colonies taken to investigate for the 
presence of cloned DNA inserts.
2.11 DNA detection and analysis
2.11.1 Spectrophotometry
This protocol was taken from Sambrook et a l  (1989). DNA absorbs UV 
light with a maximum absorbance around 260 nm, whereas protein absorbs 
more at 280nm. To assess the purity of DNA, absorbance readings at 260 and 
280nm could be taken using a Shimadzu UV-Visible scanning 
spectrophotometer. Routinely, 5 [tl DNA sample was added to 995 jil TE 
buffer or water in a quartz cuvette, which had already been used to zero the 
absorbance readings on the spectrophotometer. The 280 nm and 260 nm 
readings were then measured. When the ratio of 260 nm / 280 nm was greater 
than 1.8, the DNA was assumed to be pure. The reading at 260 nm could be 
used to estimate the DNA concentration; an absorbance reading of 1.0 related 
to 50 jig/ml of double stranded DNA, 40 jig/ml of single stranded DNA and 
20 jig/ml of dNTPs.
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2.11.2 Gel electrophoresis
2.11.2.1 Agarose gel electrophoresis
This method was adapted from Sambrook et al. (1989). DNA could be 
separated and visualised by gel electrophoresis- a method which allowed an 
estimation of the size and concentration of DNA, and, if required, separation 
of a specific DNA fragment away from a population of DNA molecules. For 
this, various gel sizes and concentrations were used, depending on how many 
samples of DNA needed to be analysed, and the expected sizes of the DNA 
fragments. Volumes of agarose varied between 50 ml and 125 ml, and 
concentrations of agarose in buffer varied between 0.7% and 2% (w/v). The 
type of agarose and buffers used depended on the use of the gel; for 
visualisation of DNA only, the buffer used was TBE, with normal agarose 
(0.7-1.5% (w/v)), whereas gels whieh were used to isolate a DNA fragment 
from a population used low melting point agarose (l%-2% (w/v)) in TAB 
buffer.
To make a gel, a solution of melted agarose was prepared. The required 
volume of Ix buffer was poured into a conical flask, and to this was added 
powdered agarose to the desired concentration. This was boiled in a 
microwave oven to melt the agarose. The solution was allowed to cool slightly 
before being poured into a gel base. A well-forming comb was then inserted at 
one end, and the gel was allowed to set at room temperature. Once set, the tape 
which sealed either end was removed, the comb taken out, and the gel, with 
base, placed in an electrophoresis tank. The tank was filled with the same 
buffer as was used in the gel, to a level where the gel became submerged.
To each DNA sample was added 0.2 vol DNA gel loading buffer (from 
Promega) and mixed. The samples were then gently pipetted into the wells in 
the gel along with a DNA ladder of known DNA fragment sizes to compare to 
the unknowns of the samples. Elecrophoresis was carried out with the negative
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electrode nearest the wells, at a constant voltage of 1 - 8  volts/cm between the 
two electrodes. The progress of the electrophoresis was monitored by the two 
dyes in the loading buffer with bromophenol blue travelling approx. as a 300 
bp fragment would and xylene cyanol moving at approx. the same speed as a 
4000 bp fragment.
DNA could be visualised by staining the gel with a 0.5 [tg/ml solution of 
ethidium bromide in water for 30 min, followed by destaining for a further 30 
min in water only, then viewing the gel on a UV transilluminator. The gel was 
photographed using either a camera or video imaging equipment. Calculation 
of sizes of DNA was carried out by comparing to DNA markers.
2.11.2.2 Acrylamide gel electrophoresis
This protocol was adapted from Sambrook et al. (1989). When an 
agarose gel was not precise enough to estimate sizes of DNA fragments, a non 
denaturing acrylamide gel could be used. The gel was of a similar type to the 
SDS-PAGE, substituting the buffer system and removing the SDS.
Gels, again with dimensions of 170 mm x 145 mm x 1.5 mm, were made 
from the following stock solutions; acrylamide (29% (w/v) acrylamide, 1 % 
(w/v) N,N’~methlenebis acrylamide), 5xTBE (445 mM Tris-borate, 10 mM 
EDTA (pH 8.0), and a 10% (w/v) ammonium persulphate solution. The 5-12% 
gel was made with 16.7-40% acrylamide solution, IxTBE (from a 5xTBE 
stock) and 0.7% (w/v) ammonium persulphate stock solution. Polymerisation 
was initiated with 0.035% (v/v) TEMED.
Gels were placed in vertical gel electrophoresis kits (BRL), and IxTBE 
buffer poured into the eleetrode tanks. The samples, with an appropriate 
loading buffer, could then be applied to wells formed in the gel, and a voltage 
of l - 8 V/cm applied. Electrophoresis was stopped when the DNA of interest 
was presumed to be in the middle of the gel, as judged by the dyes in the
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loading buffer.
DNA was visualised in the same manner as agarose gels, namely by 
staining the gel with a 0.5 [ig/ml solution of ethidium bromide in water for 30 
min, followed by destaining for a further 30 min in water only. Again, the gel 
was viewed on a UV transilluminator, photographed using either a camera or 
video imaging equipment, and the DNA sizes calculated by comparison with 
the DNA markers, either roughly by eye or graphically.
2.11.2 .3  D e n a tu r in g  (sequencing ) a c ry la m id e  gel 
electrophoresis
Two kinds of sequencing gel were used, one for automated sequencing 
and one for manual. The glass plates for both sequencing gel types had to be 
cleaned prior to use, firstly with a detergent and secondly with 70% (v/v) 
ethanol. The sequencing gel used for manual sequencing was a Bio-Rad 
Sequi-Gen sequencing cell.
For manual sequencing, the main concern in eleaning the plates was to 
prevent the formation of bubbles whilst the gel was poured. Soap or washing 
up liquid was used to clean the plates first, and an isopropanol wash to finish 
after an ethanol wash was found useful to clean the plates of dust, using a lint 
free paper towel. The spacers were placed between the plates, and the plates 
clamped together.
A sealing gel was made to seal the base of the assembly, prior to pouring 
the gel solution into the plates. The gel solution used for the main gel, Gel- 
Mix® 6  (7 M urea, 100 mM Tris-borate (pH 8.3), 1.0 mM Na2 EDTA, 5.7% 
acrylamide, 0.3% (w/v) N,N’-methylene bisacrylamide), was also used to seal 
the base rapidly. To 50 ml gel solution was added 200 [ll 25% (w/v) 
ammonium persulphate and 200 [il TEMED. This was poured into the sealing 
gel casting tray, and was absorbed into the filter paper lining the base of the
1 0 0
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tray. The plate assembly was placed into the tray, on top of the filter paper, 
and the sealing gel rose 3-4 cm into the plates by capillary action, and set 
within 5 min. The casting tray was removed, leaving the sealing gel at the end 
of the plates. Into the top of the plate assembly was poured the main gel, made 
with 150 ml gel solution, 150 [ll 25% (w/v) ammonium persulphate and 150 [tl 
TEMED. The assembly was held at a slight angle to allow the gel solution to 
flow down. If any air bubbles were generated, a Promega ‘Bubble getter’ 
could pull the bubbles out. The comb or the well former for the sharktooth 
comb was then put in place at the top of the gel, and the top of the assembly 
was clamped together using bulldog clips. The gel was allowed to polymerise 
overnight.
A more stringent protocol was used to clean the plates of the automated 
sequencing gel for two reasons. The plates had to be dust free so there were no 
air bubbles, as with the manual sequencing. Secondly, however, the plates had 
to be optically clear for the laser scanning the gel for the labelled DNA (see 
2.11.3); the laser was particularly sensitive to any dirt on the glass. The 
detergent wash was carried out with Alconox^^, using plenty of lint free 
paper towels to eliminate dust. The 70% (v/v) ethanol wash also used many 
lint free towels. The spacers were placed between the plates, and the plates 
sealed together using Permacel™  tape.
The automated sequencing required manufacturer’s gel solutions to be 
used, and the method followed was that of the instructions on the bottle; 2 0  ml 
buffer reagent were mixed with 80 ml monomer solution for each 1 0 0  ml 
required, with 0 . 8  ml 1 0 % (w/v) ammonium persulphate added to initiate 
polymerisation. The gel mix was poured into the gap between the two plates. 
Whilst pouring, the plates would be held at an angle to allow the gel to flow 
down. Air bubbles could be pulled out with the ‘bubble getter’. Once the 
plates were filled with gel solution, the assembly was laid flat, and the well 
former for the sharktooth comb was slotted into the gel. The gel was allowed
1 0 1
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to polymerise for 3-4 h. |
2.11.3 Sequencing
7Both methods used employed the Sanger dideoxynucleotide termination -
method for sequencing. This method uses in vitro synthesis of DNA based on 
the template DNA, terminated at specific points along the DNA molecule, 
depending on the sequence.
In manual sequencing, the DNA is radiolabelled. Four reactions are used, |
each one corresponding to DNA which is terminated by a different 
dideoxynucleotide, either ddATP, ddCTP, ddGTP or ddTTP. The reactions are 
electrophoresed through a gel, and separate according to size. The sequence is 
then read by exposing the gel to a photographic film. %
In automated sequencing, there is only one reaction, and the 4 different 
dideoxynucleotides are in the same tube. The different bases are identified i.
through fluorescent probes; each dideoxynucleotide species has a different ;}
fluorescent label attached. When the reaction is electrophoresed, a computer 
reads the sequence as it passes through the gel by exciting the fluorescent label ji
with a laser.
y
2.11.3.1 M anual sequencing
The protocol followed was that of Amersham’s Sequenase version 2.0.
Single stranded DNA (approx. 1 [tg) could be used directly in the sequencing 
reaction, however, double stranded DNA had to be denatured first.
To denature double stranded DNA, 3-5 [ig of DNA was incubated at y
37°C for 30 min with 0.1 vol 2 M NaOH, 2 mM EDTA. The DNA was then 
precipitated by 0.1 vol of 3 M sodium acetate (pH 5.5) and 3 vol ethanol. The 
DNA was pelleted by centrifuging in a benchtop centrifuge for 20 min at high
1 0 2
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speed, the supernate discarded and the pellet washed with 70% (v/v) ethanol, 
prior to redissolving in 7 p,l dH2 0 .
The DNA, single stranded or double stranded, could then be used in a 
sequencing reaction. The protocol included with Sequenase Version 2.0 was 
adhered to strictly, using a thermal cycler to achieve the temperature 
variations.
Primer DNA was added to the template DNA, in a 1:1 molar 
stoichiometry, along with reaction buffer. The sample was heated to 65®C for 
2  min, then the temperature was reduced to room temperature over a period of 
30 min, and finally put on ice. Labelling mix, [^^S]dATP, polymerase and 
DTT were added to the annealed DNA, and incubated at room temperature for 
5 min. This reaction mixture was added to 4 separate tubes, each containing 
one of the 4 dideoxynucleotides. The extending DNA was allowed to 
incorporate these nucleotides for 5 min before the reaction was stopped with 
the addition of a ‘stop solution’.
2.11.3.2 Automated Sequencing
Here, the Taq D y e D e o x y ™  Terminator Cycle Sequencing Kit protocol 
was followed. Single stranded DNA (500 ng) could be used, or 1 p,g double 7
stranded DNA.
Firstly, a reaction premix was made, which contained the buffer, the 
polymerase, each of the labelled ddNTPs and dNTP mix. This mixture was "
added to the template DNA, along with 0.8-3.2 pmol of primer. The reaction 
was then cycled through these temperatures:
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1) 96°C for 30 sec
2) 50°C for 15 sec
3) 60®C for 4 min
This cycle was repeated 25 times, then chilled to 4°C. The reactions were
purified by phenolichoroform extraction twice, followed by an ethanol/sodium 
acetate precipitation. The precipitated DNA was finally boiled in 4 fil 
formamide for 2  min, then kept on ice until loading onto the automated 
sequencer gel.
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3.1 Introduction
The E2 subunits from all the oxoacid dehydrogenase complexes possess 
unusually elongated mitochondrial matrix targeting presequences, varying in 
humans from 61 amino acids for BCDC-E2 (Laii et a i ,  1992) to 73 amino 
acids for PDC-E2 (Patel et a l ,  1994). Most human matrix-targeted 
polypeptides utilise a targeting sequence comprising only 19-40 amino acids, 
and as few as 12 amino acids have been shown experimentally to target a 
polypeptide (Hurt et a i ,  1985). Other extended mitochondrial targeting 
presequences are known to carry additional information, such as the
cytochrome b2 polypeptide which carries an N-terminal mitochondrial 
targeting signal followed by a inter-membrane space targeting signal activated 
once inside the mitochondrion, and the ATPase subunit 6 which has an 
extended presequence to aid in antifolding. Does the extended presequence of 
PDC-E2 also carry additional information?
To uncover the properties and physiological roles of a protein 
presequence it is common to fuse the presequence to the N-terminus of a 
‘reporter protein’ and note the change in the behaviour of the reporter effected 
by the presequence. To achieve this a chimaeric gene construct is made using 
DNA coding for the presequence fused to a reporter gene, held within an 
expression vector. This vector can be introduced into suitable cells, where the 
chimaeric construct is then expressed by the host cells, and the effect of the 
protein presequence can be evaluated.
A commonly used reporter gene is that coding for the bacterial enzyme 
chloramphenicol acetyltransferase (CAT). It can be detected relatively easily 
by enzymatic assay and immunological approaches. It is also a prokaryotic 
enzyme and is not easily confused with any proteins naturally present within 
eukaryotic cells, the common subject of such work. As such, this enzyme is 
most commonly used for promoter/repressor analyses (see Bryans et a l,  1992
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or Kamrud et al, 1995 for an example).
In the research detailed here, where the presequence of human PDC-E2 
is under investigation, the use of CAT as a reporter gene is particularly 
appropriate, since the behaviour of CAT and PDC-E2 are so similar. Both are y
acetyltransferases, possessing similar 3-D structures, as demonstrated by 
Mattevi et a l  (1992). As mentioned previously, it is also thought that the 
presequence of PDC-E2 may be involved in preventing premature assembly of 
the E2 into trimers (McCartney et al, 1997; Hunter and Lindsay, 1986) in the 
cytosol, but once cleaved allows PDC-E2 to form trimers before assembling 
into a 60-mer; here again CAT is useful, since it is only enzymatically active 
as a trimer (Fig. 1.5). CAT has also been shown to be an effective reporter for 
mitochondrial targeting studies in plants (Boutry et a l ,  1987), and therefore 
stands as a tried and tested method for this work.
After expressing an E2 presequence-CAT construct in host cells, the role 
of the pre sequence in targeting and assembly can easily be deduced. Targeting |
can be monitored by cell fractionation, followed by detection of CAT in 
various subcellular fractions by immunological approaches. Assembly of CAT 
into enzymatically active trimers can be followed by quantifying the 
enzymatic activity of CAT.
J.
n.3.1.1 Reasons for constructing a new vector
A number of methods have previously been used to make constructs for
■?:î
investigating presequences. Two common approaches involve linking the 
DNA coding for the presequence to a reporter gene. The original method 
employed DNA restriction fragments isolated from plasmids containing the 
relevant genes. The excised presequence fragment from one plasmid was 
ligated to the reporter gene excised from another plasmid, and the ligation 
product was subsequently cloned into an expression vector (see Hurt et al,
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1984).
The second, newer method, follows a similar approach, linking 
presequence DNA to a reporter gene by overlap extension by PCR, a method 
for joining DNA molecules exactly with no restriction sites or intervening 
DNA sequence (Horton et al., 1989). Again, the chimaeric product is cloned 
into an expression vector to express the new gene.
Both approaches require starting the procedure afresh for each 
presequence construct. When making many presequence-reporter gene 
constructs, or a range of presequence mutants, such methodologies can be 
labour intensive. A simpler method would be to obtain a plasmid with the 
reporter gene, and ligate various presequence DNA species into a multiple 
cloning site at the beginning of the reporter gene. For each construct, one 
would use the same plasmid, but exchange the presequence DNA by excising 
the old sequence and ligating in the new.
However, expression vectors containing the CAT gene are not usually 
designed for presequence work, and do not contain any restriction sites near 
the start of the gene. Instead, most of the unique restriction sites are present as 
a result of plasmid construction, or specifically designed to be in the promoter 
region. The nearest available site found for insertion of the presequence DNA 
in any of the plasmids investigated was a Cpol site, 60 bp upstream of the 
initiator codon for CAT in pBLSV CAT. Inserting a presequence at this point 
would have caused the translation of a portion of promoter sequence and 
introduced 20 extra amino acids to the presequence, which would have 
compromised the validity of the proposed study by substantially altering the 
presequence.
It was therefore decided, for this research and for general targeting 
studies on N-terminal presequences, to construct a plasmid which had 
restriction sites at the start of the CAT gene. A strategy was devised to mutate 
a currently existing CAT expression vector which would generate a suitable
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CAT. The restriction sites chosen were designed to result in minimal alteration 
to the amino acid sequence of CAT whilst allowing directional cloning of
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cloning site for presequence insertion. To minimise the amount of DNA 
between the presequence and the CAT open reading frame, it was decided to 
put the cloning site after the first coding ATG of the CAT gene, eliminating 
the incorporation and translation of promoter sequence. To allow directional 
cloning of sequences, 2 restriction sites would be required. The mutations 
generating these 2 new sites were also designed to minimise the changes to 
both the CAT protein and the presequence.
In summary, this new vector would be designed specifically for 
presequence analyses, using a simple digestion/ligation method to obtain 
constructs with minimal alteration to the presequence or the reporter gene, and I
utilising a reporter enzyme which can relay information about the effect a 
presequence has on expression, intracellular location and assembly.
3.1.2 Method for mutagenesis
A plasmid, named pBLSV CAT, was kindly provided by Mr. Grant 
Scotland, along with a restriction map and a full DNA sequence. This plasmid 
is a variant of pGS7, missing the 300 bp RDI insert; the history of the plasmid 
can be found in Scotland & Houslay (1995) and Luckow & Shatz (1987). In 
brief, the plasmid is based on pBLCAT2, an expression vector for CAT 
constructed in pUC18. An SV40 promoter drives the expression of CAT in 
mammalian cells, with an SV40 termination signal after the CAT gene. An 
ampicillin resistance gene provides a selectable marker for cloning the plasmid î
in bacterial host cells (Fig. 3.1).
Since no restriction sites lay near the start of the CAT gene, it was 
decided to mutate the DNA sequence to give 2 unique restriction sites for 
directional cloning of DNA fragments directly behind the initiator codon of
:l
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presequence DNA. The two restriction enzymes chosen, and their 
corresponding sites, were Nhel and HindlU, as shown in Fig. 3.2. This causes 1
minimal alteration to the expressed polypeptide, but does require the mutation 
of 8 bases in the DNA.
To change the original DNA to the new version, it was decided to excise 
a length of DNA containing the region to be mutated, using restriction 
enzymes, and replace it with a corresponding DNA molecule with the desired 
alterations, as shown in Fig. 3.3. A and B were the only usable sites in the 
region. A and B were both sites for BsiMl cleavage; site A also had a sequence 
suitable for Cpol digestion which overlapped with the site for BsiMl (Fig.
3.4).
To allow directional insertion of the mutated form of this DNA section, 
it was proposed to digest pBLSV CAT first with Cpol. This would cut the 
vector, and inactivate the ‘A’ site of making the ‘B’ site unique. To
show that this could be done, 1 jig plasmid was digested for 1 h at 30°C with 
40 units (2 p.1) Cpol (to guarantee digestion) in 10 ql Cpol buffer, followed by 
addition of 20 units (2 |il) of BsiMl and 10 pi BsiMl buffer and incubated for 
Ih at 55°C. Cpol was first shown to linearise the plasmid, cleaving at a single 
site. The double digest with Cpol and BsiMl was then compared to a single 
digestion with BsiMl only, on an acrylamide gel (not shown). A difference in 
the size of the smaller fragments (the DNA to be discarded) made by each 
digest was seen, indicating that Cpol had inactivated the A site of jB^/MI as 
predicted.
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Xinall
PstI
Rsiil
lacZ
-Xhol 620
SV40 promotor
Amp R
pBLSV CAT
CAT4544 bp
ORI
SV40 terminatorlad
Clal
BsiXl
Sad
Figure 3.1 Diagram of pBLSV CAT
This plasmid diagram illustrates how the SV40/CAT construct has been 
ligated into the multiple cloning site of pUC18.
The origin of replication (‘ORI’) allows replication of the plasmid in 
host bacteria. The ampicillin resistance gene (‘AmpR’) allows selection of the 
plasmid in bacteria.
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II
Chapter 3: Constructing a Novel Vector
ATG GAG AAA AAA ATC ACT GGA
Met Glu Lvs Lys He Thr Glyi
ATG CTAteCy^Met I Leu I Ala AAGICTTIa CT GGALys I Leu I Thr Gly
first 7 codons for CAT 
in pBLSV CAT
H in d lll
AIG^CTA GOA 
TRC GAT C
G CTT 
TTC GJ^ T | ^
ACT GGA 
TGA CCT
Figure 3.2 Mutations incorporated into pBLSV CAT to generate new 
restriction sites
The top diagram shows how many mutations must be made in order to 
obtain the 2 restriction sites shown in the bottom diagram. In all, 8 base 
changes are needed. This results in 3 amino acid substitutions, glutamine to 
leucine (a major change), lysine to alanine (a major change) and isoleucine to 
leucine, which is a conservative substitution.
Changes in the first few amino acids are expected to have little or no 
effect on the behaviour of the native enzyme since the N-terminal region has 
minimal structure, and lies outside the rest of the protein (Fig. 1.5).
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SV40
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Amp R
pBLSV CAT
4544 bp CAT
CUT
OR]
SV40
terminator
ISOLATE
ISOLATE
AND
MUTATE
LIGATE
mutated 
pBLSV CAT
4544 bp
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Figure 3.3 How to m utate the plasmid
Restriction sites near the point of mutation are chosen (A and B), and the 
plasmid digested with these enzymes. The treated plasmid is isolated from the 
fragment released by digestion. A mutated version of the fragment is made, 
and then ligated back into the digested plasmid. The plasmid is now restored 
to its original form, but with the mutations incorporated into the fragment.
114
Chapter 3: Constructing a Novel Vector
Cpol BsiMl 
631
5 ’ rcC G Œ A i lT T C  c c g g g t c  g a g  g a g  c t t g  g c g a g a t t t t  g a g  g a g  c t a a  g g
3' pCC&GGCOT
T
AAG GGC CC AG CTC CTC GAAC CGC TCT AAAA GTC CTC GATT CC
Nhel Hindi 11 
W 690 ,6 9 7
AAG CTA AAATUUt  AGC ipftUC'i"!'ACT GGAT ATACCACCGT TGATAT ATCC CA 
TTCGATTTTA CGATCG' : TTCGAA CGACCTATATGGTGGCAACTATATAGGGT\ n— i
Met C A T -^
ATG GCA TCGT AAA GAA CATT TTGAGG CATT TCA GTC AGTT GCT CAATGTA CCT 
TAG CGT AGCATTTCTT GTAAAAC TCC GTAAAGT CAGTCAACGAGTT ACAT GGA
ATA ACC AGAC CGT TCAGCTG GAT ATT ACGG CCT TTT TAAAGAG CGT AAAG AA 
TAT TGG TCTG GCAAGT CGACCTATAATGCC GGAAAAATTT CTG GCA TTTC TT
AAA TAA GCAC AAG TTT TATC CGGCCTTTAT TCA CAT TCTTGCCCGCCTGATGA 
TTTATTCGTGTTCAAAATAGGCCGGAAATAAGTGTAAGAACGGGCGGACTACT
B BsiMl
m 897 
ATGCTCAlX'CGGA
TAG GAG T ^ GGCC^
Fig 3.4 The region chosen in pBLSV CAT for mutation and replacement
The sequence above shows the positions of the restriction sites in the 
fragment removed from pBLSV CAT. The positions of the planned Nhel and 
Hindlll sites are shown.
It can be seen that BsiMl sites are at positions A and B, and a Cpol site at 
A. Cleavage of pBLSV CAT by Cpol linearises the plasmid, and inactivates 
the A site of AriMl cleavage by removing part of the recognition sequence. As 
the diagram shows, only two bases of the recognition sequence are left on the 
other strand after cleavage with Cpol.
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3.2 Site Directed Mutagenesis by Polymerase Chain Reaction
To generate the new insert, it was decided to utilise the polymerase chain 
reaction, or PCR, to synthesise a mutant version of the DNA fragment.
PCR is an in vitro enzymatic method for the amplification of specific 
sequences of DNA (see Bej et al, 1991; Arnheim & Erlich, 1992, for a 
review). Two oligonucleotides are designed to anneal to specific sequences of 
DNA flanking the region to be amplified, one anneals to the 3’ end of one 
strand, and the other binds to the 3’ end of the complementary strand. A DNA 
polymerase will then treat these oligonucleotides as primers and synthesise 
daughter strands complementary to the template DNA.
In PCR this process is repeated cyclically, denaturing the DNA at high 
temperature (at or above 94°C), annealing the primers at their melting 
temperature, then extending the primers at a temperature optimal for the 
polymerase. Since most polymerases are inactivated at the high temperatures 
required for denaturing DNA, thermostable polymerases, such as Taq, VentR® 
and Pfu polymerase are used. The optimal temperature for extension with 
these is between 72°C and 75°C. In repeated cycles, the synthesised daughter 
strands become the template for further synthesis, and the region of DNA 
between the two primers is therefore amplified exponentially.
This protocol can be used for site directed mutagenesis in two ways. The 
simplest way is to carry out a normal PCR with an altered primer (Fig. 3.5). 
Primers do not need to be exact complements to the target sequence DNA; 
there can be room for a small number of differences between them and the 
sequence they will bind to specifically. During PCR, a slightly altered primer 
can be incorporated into the daughter strands, giving a product mutated from 
the original.
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Figure 3.5 Site directed mutagenesis by PCR, using a one stage method
A PCR product is generated based on the template DNA (1). However, 
incorporated into one or both primers are mutations, shown in red with a cross. 
This leads to a product which is identical to the original template DNA, but 
with mutations where the primers diverged from the original sequence (2).
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The second method uses a two stage PCR (Fig. 3.6), as described by 
Higuchi et a l  (1988). Two PCRs are carried out on the same template DNA, 
one amplifies one section of the DNA, and the other amplifies the rest. The 
products of two PCRs overlap in the middle, in the region of the ‘inner’ 
primers. The inner primers both contain the mutations and complement each 
other. When both PCR products are mixed, denatured and allowed to anneal, 
some of the strands of one PCR product will anneal to strands of DNA 
generated by the other PCR, joining in the region of overlap. A third PCR to 
amplify the entire template sequence will use such annealed DNA as a 
template, and will exponentially amplify the joined product. The result is that 
the original DNA sequence has given rise to a product which is mutated in the 
middle of the sequence (Ho et al., 1988).
As mentioned, this research requires a CAT expression vector with 
restriction sites at the start of the CAT gene. To do this, a region of DNA 
around the start of the gene is to be excised by Cpol and BsiMl, and replaced 
by a copy of the DNA possessing the two new restriction sites in the middle of 
the fragment. Since multiple mutations were required at these sites located in 
the middle of the fragment, the second, two stage mutagenic PCR was used in 
the course of the plasmid construction.
3.3 Design of Primers
The PCR primers were based on the sequence provided by Mr. Grant 
Scotland (Division of Biochemistry and Molecular Biology, IBLS, University 
of Glasgow), modified with mutations to give the desired restriction sites, as 
described above. The design is shown in Fig. 3.7. Primers 1 and 2 (22 and 36 
bp respectively) generated the ‘left hand’ product, from a to b on Fig. 3.6. 
Incorporated into primer 2 was an extension based on the mutated sequence
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Figure 3.6 Site directed mutagenesis by PCR, using a two stage method
120
In the first stage, 2 PCRs are made based on the template DNA (1) from 
a to b and from c to d. Incorporated into primers 2 and 3 are mutations, shown d
in red with a cross. This leads to two products which have identity at the 
region where the mutation was made (at b and c). The primers are designed so 
that this region of overlap will permit annealing (2). The annealed product is 
then extended to yield duplex DNA (3), using each template strand as a primer 
for the other strand. The DNA is finally re-amplified by PCR (4) using primers 
1 and 4 to obtain a full length product similar to the original template, but â
possessing the mutations.
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primer 1
CGGTCCGGAATTCCCGGGTCGA
5'
3'
CTCGATTCCpnm er3 Nhel Hindi 11
AAATGCTAGCAAAGCTTACTGGATATACCACCGTTGA
AAGCTAAAATGGAGAAAA#AATCUlGTG<mmTACCACCGTTGATATj#qmK
TTCGATTTTACGATCGTTTCGAATGAC
r/k, primer 2
TTTATTCGTGTTCAAAATAGGCCGGAAATAAGTGTAAGAACGGGCGGAGiiCT
GGACTACT
ATGCTCATCGGGA 3'
TACGAGTAGGCCT 5'
TACGAGTAGGCCT
primer 4
Fig 3.7 The primers chosen to mutate and replace in pBLSV CAT
The sequence above shows the sequence from Fig. 3.4b, the fragment 
removed from pBLSV CAT. The 4 primers chosen to generate the mutated 
fragments are numbered according to the scheme in Fig. 3.6. The sequence of 
the planned Nhel and Hindlll sites are shown in the primers and the original 
sequence is shown in the grey box to demonstrate mismatch between the 
template DNA and the 2 inner primers.
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3.4 Optimising conditions for PCR
The right hand reaction was found to proceed under the same conditions 
but with an annealing temperature lowered to 45°C. The left hand reaction 
also preferred the above conditions, annealing only at 40°C. Both these 
annealing temperatures are well below the theoretical values for the primers, 
but since the mutagenic primers 2 and 3 have very long regions which may 
bind loosely, or not at all, to the template, this probably lowers the melting 
temperature considerably by encouraging the primer to remain free in solution. 
The control (full length) PCR, the right hand and the left hand PCRs can be 
seen in Fig. 3.8.
and not the original, incoiporating the 8 base changes. Primers 3 and 4 (35 bp 
and 21 bp respectively) generated the ‘right hand’ product, from c to d. Primer 
3 also contained sequence based on the mutated form of the DNA, 
complementary to primer 2, overlapping by 21 bp (Fig. 3.7). This would allow 
annealing of the left and right hand PCR products together, as well as 
introducing the mutations to the PCR products.
The PCR was optimised based on the performance of a positive control, 
the amplification of the template DNA from a to b using primer 1 and 4. 
Sufficient product was made when using 200 ng of each primer, 800 ng of 
plasmid DNA, 100 dNTPs, 1.5 mM Mg^+, Taq polymerase and an 
annealing temperature of ÔO'^ C (all other parameters as described in Ch. 
2 . 10 . 1).
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bp
282
248
82 u
603
310271
234194
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Figure 3.8 Acrylamide gel analysis of PCR products
5% (w/v) acrylamide/ TBE gel of PCR products.
1) Full length PCR, 282 bp
2) ‘Right hand’ PCR, 248 bp
3) ‘Left hand’ PCR, 82 bp
4) ‘DRIgest IIP markers {X HindlW digest and (j) HaelW digest)
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3.5 Initiai attempt to make mutated pBLSV CAT
3.5.1 First attempt to make full length mutated PCR product
PCR is expected to yield an amount of product which greatly exceeds the 
level of original template. It should therefore be possible to carry out final 
annealing and PCR of the two fragments straight from small aliquots of the 
previous reactions, without significant template competing in the reaction.
Each PCR reaction was used (2.5 p.1, approx. 25 ng each product) to 
generate the final full length product in a second stage PCR, using primers 1 
and 4. The final PCR utilised the same conditions as the PCRs for the left and 
right reactions, annealing at 40°C. This yielded a PCR product of the correct 
size.
3.5.2 Ligation of mutated product into pBLSV CAT
The PCR product was then isolated from a gel, and purified using Qiaex. 
The purified product was digested with Cpol, at 30°C for 1 h, and 
subsequently with at 55°C for 1 h.
PBLSV CAT was similarly cut with Cpol and BjiMI, and the larger part 
of the vector purified in the same manner, using Qiaex, to isolate it from the 
insert. The linearised vector was then dephosphorylated using calf intestinal 
alkaline phosphatase (CIP) to ensure no religation of any plasmid which may 
have been cut only with BsiMl, and had escaped digestion with Cpol.
A ligation was carried out using 16 ng of the PCR generated fragment 
and 16ng of the linearised plasmid, for 18 h at room temperature with 3 units 
of T4 ligase, 0.5 mM ATP, and 1 pi ligase buffer in 10 pi total volume. The 
reaction mixture was then transformed into E. coli XLl Blue, made competent 
by CaCQ treatment. The transformed cells were incubated for 1 h at 37°C 
before plating out onto LB agar plates with ampicillin (50 pg /ml).
1 2 4
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Few clones were obtained, so only 2 colonies were selected to be 
analysed by sequencing the plasmid DNA. Overnight cultures (50 ml) were 
grown from the colonies, and the plasmids harvested using Qiagen Midi Preps. 
The DNA was then sequenced using the ABI 'Taq  Dyedeoxy Terminator 
Cycle Sequencing Kit’, and read from an ABI automated sequencer. The 
sequences revealed that the clones contained wild type plasmid.
It was reasoned that the problem lay with the PCR product. It was likely 
that the PCR product had not been digested fully since the restriction sites lay 
at the ends of the primers, which can often inhibit digestion. This would 
therefore prevent ligation into the plasmid. As a result, the only clones 
obtained were the small numbers of self-ligations, plasmids which had only 
been cut once, and were able to religate to give the original pBLSV CAT.
To overcome these difficulties it was decided to blunt-end ligate the PCR 
product into another vector, allowing easy amplification of the product, and 
permit its full digestion. To prevent self-ligation of pBLSV CAT, more 
enzyme was to be used to ensure complete digestion.
3.5.3 Ligating and sequencing PCR product in pCRScript™
The PCR product was then blunt end ligated and subsequently 
transformed into supercompetent E. coli XLl Blue using the pCRScript™  
protocol.
White colonies were then selected from the agar plates, small cultures of 
these were grown overnight and plasmids purified from the cultures using the 
Mini prep method (Ch. 2.9.2).
These plasmids were then sequenced manually using Sequenase V2.0. 
The results revealed that the PCR product was wild-type, and did not contain 
the mutations.
This was a result of amplifying the wild type sequence, in preference to
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the annealed PCR products, during the third and final PCR. In the final PCR 
very small amounts of the original template DNA would be present, carried 
over from the first 2 PCRs. From this we can deduce that the annealing step 
when the two PCRs interact with each other over a region of 21 bases is a 
relatively inefficient one.
It was therefore decided to isolate the left and right hand reaction 
products away from the template plasmid DNA first, then carry out the final 
PCR on these products in the absence of original template plasmid DNA, 
sequencing the final product before ligation into pBLSV CAT.
3.6 Purification of left and right hand PCR products to make 
full length PCR product
Three methods of isolating the primary PCR products from their 
template were tried simultaneously, to guarantee success in creating the full 
length PCR product. This proved fortuitous, since a reagent in the 
pCRScript™  kit, used in all three methods, proved to be faulty. After testing 
of the kit it was found that the supplied T4 ligase had lost activity, and was
replaced in time to complete the last of the three protocols.
g:
I
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3.6.1 I s o l a t i n g  t h e  l e f t  a n d  r ig h t  h a n d  PC R  p r o d u c t s  by c lo n i n g
in t o  p C R S c r i p t ™
I
The first method used to isolate the PCR products from the template 
involved cloning the products of each PCR into a vector and selecting for this 
vector over the wildtype template plasmid. The kit used to clone the PCR 
products was the pCRScript^M kit (Ch. 2.10.4.2), which uses blunt end 
ligation of the PCR products into a pre-digested cloning vector.
DNA from the left and right hand Taq generated PCRs was purified by 
chloroform/phenol extraction and precipitation, and redissolved in water.
From a total of 20 |.l1, 4 |0,1 each PCR was used in the pCRScript^M method, 
including the ‘polishing’ reaction to ensure all PCR products had blunt ends.
A number of white colonies were obtained, and approx. 10% of these colonies 
were isolated for analysis.
PCR was used as a method for detecting the presence of the left, right 
and full length products in the plasmids. Some of the clones obtained were 
expected to be false positives, generated by transformation of the E. coli XLl 
Blue with pBLSV CAT which had been carried over from the PCRs. The 
presence of a full length PCR product would indicate the presence of the 
original plasmid, and not pCRScript™.
PCR demonstrated that only the original template plasmid was present in 
any of the clones. Although some clones were expected to have pBLSV CAT, 
others were expected to have been transformed with the pCRScript^M/pcR 
product. The protocol was repeated, using VentR® (exo-) generated fragments, 
on the possibility that ragged Taq generated ends were not being polished, and |
therefore not ligating. Again, left and right VentR® (exo-) generated PCR 
products were cleaned by phenol/chloroform extraction and precipitation, and 
redissolved in water. Using 4 jttl (from a total of 90 jll, as described in the 
Stratgene protocol) in the ligation with pCRScript™ . The subsequent
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transformation generated a number of white colonies for each product.
Again, only template plasmid was found in any of the clones tested. This 
result may be indicative of a faulty kit; possibly the T4 ligase supplied was not 
active. Alternatively, this result could be due to the large amount of template 
plasmid used in the PCR. In the ligation, there could be up to 32 ng of pBLSV 
CAT carried over from the PCR, compared to 10 ng of pCRScript vector in 
the reaction. It is possible therefore that the majority of white colonies were 
derived from the PCR template DNA, even if the PCR product had been 
cloned into pCRScript. It was expected that the dénaturation of pBLSV CAT 
during PCR would render the plasmid unable to transform cells, but this
appeared to be not the case.
In view of the high level of template plasmid contamination, it was 
decided to purify the PCR products away from the template prior to cloning.
3.6.2 Isolating the left and right hand PCR products by
electroelution from gels
3.6.2.1 Electroeluting PCR products
The second method used to isolate the left and right PCR products was 
the electroelution method. This method was chosen in light of the above result, 
demonstrating the requirement for purified PCR product before cloning.
Each PCR product (100 pi total) was electrophoresed through a TAE gel 
over a number of lanes, and PCR products excised, leaving the template 
plasmid in the gel. The DNA was then electroeluted and precipitated. Approx. 
SOOng of each product was recovered and redissolved in 50 pi TE buffer. Of 
this, 5 pi was then used in a PCR to show the fragment could be reamplified, 
under the conditions previously described. Both PCR products could be 
amplified satisfactorily (not shown). Since both products had been isolated 
and were capable of amplification, it was decided to proceed to make full
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length product.
3,6.2.2 G enera ting  the full length PCR p roduct from  
electroeluted DNA
3.6.2.3 Cloning full length product made from electroeluted 
])NA into ]P<:FUScrq)tTAf
The PCR product was subsequently cloned into pCRScript"*"^ as 
described (Ch. 2.10.4.2). No white colonies were obtained; only a small 
number of blue, non-recombinant colonies were found, indicating that vector 
was present, but that the ligation itself had not been efficient. Control ligations 
also failed. The cells themselves were shown to be competent with a positive 
control.
It was concluded that the kit was faulty (specifically the T4 DNA ligase), 
and replacement reagents were obtained. It was also concluded that the kit was 
probably responsible for the failure of the previous attempt to ligate the 2 PCR 
products.
Electroeluted left and right products (5 pi each) were used in a PCR 
reaction, (conditions as previously described) to obtain the final full length 
product using VentR® (exo-) polymerase. The full length product was made, 
as can be seen in Fig. 3.9.
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Figure 3.9 Agarose gel analysis of PCRs of electroeluted DNA fragments
1.5% (w/v) agarose gel of full length PCR product made from 
electroeluted PCR products. Though PCR has occurred, the products were too 
weak to be visualised without long exposure.
1) ‘DRIgest IIP markers {X HindUl digest and (j) Haelll digest)
2) Full length control PCR from original template, 282 bp
3) Full length control PCR from 10 pi electroeluted right hand PCR and 10 pi 
electroeluted left hand PCR, 282 bp
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3.6.3 Direct PCR on gel slices of left and right PCR products to
make full length product
3.6.3.1 Isolation of DNA in gel slices
131
The third method which was used in conjunction with the methods 
described in sections 3.6.1 and 3.6.2 was that of direct PCR on gel fragments 
containing DNA. The left and right PCR products were each electrophoresed |
through a 1.5%(w/v) agarose gel. PCR products were cut out of the gel, again 
leaving the template plasmid in the gel. Each gel slice (1-10 pi, melted at 65°C 
to mix the DNA throughout the agarose) was used in a final annealing/PCR.
The first time this was attempted, no final product was made. It was |
suspected that insufficient template DNA was present in the gel slice, since 
only 50-200 ng would be present in the entire slice, and of that, only a small 
amount (less that 25%), was used in the PCR. To use more of the agarose slice 
could be detrimental to the PCR, since agarose contains contaminants which 
are known to affect the quality of the reaction.
Therefore 4 PCRs of both left and right fragments were carried out, and 
electrophoresed through an agarose gel as before. On this occasion less 
agarose was taken with each DNA band, and considerably more DNA was 
recovered. After melting (65°C) the agarose to mix the DNA through the 
solution, 5 pi of each gel slice was used in a PCR reaction to show the 
presence of the PCR product and to demonstrate that direct PCR could be 
achieved successfully. The results of this experiment showed that the PCR 
products were purified, and were capable of amplification by PCR with 
agarose present (Fig. 3.10).
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Figure 3.10 Agarose gel analysis of direct PCRs on gel isolated DNA 
fragments
1.5% (w/v) agarose gel of PCR products made from gel isolated PCR 
products to show the presence of the DNA fragments, and their ability to be 
reamplified by PCR.
1) Left hand PCR reamplified from 5 pi gel isolated left hand PCR, 82 bp
2) Right hand PCR reamplified from 5 pi gel isolated right hand PCR, 248 bp
3) Full length control PCR from original template, 282 bp
4) ‘DRIgest IIP markers {X Hindlll digest and (j) Haelll digest)
Although faint and contaminated, a light band can be seen towards the 
bottom of the gel in lane 1, indicating that some of the 82 bp product is present 
(indicated by the arrow).
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3.6.3.2 Generating the full length PCR product by direct PCR 
on gel slices of left and right PCR products
:l;.
'.S'
Using the previous method, with 5 pi of gel from both PCR products, |
PCRs were carried out to make the full length DNA using VentR® (exo-) 
polymerase.
3.6.3 3 Analysing the PCR product J
-j
The PCR product was checked by digesting with Hindlll, one of the 6
enzymes that should cleave the mutated form of DNA, but not original wild- )
type DNA. Fig. 3.12 shows that the full length PCR product had been 
generated and could be cleaved by Hindlll into smaller, left and right PCR 
sized fragments, indicating that it contained a new ^fmdlll site, and therefore 
behaves as expected for the desired mutated fragment.
3.6 3.4 Cloning full length product from direct PCR on gels
into p C R S c r ip t T M
The PCR products were then cleaned by W izard™  PCR Preps, prior to 
cloning. From the 50 pi of cleaned product obtained, 4 pi was used to clone 
the PCR product into pCRScript™  as previously described. The PCR product ?
was ligated and a large number of white colonies were obtained. |
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Figure 3.11 Restriction analysis of full length PCR product
The figure shows a 5% (w/v) acrylamide gel of full length PCR product 
which has been cut by HindlW.
1) ‘DRIgest IIP markers (À HindWl digest and (j) HaeWl digest)
2) Control full length PCR from template plasmid
3) Full length PCR made from excised gel pieces of left and right PCR
4) PCR from lane 3 cut with HincHW
The shift in mobility in lane 4 is caused by a loss of approx. 45 bases, 
though this fragment is too small to be detected in the gel. The mobility shift is 
due to cleavage of the PCR product by Hindlll into left and right hand 
fragments.
Again, the sizes of the PCR products and digestion fragments appear to 
be larger than expected. This may be due partly to the presence of PCR and 
restriction enzyme buffers not present within the DNA markers.
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3.7 Analysing clones
3.7.1 Restriction digests of the clones
Mini plasmid preps were performed on 3 clones and on the original 
pBLSV CAT. These plasmids were then used for 2 restriction digests, as 
shown in Fig. 3.12. Lane 3 shows that the full length PCR is present, cutting at 
two BslMl sites that did not previously exist and giving the correct sized 
fragment, whilst lane 4 indicates the presence of an insert with an extra 
Hindlll site.
3.7.2 PCR of clones
The clones were then tested for their ability to yield products from the 
left, right, and full length PCRs, as were initially carried out on the original 
plasmid. Fig. 3.13 shows a typical result, confirming the restriction digest data 
that the cloned product is the correct, mutated version of the desired DNA 
fragment.
3.7.3 Sequencing of the clones
Single stranded DNA was made from the plasmids using the M l3 single 
stranded DNA prep. This was sequenced manually with the Sequenase V2.0 
kit, using M13 -40 primer. The results showed that the plasmid contained the 
correct full length PCR with the new restriction sites in the appropriate place.
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Figure 3.12 Acrylamide gel analysis of digestions of cloned full length 
PCR
The results of 4 digestions of the cloned mutated PCR product in 
pCRScript^^ are shown on an 8% (w/v) acrylamide/TBE gel. Expected 
results are calculated for either orientation of the inserted PCR product.
1) Markers; 100 bp ladder
2) Uncut plasmid
3) Plasmid cut with BsiMI only. Expected 266 bp for either orientation. 
Fragment is approx. 300 bp
4) Plasmid cut with Hindlll only. Expected 109 bp or 238 bp fragment. 
Fragment is approx. 150 bp
The presence of two Hindlll sites alone in lane 4 would suggest the 
presence of the insert since the unmutated PCR product does not cut with 
Hindlll, and pCRScript^^^ only cuts once (not shown). The sizes of the 
fragments are close to the expected size, it is therefore concluded that the 
cloned product is the correct one.
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Figure 3.13 Acrylamide gel analysis of PCR products
5% (w/v) acrylamide/ TBE gel of PCR products made from pCRScript 
with cloned full length PCR product
1) ‘DRIgest I i r  markers Hindlll digest and ^ Haelll digest)
2) Full length control PCR from pBLSV CAT, 282 bp
3) ‘Left hand’ PCR, 82 bp
4) ‘Right hand’ PCR, 248 bp
5) Full length PCR, 282 bp
I '
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3.8 Excising and purifying mutated fragment
PCRScript plasmid (5 |Llg) containing the PCR product was made, and 
then digested overnight at 30®C with 20 |ll (100 units) Cpol in a total vol of 
500 \i\ with appropriate buffer. After this, the buffer was changed by 
precipitating the DNA with 4 M ammonium acetate. The DNA was 
redissolved in 300 |il BsiMI buffer and digested overnight at 55^C by 20 pi 
(200 units) BsiMI. In this way, maximum digestion of the DNA was achieved, 
ensuring that there was enough DNA to recover from gels later.
The cut DNA was loaded onto 2 TAE agarose gels and electrophoresed 
to permit isolation of the 282 bp fragment. The fragments were excised from 
the gels and purified using W izard™  PCR Preps. DNA (200 pi) was isolated 
at 0.1 mg/ml, but was impure. It was repurified using a phenol/chloroform 
extraction and a sodium acetate precipitation. The DNA fragment was checked 
for plasmid contamination by gel analysis (Fig. 3.14).
3.9 Digesting and purifying pBLSV CAT
PBLSV CAT (5 pg) was treated in the same way as above, to remove the 
region of DNA being replaced. The plasmid was also purified by W izard™
PCR Preps from a TAE agarose gel, leaving the insert, and retaining the 
vector. A total of 75 pg vector was isolated.
To ensure that plasmid which had only been cut by one of the enzymes 
was not allowed to religate, the cut pBLSV CAT was then dephosphorylated |
by CIP.
Enzymes were removed by extraction with phenol/chloroform, and the 
DNA precipitated by sodium acetate and ethanol. The DNA was then taken up
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Figure 3.14 Agarose gel analysis of purified insert from p C R S crip t^ ^
1.5% (w/v) agarose/TBE gel of purified insert and pBLSV CAT
1) Isolated full length fragment excised from pCRScript™ vector using Cpol 
and BsiMI
2) pBLSV CAT plasmid, uncut for comparison
3) ‘DRIgest III’ markers (A, Hindlll digest and (j) Haelll digest)
The gel shows that the cloned PCR product has been excised and 
isolated with no contaminating template or vector plasmid
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into 200 pi CIP buffer, and 20 pi CIP added. Enzyme treatment was 
performed for Ih at room temperature before heat inactivation. The DNA was 
then repurified using a extraction with phenol/chloroform and a sodium 
acetate precipitation.
3.10 L igating  m u ta ted  fragm ents into pBLSV CAT
Ligations were performed in a total vol of 10 pi, both using 250 ng cut 
vector and 250 ng excised PCR fragment. The ligations were carried out 
overnight or over the weekend, using Stratagene T4 ligase used in conjunction 
with 1 pi 10 mM rATP. The ligations were then transformed into DH5a cells 
supplied by Dr. S. Khan. The transformed cells were spread on LB agar plates 
containing 50 pg/ml ampicillin. It was discovered that ligating the DNA 
overnight gave rise to only 9 colonies in total, whereas ligation over a 
weekend provided a total of 90 clones.
3.11 Digests of pSoUP
This new variant of pBLSV CAT, designed to support experiments upon 
uncharacterised presequences was called ‘pSoUP’ (plasmid supporter of 
uncharacterised presequences).
To find those ligations which had successfully yielded the correct 
pSoUP, a small number of colonies were taken from ligation 3. W izard™  
Mini Preps of the clones were used in restriction digests to generate a 
restriction map of the plasmid, to ensure greater chance of sequencing the 
correct ligation.
All three selected clones behaved as predicted for pSoUP when digested 
with Psti, Cpol, Nhel with Pstl and Hindlll with 5acl (not shown). A further 
restriction digest determined that the PCR product had ligated in the correct
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Figure 3.15 Restriction analysis of pSoUP to show orientation of m utated 
DNA.
The results of 2 digestions on pSoUP are shown on an 8% (w/v) 
acrylamide gel. Expected results are calculated for the correct orientation of 
the mutated DNA and the incorrect.
1) ‘DRIgest I i r  markers (À HindUl digest and (j) Haelll digest)
2) Plasmid cut with Cpol and Nhel. In the correct orientation, the fragment 
expected would be 61 bp. Incorrectly inserted, the fragment would be 204 bp. 
Fragment is approximately 70 bp.
3) Plasmid cut with Hindlll and Pstl. In the correct orientation, the fragment 
would be 75 bp, incorrectly oriented, it would be 204. Fragment is 
approximately 95 bp.
Incorrectly inserted, both digestions would produce a fragment of the same 
size (204 bp). Since each digestion produces a fragment of a different size, it
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Figure 3.15 cont’d.
would appear that the PCR product is in the correct orientation. The reason 
why both fragments appear to be 10-20 bp larger than expected may be due to 
the presence of digestion buffers or traces of salt and protein affecting running 
of the gel.
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orientation, as can be seen in Fig. 3.15.
3.12 Sequencing of pSoUP
One of the clones was sequenced. The plasmid was prepared by 
W izard™  Mini Prep and then sequenced using the ABI automated sequencer 
and sequencing kit. All four of the primers which were initially used to 
generate the PCR product were used as sequencing primers. The sequence 
obtained demonstrated that the plasmid was exactly as predicted, containing 
both the new restriction sites without any other alterations to the CAT gene in 
the region. This clone was subsequently used to establish a permanent frozen 
stock.
3.13 Discussion
One of the difficulties faced in this series of experiments which isolated 
the left and right hand products was that of size. At the beginning of this 
research, it was not anticipated that small fragments of PCR amplified DNA 
would often not precipitate or purify by many of the available methods. The 
82 bp fragment in particular was difficult to purify in quantity, and there was 
frequently less material to use than desired. This problem led to all subsequent #
DNA manipulations being performed on a larger scale than would otherwise 
be necessary.
Another problem encountered seems to have been caused by the unusual 
PCR conditions. After optimisation, up to 10 times more plasmid was 
employed in the PCR than is often required. In the case of primer 2 and 3 
inefficient binding of the primers with long extensions could lead to more 
template being required, but this does not explain the requirement in control 
reactions where the primers match exactly. It is likely that the plasmid is
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especially resistant to heat dénaturation, and a longer period of heating was 
required at the start of the PCR. This initial step was never examined since the 
standard time used was considered adequate before the other reaction 
conditions were optimised. As a result of using large quantities of template 
plasmid to overcome this dénaturation problem, wild-type pBLSV CAT has 
contaminated many of the efforts to use reaction products directly. This could 
also explain the number of false positives seen in section 3.6.1. In this 
experiment, pBLSV CAT was carried over from the initial PCR, through the 
ligation reaction, to the transformation. If the pBLSV CAT was not fully 
denatured during the PCR, then it would retain the potential to transform 
bacteria at this stage, as appears to be the case. The annealing temperatures for 
the PCR were also unusually low. The left and right hand reactions were over 
10°C lower than expected, probably due to the extended 5’ overhang. Many 
site directed mutagenesis PCRs do not require the lower temperature seen 
here. This is because, in place of the more common single restriction site, 2 
sites (14 and 17 bp for left and right hand reactions respectively) were 
required.
Due to the large amount of plasmid required, isolation of the mutated 
PCR product was necessary. Three methods were used to isolate DNA species, 
all of which utilised a kit called pCRScript'^^. Two of these methods failed 
due to a faulty ligase in the kit, undetected due to the omission of a suitable 
positive control. Until the failure of the method to clone the electroeluted 
DNA it was thought that plasmid contamination was the sole cause of failure 
in previous experiments, since the p C R S c r ip t ^ M  kit had previously given 
excellent results (see chapter 4). The full length clone had been generated by 
the electroelution method (section 3.6.2.2) from isolated left and right PCR 
products, in the absence of a full length template DNA. If the faulty ligase had 
been detected earlier, the electroelution method would probably have 
succeeded also.
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What other methods for DNA mutation were available, and why were 
these not used? The first method considered was based on similar approach.
The theory was to excise a fragment around the mutation site small enough to 
be replaced by a synthesised oligomer. This method would have been ideal if 2 
unique sites had been available close together, near the first coding methionine
?
of the CAT gene. However, the nearest sites found were 282 bp apart, and 
such an oligomer could not be made satisfactorily.
It was also suggested that using a long range polymerase, such as pfu, 
one could take 2 primers, with the appropriate mutations, and polymerise 
daughter strands completely round the plasmid, a technique now commonly 
referred to as ‘inverse PCR’. This method would avoid a second stage PCR, 
and avoid any ligations. However, only a small number of mutations had ever 
been attempted at one time (Dr. Alan Wise, private communication). It was 
unlikely that the primers, with the 8 mutations required, would anneal easily 
enough to permit this difficult procedure.
Finally, the most common method for site directed mutagenesis, the site 
directed mutagenesis kit (e.g. Amersham’s S c u l p t o r ™  kit), was discounted 
for the same reason as above. It may be that such a kit would have succeeded 
in less time, by generating the mutations one at a time. As site directed 
mutagenesis becomes more common place, so newer kits make such 
procedures easier, and should this be done again, such a kit may be the method 
of choice.
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Preliminary Investigation into Cloning of the E2
Presequence DNA
«Chapter 4: Preliminary Investigation into Cloning of the E2 Presequence DNA I,
4.1 Introduction f
As discussed in chapter 3, to investigate the possible roles for the 
extended presequence of PDC-E2, a presequence/CAT reporter gene construct 
was to be made and expressed in mammalian cells. Vital to the creation of a I
presequence/reporter gene construct was the isolation of the DNA coding for 
the presequence. However, no clone which included the complete PDC-E2 
presequence was available to us. There were two published sequences which 
existed at the time this research commenced (Coppel et a i ,  1988; 
Thekkumkara et a i,  1988), as shown in Fig. 4,1. The presequences of the pre-
E2 polypeptide are identical over their C-terminal region (amino acid 59-75 in
■'Ïthe figure). However, from amino acid 1 to 59 the two presequences are totally 
divergent. It was revealed to us in communication with R. Coppel and co­
workers that a recombination event had taken place, and that the rest of the 
sequence was derived from the cloning vector (Dr. M.E. Gershwin, private 
communication). The sequence published by Thekkumkara et al. (1988), from 
a cDNA clone, did not have the entire presequence since it possessed no 5’ 
initiation codon, so could not be used in this investigation.
During the course of this research it was found that the sequence for the 
entire human PDC-E2 presequence had been elucidated, but left unpublished.
Sequencing of a ‘genomic clone’ had been carried out by Dr. P. Leung (Dr.
M.S. Patel, private communication) to obtain the sequence of the upstream 
promoter region. Subsequently, the full presequence had also been determined, 
and this was made available to us, although the clone, however, was not 
available.
We therefore had the DNA sequence but no clone of the PDC-E2 
presequence; we had to obtain this ourselves from a cDNA library or genomic 
DNA.
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Figure 4.1 Sequence alignment of the 3 PDC-E2 presequences
The three available PDC-E2 presequences are aligned above to give the 
correct overall sequence. Regions of identity are shaded yellow. The two 
published sequences (Thekkumkara et aL, 1988; Coppel et at., 1988) agree 
over the entire DNA sequence coding for mature PDC-E2, and for the final 14 
amino acids of the presequence. However, the two sequences are completely 
divergent over amino acids 1-59 of the presequence. The point at which the 
sequence by Coppel et at. ( 1988) diverges from the other two is thought to be 
due to genetic recombination in the cDNA library, and this point is shaded in 
red.
Sequence from the genomic clone (a plasmid called pShl02), shown on 
the top line, agrees with the sequence published by Thekkumkara et al. (1988).
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4.2 Designing primers to amplify the presequence DNA
Primers were designed to amplify the PDC-E2 presequence DNA coding 
for the region between the N-terminus of the presequence and the N-terminus 
of the mature protein (designated ‘presequence only’), based on the sequence 
provided. Both primers incorporated restriction sites for directional cloning 
into pSoUP (Fig. 4.2). A third primer was also designed after the discovery 
that this PCR generated multiple products when amplifying from cDNA. This 
new primer was identical to a region within the open reading frame of mature 
PDC-E2. This would be employed along with the primer designed to the N- 
terminus of the presequence to amplify a ‘partial clone’, coding for the 
presequence and part of the mature PDC-E2 polypeptide, as shown in Fig. 4.2. 
Being able to amplify this product would demonstrate that the presequence 
was adjacent to the rest of the PDC-E2 gene, and would support the genomic 
sequence supplied. This amplified product could then be used as the template 
for the original PCR to obtain the presequence alone, with appropriate 
restriction sites.
4.3 Obtaining E2 presequence by PCR from a XgtlO cDNA 
library
4.3.1 Obtaining the E2 presequence from IgtlO by PCR
A number of attempts were made to amplify the ‘presequence only’ 
DNA from a human foetal cDNA library housed in ÀgtlO, assuming heat 
dénaturation of the ikgtlO coat protein would release the viral DNA for 
amplification. This is a standard approach occasionally used to amplify from 
whole bacterial cells. Each primer (0.3 pg) was used to amplify the 
presequence from 10^ pfu of IgtlO.
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Am prim er A, with Nhel site
^GGCGGGACTCCAGGACTCGGTGGAC
3' jTAQCC<5dCG*GltôWCÏGiAGCCXCÎC^^
Met
îCCîCGirdÔCAACA
ZTACAGGG^ A^ IiGCQGGQTCCGGaCACtrC 
ITGTCCCAI^ C(X:CCCAQGCCC#GACACGCÙ@À(
fm a t
:TGGGGCCACGCCGCQ0MkÆÎCGCtï?5!ACÏXK?lMSCA<^  ^
lGACCCCGGTGCGCX:œC$%dQCGAAaüaKXï&CGTCmAAACœ^
CCCCAG
, ature PDC-E2
GCCCGGCCGCCOTAT
cgggccggcggosAt i
CGGGCCGGCGGCGATAATGTCAAa GCt j^,
prim er B, with H indlll site
IGGTGACCTAATTGCAGAGGTTGAAAC 
:$TCCACTGGATTAACGTCTCCAACTTTG
AACTTTG
TQATAAAGCCACTGTTG5'
ACTATTTCGGTGACAAC 3'
ACTATTTCGGTGACAAC
prim er C with no restriction site
Figure 4.2 The sequence for PDC-E2 up to the internal primer site, and 
the 3 primers designed to amplify the DNA
The two original primers (A and B) designed to amplify the presequence 
are shown, both possessing one of the restriction sites which would allow 
directional
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Figure 4.2 coutM.
cloning of the presequence into pSoUP. Primer A was identical to the 
sequence shown, up to the first codon (shown in red) with an additional 
restriction site (shown in blue), designed for in-frame insertion into pSoUP. 
Primer B was designed to the reverse complement of the 3’ end of the DNA 
coding for the presequence (in red), also including a restriction site (in blue) 
for directional cloning into pSoUP. The third primer (Primer C) was designed 
to work with primer ‘A ’ to amplify the ‘partial clone’, but possessed no 
restriction site.
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The PCR was carried out using Ventj^® (exo-) polymerase using the following 
steps:
1 ) 94°C for 3 min initial dénaturation
2) 30 cycles of
94°C 1 min 
45°C 1 min 30 sec 
72°C 1 min 30 sec
3) 72°C for 5 min final extension
This did not yield any products, so the method was repeated, using a 
lower annealing temperature (40°C instead of 45®C). This gave faint multiple 
PCR products (Fig. 4.3). Whilst heat dénaturation followed by PCR is an 
accepted technique for amplifying DNA directly from bacterial cells, it 
appeared to be unsatisfactory for amplifying DNA held in viral caps ids. It was 
decided to use a standard protocol to isolate the DNA from the phage particles, 
and PCR directly from the DNA.
4.3.2 Using purified XgtlO DNA in the E2 presequence PCR
DNA was purified from the phage for use in PCR applications, as 
described in the methods section (2.9.5). Using previous conditions, annealing 
at 45°C, the ‘presequence only’ PCR was attempted. This generated faint, 
multiple products. A third primer, primer C’ in Fig. 4.2, was made to amplify 
a ‘partial clone’ DNA (as described in section 4.2). PCRs using primer A and 
C to amplify the ‘partial clone’ also gave rise to multiple products, but, in 
contrast to the reaction using primers A and B, one band predominated. The 
contrast between the two PCRs can be seen in Fig. 4.4, where ‘presequence
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2 3
Figure 4.3 Agarose gel analysis of the first PCRs for PDC-E2 presequence
Agarose gel 1.5% (w/v) of two PCR reactions carried out on XgtlO 
demonstrates the variability of the PCR carried out on whole phage. The 
products were too weak to be visualised without long exposure. Expected size 
of correct PCR product is 234 bp.
1) ‘DRIgest IIP markers {X Hindlll digest and ({) Haelll digest)
2 and 3) Independent PCRs carried out as described on heat-treated phage to 
amplify the ‘presequence only’ DNA, demonstrating variability as well as a 
lack of specific product of the correct size.
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only’ and ‘partial clone’ PCRs are compared over a range of template DNA 
concentrations. The expected size of the product from PCR with primers A 
and C was 343 bp, PCR with primers A and B should give a product of 228 
bp. The predominant band found in the ‘partial clone’ PCRs was larger than 
expected, but it was decided to pursue investigation of this product despite the 
large size. Unfortunately, attempts to clone this product into pUCl 18 failed, 
due to a contaminated stock of the plasmid. All other cloning experiments 
were therefore carried out using pCRScript™,
4.4 Cloning and analysis of PDC-E2 PCR product
4.4.1 C loning ‘p resequence only^ PC R  product into
pCRScript™
Difficulties were encountered at this point, caused by a batch of faulty 
Tag polymerase. During this time, the products of the ‘presequence only’ PCR 
made above were ligated into pCRScript^^, according to the manufacturer’s
!
protocol. A number of recombinant clones were isolated, and five of these 
were selected for further analysis.
4.4.2 A nalysing ^presequence only' PC R  product in
pCRScript™
W izard™  Mini Preps of plasmid DNA from each of the 5 selected 
clones were made, and 20 fll plasmid (1 p,g) was digested with 10 units Nhel 
and 20 units Hindlll for 3 h, 37°C. The restriction digestions were then 
analysed on a 1.5% (w/v) agarose gel. Of the 5 digestions, 4 yielded products, 
which were all estimated to be approx. 300 bp, which corresponds approx. to 
the predicted size of 226 bp (Fig. 4.5).
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la  lb  2a 2b 3a 3b 4a 4b 5a 5b 6
Predominant band irij 
partial clone PCRs
Figure 4.4 Agarose gel analysis of PDC-E2 presequence PCRs on purified 
phage DNA
This 1.5% (w/v) agarose gel of ‘presequence only’ and ‘partial clone’ 
PCRs carried out on ÀgtlO DNA shows the variability of the PCR with 
different amounts of initial template. Expected size of correct ‘presequence 
only’ PCR product is 234 bp, expected size of ‘partial clone’ PCR product is 
343 bp.
PCRs are labelled ‘a’ for ‘partial clone’ PCR and ‘b’ for ‘presequence only’ 
PCR.
la,b) PCRs using 3 ng template 
2a,b) PCRs using 30 ng template 
3a,b) PCRs using 150 ng template 
4a,b) PCRs using 325 ng template 
5a,b)PCRs using 650 ng template
6) ‘DRIgest III’ markers (A, Hindlll digest and (j) Haelll digest)
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At this point it was felt that the XgtlO cDNA library available to us may 
represent a poor source of the template DNA required. Many researchers have 
had difficulties obtaining full length clones from cDNA libraries, including the 
authors of the two published human PDC-E2 sequences, who were unable to 
find correct full length cDNA clones in their original publications of the PDC- 
E2 gene sequence.
It was decided to use human genomic DNA in further PCRs, which had 
proven to be a useful source of template DNA for related PCR work.
Blood was kindly given by Prof. Gordon Lindsay, and DNA purified 
from it by Susan Richards, using a proteinase K treatment followed by a 
phenol/chloroform purification and sodium acetate precipitation. The DNA 
was found to be at a concentration of approx. 0.47 mg/ml.
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4.4.3 Sequencing ‘presequence only' PCR product in
pC R Scrip t™
Since identical fragments were excised in all the restriction digests, only 
one of the clones was sequenced. Single stranded DNA was made from the 
clones, and was manually sequenced with M l3 -40 primer. The insert was 
detected, but the sequence bore no homology to the expected sequence, except 
in the region of the primers.
4.5 Obtaining E2 presequence by PCR from human genomic 
DNA
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Figure 4.5 Agarose gel analysis of digestion of 4 clones
The plasmids obtained from the ‘presequence only’ clones were digested 
with Nhel and Hindlll, and were then examined on a 1.5% (w/v) agarose gel. 
The expected size of the fragment generated by digestion of the correct 
product in pCRScript^^ would be 228 bp. Variation in the running of 
individual lanes of the gel made accurate sizing of the fragments difficult, but 
the product appears to be approx. of the correct size.
1-4) Successful digestions, all yielding products of approx. 250-300 bp.
5) ‘DRIgest III’ markers (X Hindlll digest and (}) Haelll digest)
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PCRs for the presequence, using both ‘presequence only’ and ‘partial 
clone’ primers, were optimised to provide a reasonable yield of PCR product.
Optimum conditions were similar to before, using 5 ftl genomic DNA in 50 ft! 
reactions with 0.3 jig each primer. Taq polymerase was preferred to VentR®
(exo-), since Taq gave more product with this template. All PCRs gave
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multiple products (Fig. 4.6). This is in contrast to a control PCR, using primers 
based on confirmed published sequence to amplify the lipoyl domains and E3 
binding site of PDC-E2. This PCR gave a much cleaner product at precisely 
the size expected.
.y■•I
4.6 Cloning and analysing all PCR reaction products in
pCRScript™
Since the PCR had a number of DNA species within the DNA mixture it 
was deeided to clone the mixture of reaction products into pCRScript™ .
From this, individual clones could be selected, and the fragments cloned could 
be identified by restriction digestion. The correct clone should yield a 
fragment of 228 bp.
Only the ‘presequence only’ PCR products were used. The possibility 
was noted that the presequence may be on a different exon to the rest of the 
gene; the correct ‘partial clone’ PCR product could therefore be very much 
larger than predicted. A number of ‘presequence only’ PCRs were purified by 
sodium acetate and ethanol precipitation. The purified DNA mixture, at 10 
ng/gl, was ligated into pCRScript™  as previously, and used to transform 
E.coli XLl Blue with recombinant plasmid. A large number of recombinants 
were made, 20 of which were selected for analysis to find a clone for each 
PCR product that was made.
-,
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(a) 1 2  3 (b) 1 2  3
Figure 4.6 Gel analysis of PCRs from human genomic DNA 
Figure 4.6(a)
The products obtained from the presequence PCRs were visualised on an 
8% (w/v) acrylamide gel. Whilst there are a large number of amplified 
products in each reaction, there are some major bands present. In the 
‘presequence only’ reaction, there is one candidate at approx. 220 bp, which is 
the expected size for the correct PCR product.
1) ‘DRIgest III’ markers (k  HindlW digest and (j) HaeWl digest)
2) PCR to amplify ‘presequence only’ DNA. Expected size 234 bp
3) PCR to amplify ‘partial clone’ DNA. Expected size 343 bp
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There was a degree of variability between PCRs (such as ‘presequence 
only’ PCR in panels a and b). However, the same DNA bands were usually 
present in each PCR, in varying concentrations.
g
. -Chapter 4: Preliminary Investigation into Cloning o f the E2 Presequence DNA 
Figure 4.6(b)
The control PCR was compared to the products of a ‘presequence only’
PCR on a 1.5% (w/v) agarose gel. The control PCR, amplifying a section of 
DNA from the PDC-E2 gene, gives a single, clean product, whilst the 
experimental PCR gives a range of products.
1) PCR to amplify DNA coding for E3 binding domain and lipoyl domain of 
PDC-E2. Expected size 543 bp
2) PCR to amplify ‘presequence only’ DNA. Expected size 234 bp
3) ‘DRIgest III’ markers (X Hitidlll digest and (j) Haelll digest)
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4.6.2 A nalysing P C R  clones by restric tion  digest analysis
1L
W izard™  Mini Preps were made from the selected clones, and the 
plasmids obtained digested with N hel and Hindlll. Each plasmid (20 p,l, 
approx. 1 fig) was digested with 10 units Nhel and 20 units Hindlll overnight,
37°C. A sample of the 20 digestions is shown in Fig. 4.7. The result obtained 
was surprising since it was expected that cloning the whole PCR reaction
;should yield clones of the various products found in the PCR. From the 20 f
clones analysed, only 2 varieties of recombinant emerged; one which did not 
digest with the 2 enzymes used, and one which gave a fragment of approx. 400 /
bp, which was regarded as too large to be the desired presequence, and was 
therefore discarded. ?
:P.
4.7 C lon ing  a n d  analysis o f in d iv id u a l P C R  p ro d u c ts  in to
p C R S c r ip t™
4.7.1 Iso lation  of indiv idual P C R  products
It was not known why a 400 bp product from this PCR should be 
selectively ligated so it was decided to isolate all candidate PCR products on a 
gel, and clone each species into pCRScript™  separately. Again, the 
‘presequence only’ PCR products were used.
The ‘presequence only’ PCR products were precipitated using sodium 
acetate and ethanol, and the washed, purified DNA pellet re suspended in half
;;
the original volume for loading onto a 1.5% (w/v) agarose/TAE gel. All the 
major PCR products (a, b, c and d), as shown in Fig 4.8, were excised from the 
gel, and the DNA isolated using the W izard™  PCR prep kit. Of the 4 bands 7
purified, 1 did not yield sufficient DNA to continue (band ‘a’), and another 
was approx. 150 bp too large to be the presequence (band ‘d’). The other two 
bands (band ‘b’ and ‘c ’) were isolated both individually and together in a
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1 2 3 4 5
Figure 4.7 Agarose gel analysis of digested plasm id clones of hum an 
genomic PCR
The plasmids obtained from the recombinant clones were digested and 
analysed on an 1.5% (w/v) agarose gel. The figure shows a representative 
sample of the 20 digestions, which all gave patterns identical to 1 of the 4 
above.
1 and 4) partial digestion of the plasmid to yield a 400 bp fragment
2 and 3) no digestion of the plasmid
5) ‘DRIgest III’ markers {X Hindlll digest and ()) Haelll digest)
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PCR products ^
primers
3 45  6 7 8 9 10
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Figure 4.8 Agarose gels showing isolation and analysis of various PCM 
products from  hum an genomic DNA
The precipitated DNA was electrophoresed (lane 1, top gel), and 4 major 
bands isolated (a, b, c, d). The isolated products are shown in the lower left 
gel. After discovering band ‘c’ was contaminated, it was re-isolated, as shown 
in the lower right gel. All gels were 1.5% (w/v) agarose. Band ‘a ’ was not re­
isolated, since, on reflection, it was too small to be a suitable candidate.
1) PCR DNA prepared for isolation
2) ‘DRIgest I i r  markers (X Hindlll digest and (|) Haelll digest)
3) Purified band ‘a’
4) Purified band ‘b’
5) Purified band ‘c ’
6) Purified band ‘d’
7) ‘DRIgest n r  markers (X Hindlll digest and (|) Haelll digest)
8) Purified band ‘b’
9) Purified band ‘c ’
10) ‘DRIgest IIP markers (X Hindlll digest and (j) Haelll digest)
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mixture of the two.
These purified PCR products were then precipitated from 50 fil to 20 |il, 
and 10 ftl of this used in the pCRScript™  protocol, at approx. 20 ng/ml. The 
‘polish’ step was included to promote blunt-end ligation of the Taq generated 
DNA. The ligation was transformed into E. coli XLl Blue, according to the 
protocol, and recombinants from the procedure selected for further analysis.
4.7.2 Analysing various isolated PCR products
W izard™  Mini Preps were made from some of the clones of both 
products, and were tested for the presence of a PCR generated insert with Nhel 
and Hindlll sites, by digesting with the 2 enzymes as previously. It was found 
that both selected products had been cloned individually. A clone was also 
found which had been generated from a ligation of the mixture of the two 
products into pCRScript™  (Fig. 4.9). Single strand DNA was made from 
each clone, which was then manually sequenced, using the M13 -40 primer. 
None of the sequences were found to have homology to the presequence DNA 
expected.
4.8 Cloning and analysis of ‘partial clone' PCR
Since none of the PCR products utilising primers A and B had yielded 
correct products, it was decided to check the sequence of the products made by 
the PCR using primers A and C. For simplicity, it was assumed that the DNA 
sequence for the ‘partial clone’ would be on the same intron, and the expected 
product would be 343 bp. A ‘partial clone’ PCR was electrophoresed on a 
1.5% (w/v) agarose TAB gel, and a band seen at approx. 350 bp (data not 
shown) was isolated using the W izard™  PCR prep, into a total of 50 p.1.
Approx. 5 ng purified DNA was cloned using the pCRScript™ method, and a
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Excised
fragments
Figure 4.9 Agarose gel analysis of digested clones of individual PCR 
products
The isolated PCR products cloned and digested with Nhe\ and Hindlll, 
analysed on a 1.5% (w/v) agarose gel. The expected size of a ‘presequence 
only’ PCR product is 234 bp; digested this product would be 228 bp.
1) Clone of b and c mixture. Band c is cloned (approx. 260 bp), but a shorter 
fragment, unlikely to be band b, can also be seen.
2) ‘DRIgest III’ markers (A, Hindlll digest and (j) Haelll digest).
3) Clone of band b. Fragment approx. 220 bp
4) Clone of band c. Fragment approx. 260 bp
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number of recombinant clones selected for analysis.
W izard™  Mini Preps were made from the selected clones, and these 
were tested for the presence of a Pstl site by restriction digestion along with 
N hel (found in the primer) as previously described. A Pstl site would be 
present within the correct ‘partial clone’ sequence.
When the products of the digestion were analysed by electrophoresis 
through a 1.5% agarose gel, no fragments were obtained, indicating the lack of 
a Pstl site.
Single stranded DNA was made from the clones, which were manually 
sequenced using M l3 -40 primer. The sequence data revealed the presence of 
the primers, but the sequence between the primers exhibited no homology to 
the PDC-E2 presequence DNA.
4.9 Using shorter primers to PCR the presequence
It was suggested that the restriction sites incorporated into the primers 
were causing priming at incorrect locations. Upon this advice, new primers 
were ordered. These corresponded to primers A and B, but possessed no 
restriction sites and were only 17 bases in length. It was expected that these 
new primers would not generate so many products, only the PDC-E2 
presequence. The presequence would be cloned into pCRScript™  , and from 
there it would be re-amplified using the older primers.
All parameters for the PCR were varied to optimise conditions, but again 
only a wide range of multiple products could be made. Since this method had 
proven to yield no purer PCR products than previous attempts, it was decided 
not to pursue this line of investigation any further.
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4.10 Discussion
This chapter describes a number of attempts to amplify a segment of 
DNA coding for the presequence of PDC-E2 from a XgtlO human foetal 
cDNA library and human genomic DNA by PCR.
As mentioned already, it is not surprising to find that the A.gtlO human 
foetal cDNA library did not yield the correct product. Since cDNA is 
generated by reverse transcriptase, long stretches of DNA can frequently be 
truncated by the enzyme, and can also cause deletions where the mRNA being 
transcribed possesses strong secondary structure.
More difficult to understand is how genomic DNA, the source of the 
original, full length sequence, failed to give the correct PCR product. It is 
possible that the PCR had not been fully optimised. Although optimised for 
annealing temperature, DNA concentrations, dNTP concentrations and 
enzyme type, it could be that other factors, such as length of time spent in the 
initial dénaturation, were not optimal. If the region of DNA supposed to be 
amplified is left in a native state with large regions of secondary structure, this 
could prevent the correct PCR product being synthesised whilst many 
incorreet ones were made. This would not be the case for the original 
investigator, who possessed this DNA in a plasmid which would aid such 
work.
It was not expected that the presequence is encoded on more than one 
exon, but it may be that an intron lies after the end of the presequence, 
separating the DNA coding for the presequence and the mature part of PDC- 
E2. This region is known only by cDNA sequence and not covered by the 
genomic sequence given to us. If this were the case the ‘partial clone’ PCR 
products would be considerably larger than expected, or could be too long to 
be completed by the polymerase during the extension cycle. When the 
research commenced it was considered unlikely that this short stretch of DNA
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would overlap an intron , especially since it has been shown that the nearby E3 
and lipoyl domains are encoded on one exon. However, in the light of the 
difficulties encountered, the possibility that an intron towards the end of the 
presequence exists must be considered.
Though we have been unable to amplify the presequence based on the 
given sequence, we have successfully carried out a control PCR reaction on a 
segment of the PDC-E2 gene near to the presequence, based on other sequence 
data. It is possible therefore that the sequence given to us was incorrect, but 
this does not seem likely. The sequence in question agrees with previously 
published data, is in frame with this sequence, and has been obtained from 
genomic sources. A possible explanation for the difference between the 
presequence PCRs and the control reaction may be a large intron in the PDC- 
E2 gene, separating these two regions. This would allow the control reaction 
to proceed, but, as mentioned above, could interfere with the experimental 
PCRs. It must also be noted that the primers could also be at fault. A number 
of minor flaws in the design (e.g. 5’ GC rich regions) were found which could 
lead to mispriming at temperatures below the the Tm of the primer. Possibly 
this is the cause of the multiple bands in the presequence PCRs, in direct 
contrast to the single strong band generated by the control reaction.
The employment of a new PCR based application called ‘rapid 
amplification of cDNA ends’ (RACE) could aid in obtaining this presequence 
in future. By combining cDNA synthesis and PCR techniques, this method can 
be used to discover the sequences at the 3’ and 5’ ends of a gene. Subsequent 
to this, the newly sequenced terminals of the gene can be used as primers in a 
standard PCR to amplify the whole gene.
In conclusion, a number of different primers designed to amplify the 
DNA coding for the presequence of PDC-E2 have been able to amplify many 
products from genomic DNA, none of which appear to be the correct target
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sequence. Whilst this may generate doubt over the validity of the proposed 
sequence, it is felt that the problem lies in the template DNA, and not in the 
DNA sequence or the design of the primers.
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5.1 Introduction
The aim of this research was to determine possible functions of the PDC- 
E2 presequence in targeting and preventing premature folding/assembly of the 
polypeptide, and specifically to discover if a limited section of the 
presequence was sufficient for targeting. In other extended targeting 
presequences, additional information is often incorporated into the 7
presequence. For example, the bipartite presequence for yeast cytochrome b 
contains firstly an N-terminal mitochondrial-matrix targeting signal. C- 
terminal to that is another sequence which redirects the polypeptide from the 
matrix to the intermembrane space. Another example is the subunit 6 of the 
ATPase in yeast. This 81 amino acid long polypeptide possesses a 66 amino 
acid presequence. The presequence is not only responsible for targeting the 
subunit to the mitochondrion, but it is also required for keeping this 
hydrophobic polypeptide in a soluble form during targeting.
It was intended to use sections of the presequence to assess the functions 
played by various parts of the polypeptide, using a PCR based approach to 
amplify sections of the cloned presequence. In the absence of such a clone, the 
presequence segments had to be made de novo, without the use of a template 
DNA, using synthetic oligonucleotides instead.
A long oligomer, up to 90 bp, can easily be synthesised by most custom 
DNA suppliers; DNA coding for presequence mutants could therefore be 
manufactured as a single stranded oligomer. Transforming this oligomer into |
double stranded DNA could be performed by annealing a short primer to the 
3 ’ end of the oligonucleotide and extending the primer using a DNA 
polymerase, such as Taq or Ventp® (exo-), as shown in Fig. 5.1. This DNA 
could then be cloned into the N h e l  and Hindlll sites of pSoUP, and 
subsequently used in transfection studies.
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1) Oligonucleotide deagqed 
according to sequence t
.
I
II
2) Anneal primer aM extend ?
Figure 5.1 Schematic diagram showing how a single stranded oligomer 
could be made double stranded
An oligomer is made which is identical to the sequence being tested. A 
primer is also made which is the complement of the 3’ end of the oligomer. 
The primer is then extended by a polymerase.
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5.2 Analysis of the primary structure of PDC-E2 presequence
Sequence analysis of the presequence segments was also carried out 
prior to the transfection studies. These sequence analyses were designed to 
detect the presence of any mitochondrial targeting motifs suitable for further 
study.
A comparison of the targeting presequence of PDC-E2 with previously 
characterised presequences was made. Sequences targeting proteins to the 
mitochondrion are often 20-30 amino acids long and are frequently shown to 
have an amphiphilic nature when folded into an a-helix, with polar residues 
(especially hydroxylated and positively charged residues) on one side of the 
helix and non-polar or hydrophobic residues on the other. They also have a 
tendency to contain alanine, arginine, leucine and serine, and a strong bias 
against aspartate and glutamate (Rusch and Kendall, 1995). By comparison, 
the sequence for the targeting signal of PDC-E2 is 73 amino acids long, with 
no overall amphiphilic nature and containing an aspartate residue. It does 
however contain a large number of leucine, serine and arginine residues, 
especially in the C-terminal region of the sequence.
A number of different programmes were employed to find any sub- 
domains which had the features typical of a targeting polypeptide within the 
presequence. Two programmes were used: GCG on UNIX, from the Genetics 
Computer Group (Genetic Computer Group, Inc., Madison, Wise., USA), is a 
piece of DNA/protein sequence analysis software. GCG was used to generate 
alpha-helical wheel plots, which can reveal amphiphilic nature over short 
stretches of sequence (Fig. 5.2). Sybyl, from Tripos, Inc (St. Louis, Mo., 
USA), on the Silicon Graphics Indy workstation, is a programme for 
modelling and analysing the 3-D structures of molecules. Sybyl was used to 
generate 3-D models of the presequence, forced into an a-helix, to give further 
insights into the polypeptide (Fig. 5.3), such as spiralling ridges of polar
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molecules, which can be associated with the C-terminal 10-12 amino acids of 
presequences (Heijne et a l, 1989 ).
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From the figures, it can be seen that the PDC-E2 presequence is not an
'‘ideal’ mitochondrial signal, having no overall amphiphilic nature. However, 
in the N-terminal and C-terminal thirds of the polypeptide, there is some 
similarity to a mitochondrial signal, with these regions possessing many of the 
features normally associated with such sequences. The centre of the E2 
presequence, between 2 proline rich regions, appears to have less 
amphiphilicity. This is in comparison to the presequences of cytochrome c- 
oxidase subunit IV and OGDC-E2. In cytochrome c-oxidase subunit IV, all 
the charged residues cluster together to give a defined amphiphilic helix. In 
the OGDC-E2 presequence, the N-terminal region of the sequence has 
considerable similarity to a mitochondrial targeting signal. The C-terminal 
region of that sequence, however, does not have a recognisable mitochondrial 
targeting motif.
To assess whether the N-terminal region of the PDC-E2 presequence 
was sufficient for targeting to the mitochondrion, it was decided to analyse the 
first 22 amino acids. The first few amino acids, being the first released into 
cytosol from the ribosome, should logically contain the mitochondrial 
targeting signal (Hurt et a l,  1985). The last 24 amino acids were also selected 
for testing since they too formed a convicing amphiphilic helix, and were 
therefore considered as interesting to study. The lengths of both sequences 
match the regions where the helix appears to have a dual nature.
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Figure 5.2 Alpha-helical wheel plots of E2 presequence segments
7
Alpha-helical wheel plots were generated by the GCG programme on a 
UNIX computer based on the whole presequence and segments of it. The 
angle between each residue is taken as 100°. The programme highlights 
‘hydrophobic’ residues in grey boxes. Charged residues have also been 
illustrated to aid identification of targeting motifs (circled positive and 
negative symbols). Glycine, interpreted by GCG as hydrophobic, has been 
assigned no status in these diagrams, since glycine is a flexible and 
amphiphilic residue.
The alpha-helical wheel plot of the entire PDC-E2 presequence (not 
shown) revealed no obvious overall characteristics; plots were subsequently 
performed on thirds of the presequence, shown in Fig. 5.2b. These plots are 
compared to (a) a typical mitochondrial presequence and (c) the 0GDC-E2 
pre sequence.
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1-18 ammo acids of 
Cytochrome C 
oxidase subunit IV 
presequence
hi'v
Figure 5.2a Alpha-helical wheel plot of a typical mitochondrial 
presequence: the cytochrome c-oxidase subunit IV presequence
The first 18 amino acids of the presequence are shown as an example of 
an ‘ideal’ mitochondrial presequence. Although polar residues are scattered 
throughout the hydrophobic section of the helix, the charged residues are 
clustered in a single region, giving the helix a typical amphiphilic nature. It 
should be noted that the first methionine in the sequence will carry a positive 
charge, though GCG recognises all methionine residues as hydrophobic.
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Figure 5.2b Alpha-helical wheel plots of PDC-E2 presequence segments
ammo acids 
presequence
Thr
N-terminal 1-24 amino acids
The plot reveals poor amphiphilicity, with a large number of positively 
charged residues oposite a small number of hydrophobic residues. In the first 
18 amino acids (inner circle) there is clustering of the charged residues 
towards the bottom of the diagram. This may indicate the presence of a 
targeting signal, although the first methionine, as mentioned, will carry a 
positive charge and disrupt this pattern. The negatively charged glutamate is 
atypical of mitochondrial presequences.
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■ ;
aiiuno
presequence
.f
Ser Gly
Amino acids 24-48
The plot shows a partly hydrophobic sequence of amino acids, with 
some scattered polar residues and a polar strip made from tyrosine, arginine, 
and threonine. There appears to be a very slight amphiphilic tendency to this 
section of the presequence.
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ammo
presequence
HvTIThi-
Amino acids 49-73
The plot reveals a number of arginine residues scattered over one half of 
a largely hydrophobic helix. This then has a slightly amphiphilic nature, and 
may be worth investigation as a putative matrix targeting signal.
" ' I
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Figure 5.2c Alpha-helical wheel plots of OGDC-E2 presequence segments
ammo 
OGDC 
presequence
^Lys
Gin
N-terminal 1-24 amino acids
The alpha-helical wheel plot for the first 24 amino acids of the OGDC- 
E2 presequence shows more similarity to the typical mitochondrial 
presequence than the corresponding amino acids in PDC-E2, with the majority 
of charged residues clustered in a small part of the helix. Note again however 
that the first methionine, which is charged, falls outside this cluster of charged 
residues.
1 8 1
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Pro Pro
Ser Argtf>
ammo acids
OGDC-E2 presequence
Pm
Amino acids 25-48
The middle portion of this sequence has a large number of charged 
residues scattered among a number of hydrophobic amino acids. The 
amphiphilic nature noted in the first 24 amino acids is not present within this 
section.
182
Chapter 5: Making PDC-E2 Presequence Segments
amino acids 
OGDC 
presequence
EH E 3
Amino acids 49-68
This final part to the OGDC-E2 presequence also does not appear to be 
amphiphilic, since it has a number of charged arginine residues scattered 
throughout a largely hydrophobic helix.
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Figure 5.3 Molecular model of PDC E2 presequence
4
185
The amino acid sequence for the PDC-E2 presequence was used by the 
Sybyl molecular modeling software to generate this drawing. The sequence 4
was forced into an alpha-helix, with proline residues breaking the structure, to
.'isearch for targeting motifs. Residues were coloured brown for hydrophilic and J
blue for hydrophobic, using the same definitions for hydrophobic/hydrophilic 
used in the GCG programme. Proline is coloured red. Glycine has been treated 
here as hydrophobic. No part of the sequence exhibits strong amphiphilicity.
The illustration shows that the N-teminal region displays the properties 
of a potential targeting motif for the first 16 amino acids. The helix then 
changes from a hydrophobic helix with a hydrophilic strip to a hydrophilic 
helix with a hydrophobic strip for a single turn.
The middle segment does not have the amphiphilicity that the alpha- 
helical wheel plot suggested, here being drawn as a sequence of hydrophobic 4
and hydrophilic segments.
The C-terminal region has 2 segments of amphiphilic helix according to 
the model, the first 6 amino acids are largely hydrophilic, the last segment of 
the presequence also forms a helix with a reasonably convincing dual nature.
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5,3 Method for making presequence segments
5.4 Making the DNA fo r the N-terminal segment of the PD C - 
E2 presequence in pSoUP
Each section of the presequence was to be made from single stranded 
oligomers as described. The double stranded DNA would then be blunt end %
ligated into pCRScript^^ for amplification of the fragment. It could then be 
excised by restriction digestion, purified, and finally cloned into pSoUP (Fig. 
5.4).
The DNA corresponding to the N-terminal 22 amino acids was made 
first, to ensure the feasibility of the technique before continuing with the 
design of further constructs. The DNA fragment corresponding to the N- 
terminal 22 amino acids was named ‘E2n’.
5.4.1 Making E2n
,ï
An oligonucleotide was made coding for the first 22 amino acids of the 
PDC-E2 presequence, however, an extra 2 amino acids was introduced 
directly after the first methionine by the addition of an Nhel restriction site for 
cloning into pSoUP. The Hindlll site included for cloning into pSoUP would 
not affect the presequence, and was already present within pSoUP. The 3:'
oligonucleotides made to generate this DNA can be seen in Fig. 5.5.
.4To make the DNA double stranded, 40 pg primer was added to 11.6 pg 
81 bp oligonucleotide. This gave an excess of primer, ensuring that all the 81 
bp oligonucleotide was converted into double stranded DNA. The DNA was 
diluted to 50 pi total, in VentR® (exo-) buffer, and was heated to denature at 
75°C for 1 min. The DNA was then annealed by cooling to 30°C over a 15
186
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pCRScript
LIGATE
Nhe Î+ H indlll
pCRScript
CUT
pSoUP cleaved with
Nhel+H ind III
LIGATE
pSoUP 
with 
E2 insertpSoUP
'I:
r
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Figure 5.4 Using pCRScript to amplify oligomer and allow sticky end 
ligation into pSoUP
After making a single stranded oligomer double stranded, it can be blunt 
end ligated into pCRScript. Once cloned, the oligomer can be sequenced and 
amplified in the plasmid. In this way, large amounts of the DNA can be made, 
and the oligomer can be excised from the plasmid using Nhel and Hin&lll,
ready for ligation into the expression vector, pSoUP.
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Oligomer ^  g g c g g g a c t c c a g g a c t c g g t g g a c g g a c c t t g c a g g a g g t a c c c g g
PDC-E2 s'TAccCGICCiS^GlS^ÎCCTaft^Cato?^ 
Oligomer a a c t c c a c g a g t g a c c p ^
Primer ttgaggtgctcactg(T7>cg^
c<X!àd‘BGii«?éîPCcciÈrAccGCcc<^^
TCAA(»CCCCGG1?GCGGCGCCTTG<K:GAATQACGACGTCGAAAACCCC|«5
Figure 5.5 Design of oligomer DNA and primer to make first PDC E2 
presequence segment
The first 200 bases of the DNA coding for the PDC E2 presequence are 
shown, along with the 2 oligomers designed to make the presequence segment 
which would code for the first 21 amino acids (after the initial methionine), as 
described in Section 5.1. The PDC-E2 presequence is shaded in grey. The 
oligomer and primer are shown in red, with the additional restriction sites 
coloured blue.
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15 min period, after which 12.5 mM dNTPs and 2 pi VentR® (exo-) 
polymerase were added to start polymerisation of the second strand. To ensure 
the polymerase performed adequately, the reaction was slowly warmed over 
10 min to 50°C, and left to incubate for 30 min.
Gel electrophoresis was employed to detect any shift in mobility as a 
result of changing the piece of DNA from single stranded to double stranded. 
The polymerase treated DNA was compared with the original oligomer on a 
10% (w/v) acrylamide gel (Fig. 5.6). Such analysis is capable of 
demonstrating whether or not the DNA had been altered.
5.4.2 Cloning and analysis of E2n in pCRScriptTM
The E2n DNA fragment was cloned into p C R S c r ip t ™ ^  according to the 
manufacturer’s protocol. A large number of recombinants were made, 4 of 
which were tested for the presence of an insert. Wizard^M Minipreps were 
made of each of the 4 selected clones. These plasmids (5 |ig) were then 
digested for 2 h with 20 units Nhel and HindUl at 37°C. The results are shown 
in Fig. 5.7. The 3 clones which were found to have inserts were used to make 
single stranded DNA, which was sequenced with the Sequenase kit using M l3 
-40 primer. One of the clones which was found to have the correct sequence 
was taken forward for cloning into pSoUP whilst the others were discarded.
5.4.3 Cloning of E2n into pSoUP
A fresh W izard™  M iniprep was made of the E2n clone in 
pCRScript™. The E2n clone (5 |i,g) was digested in 50 jil Nhel buffer with 20 
units Nhel overnight at 37°C, to ensure digestion. To this was added 20 p.1 
Hindlll buffer, along with 20 units Hindlll. The reaction was then incubated 
for 3 h at 37°C. The excised fragment was isolated and purified, using the
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1 2  3 4
« 0  #  W .#
Figure 5.6 Acrylamide gel analysis of double stranded oligomer
The new double stranded oligomer was compared to the original single 
stranded oligomer on a 10% (w/v) acrylamide gel. The gel shows that the 
oligomer has lost mobility, an indication that it has become double stranded.
1) ‘DRIgest I i r  markers (k  Hindlll digest and (() Haelll digest)
2) Single stranded oligomer
3) Double stranded oligomer
4) ‘DRIgest I i r  markers {X Hindlll digest and (|) Haelll digest)
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MERmaid® kit. The DNA was quantified to be at 900 ng in 30 |ll.
pSoUP (12 pg) which had been purified by density centrifugation was 
digested with 50 units Nhel for 6 h ( to ensure digestion) at 37°C in a total of 
50 pi Nhel buffer. This was diluted with 50 pi Hindlll buffer, and redigested |
with 50 units HindUl for 6 h at 37°C. Full digestion of the plasmid was 
checked by ligating 50 ng for 5 h with 1 unit T4 DNA ligase, and transforming 
into supercompetent cells (supplied by Stratagene). A low background was
'I,obtained, presumably from religation of a small amount of the excised linker.
It was decided to ligate the E2n DNA fragment into the cut vector 
without further purification of the vector away from its own linker DNA.
Excised E2n DNA (80 ng) was ligated to pSoUP (60 ng), an 80x excess of r;
insert, using 1 unit ligase into 10 pi total volume. The reaction was incubated 
at room temperature for 4 h, and transformed into supercompetent cells. Of the 
colonies obtained, 5 were tested for the presence of an E2n-pSoUP construct, 
called ‘pE2nSoUP’.
5.4.4 Analysis of pE2nSoUP
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Plasmids were prepared from the clones by W izard™  Minipreps, and 2 
pg of each digested with 10 units Hindlll and Nhel for 1 h at 37°C. The result, 
shown in Fig. 5.8, shows that 4 of 5 clones tested were suitable. The DNA was 
then manually sequenced with the Sequenase™ kit, utilising the PCR primers 
1 and 4 (see Ch3) to sequence pSoUP in both directions from outside the 
cloning site. A clone was found with absolutely correct sequence, which was 
grown overnight and frozen down in glycerol to establish a permanent stock. 
With the procedure established, the second presequence segment could be 
made.
,1A-
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la  lb 2a 2b 3a 3b 4a 4b 5
Figure 5.7 Agarose gel analysis of restriction digests of oligomer clones
Restriction digests of the 4 tested clones, analysed by electrophoresis 
through a 2% (w/v) agarose gel. Plasmids were digested with Nhel and 
Hindlll (a), or left undigested (b).
Lanes 1-4) The digested and undigested clones
5) ‘DRIgest IIP markers {X Hindlll digest and (j) Haelll digest)
From the gel, it can be seen that there are 2 different types of ligation 
product. The clone in lanes 4a and b, gives a restriction fragment in lane 4a 
which is considered to be too large to be the correct ligation. The origins of 
this fragment are unknown; it is possible that the N hel digestion has not 
occurred, and a Hindlll fragment has been excised.
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Fig 5.8 Agarose gel analysis of restriction digests of pE2n SoUP clones
Restriction digests of the 5 clones tested for the presence of an insert by 
digestion with Hindlll and Nhel were analysed by electrophoresis through a 
2% (w/v) agarose gel.
1 ) ‘DRIgest Iir markers {X Hindlll digest and (j) Haelll digest)
2-6) Digestions of 5 selected clones
From the gel it can be seen that 4 of the 5 clones yield the correct size of 
fragment upon digestion. Those clones which yielded a fragment were suitable 
for sequencing.
194
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5.5 Making the second PDC-E2 presequence segment in pSoUP
5.5.1 Making the DNA coding for the C-terminal presequence 
segment
The last 24 amino acids in the presequence were selected for the second 
set of experiments. In addition to the 24 amino acids, 3 amino acids caused by 
the inclusion of an Nhel linker sequence in the DNA would be encoded by the 
oligomer. In addition to this, DNA coding for a single serine at the 3’ end of 
the presequence DNA was included. This serine, from the start of the mature 
PDC-E2, is the point at which the mitochondrial processing peptidase cleaves 
the presequence. Including it allows us to test whether this sequence is 
sufficient for signal cleavage. Again, a Hindlll site is included for cloning into 
pSoUP, but does not form part of the presequence. This segment of DNA was 
called ‘E2c’.
The oligonucleotide sequence desiged to code for this polypeptide is 
shown in Fig. 5.9, along with the primer used to make the single stranded 
DNA double stranded. The DNA was made double stranded as before, using 
40 pg primer and 12 pg 87 bp oligonucleotide (an excess of primer). The 
DNA was diluted to 50 pi total, in VentR® (exo-) buffer, and was denatured at 
75°C for Imin. The DNA was then annealed by cooling to 30^0 over a 15 min 
period, after which 12.5 mM dNTPs and 2 pi VentR® (exo-) polymerase were 
added to start polymerisation of the second strand. To ensure the polymerase 
performed adequately, the reaction was slowly warmed over 10 min to 50°C, 
and left to incubate for 30 min. The DNA was electrophoresed on an 
acrylamide gel as before, but not all DNA had converted from the single 
stranded form to the double stranded. It was decided to proceed, and select for 
clones in pCRScript by sequencing.
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ÏT9 5'ATGGGC<3G<aiC1x;<»aGîyC^EC<3G^PGGkCG<»ÆC!^ ^
3'!TACCC0CÇCTÛlM»^<:.1?GAJ(SCCAœTGCC®GGlWGl!CCÏCa^^
Oligomer ag ttc tg g g g c c a c g c c g c g g a a c c g c t ta c t g c tg c a g c t t t tg g g g t c
Oligomer g c c c g g c c g c c g c t a t t a c a g t  a a g c t t  <K:ccaGcx:<»^^ 
CGGGCCGGCGGCGA1IAA7G4?CA Primer c g g c g g c g a t a a t g t c a j > 7,
Figure 5.9 Design of oligomer DNA and primer to make second PDC E2 
presequence segment
The DNA coding for the PDC-E2 presequence is shown, along with the 
2 oligomers designed to make the second presequence segment. The mutant 
DNA codes for the last 24 amino acids of the PDC E2 presequence and the 
first serine of the mature PDC-E2. The PDC-E2 presequence is shaded in grey. 
The oligomer and primer are shown in red, with the additional restriction sites 
coloured blue.
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5.5.2 C loning and  analysis of E2c in  p C R S c r ip t™
The E2c DNA fragment was cloned into pCRScript^M^ as described 
previously. A large number of recombinants were found, 27 of which were 
tested for the presence of an insert. Wizard™  Minipreps were made of each of 
the selected clones, and digested with N hel and H indlll as before. Of the 
clones which were found to have inserts, 2 were used to make single stranded 
DNA, which was manually sequenced with the Sequenase kit using M l3 -40 
primer. Both clones were found to have the E2c insert, and one was taken 
forward for cloning into pSoUP.
5.5.3 Cloning of E2c into pSoUP
Plasmid was made from the E2c clone by W izard™  Miniprep. The 
plasmid (5 pg) was then digested in 50 pi Nhel buffer with 20 units Nhel 
overnight at 37°C, to ensure complete digestion. To this was added 20 pi 
Hindlll buffer, along with 20 units HindUl. This was incubated for 3 h at 
37°C. The excised fragment was then isolated and purified, using the 
MERmaid® kit. pSoUP was also digested as before.
Excised E2c DNA (100 ng) was ligated to cut pSoUP (70 ng), using 1 
unit ligase in 10 pi total volume. Again this ligation uses approx. 80x excess 
of insert to vector. The reaction was incubated at room temperature overnight, 
and transformed into supercompetant cells. A large number of colonies were 
obtained by this method, 10 of which were tested for the presence of an E2c- 
pSoUP construct, called ‘pE2cSoUP’.
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5.5.4 Analysis of pE2cSoUP
5
W izard™  Minipreps were used to make plasmid DNA of the clones, 
which were digested with Nhel and Hindlll as before. Clones which posessed 
an insert were frozen down to form permanent stocks, and were then 
sequenced using the Sequenase kit, utilising the PCR primers 1 and 4 (see Ch.
3) to sequence pSoUP on either side of the cloning site. This did not give 
satisfactory results, so W izard™  Maxipreps were carried out to obtain better 
quality DNA. A number of clones verified the presence of the desired insert, 
and one of these was sequenced fully, revealing absolutely correct sequence 
for the insert except for a single base deletion. This deletion was interpreted as 
a sequencing error since the missing base was in the region of DNA 
synthesised by the manufacturers of both the primer and the oligonucleotide, 
and could not have been introduced by the polymerase.
5.6 Discussion
Analysis of the presequence DNA revealed regions possessing targeting 
signal-like motifs and regions where the sequence was distinctly unlike a 
targeting signal. The N-terminus of the sequence has the capacity to form an 
amphiphilic helix, and bears some (though poor) similarity to typical targeting 
signals. Interestingly, the C-terminal region also has a similar motif, whilst the 
middle portion of the presequence has no such amphiphilicity nature. This is 
in contrast to the mitochondrial signal for the E2 subunit of OGDC, which had 
a more pronounced amphiphilic nature at the N-terminal region in Fig. 5.2c, 
and no recognised motif at the C-terminus, which is the expected nature of a 
targeting presequence.
The aim of this research was to determine the reason for and functions of 
the extended presequence on immature PDC-E2 polypeptides. This domain-
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like structure to the presequence suggests that there is more than one function 
and that the targeting signal may be held in one part of the presequence whilst 
additional information is held elsewhere.
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Chapter 6: Transfection o f COS-7 Cells with pSoUP Constructs
6.1 Introduction
The aim of this research was to characterise the pre sequence of PDC E2, S
by elucidating whether the N-terminal region of the presequence carried all the 
information for targeting and antifolding for the E2 polypeptide. This would 
be decided based on the ability of the presequence to cause translocation of 
CAT to the mitochondrion. In addition, the nature of the C-terminal region, 
which had an amphiphilic nature similar to the N-terminal region, was to be 
tested for similar targeting properties. A fourth version of the plasmid was also 
tested in parallel with those described in Chapter 5; an oligonucleotide 
construct of the entire PDC-E2 presequence, made by Dr. L. Briand, was used 
in pSoUP to replace the cloned product which could not be obtained in 
Chapter 4. This plasmid would be used to test the properties of the native :f
PDC-E2 presequence.
Transfection studies using COS-7 cells, a monkey kidney fibroblast cell 
line commonly used in such work, would reveal the behaviour of the CAT 
polypeptide constructs. The plasmids made in chapter 3 and 5 could be 
transfected into the cells and, once they had expressed the various chimaeric 4
proteins, the cells would be harvested. These cells could subsequently be 
analysed to find the position and enzyme activity of CAT; the subcellular 
location of CAT would reveal the targeting properties of the presequence, and 
the enzyme activity would demonstrate whether or not the CAT trimer had 
been able to assemble.
To detect assembly of the CAT trimer, the CAT assay of Seed and Sheen 
(1988) was used, as detailed in the methods section (2.7.1.6). This assay can 4
establish assembly since CAT is only active once it has folded correctly and 
formed a trimer. To discover the location of the CAT, cells were fractionated 
into various subcellular compartments using digitonin, and the expressed CAT 
detected immunologically. Digitonin is a useful detergent which interacts
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specifically with cholesterol. Digitonin can therefore selectively disrupt 
membranes based on their cholesterol content. Since the plasma membrane of 
mammalian cells contains 17% cholesterol (liver cells) in comparison to 
mitochondria which have only 3% cholesterol (inner and outer membranes 
combined), the plasma membrane of cells such as COS-7 will be ruptured at a 
lower digitonin concentration than that required to disrupt mitochondria. This 
allows efficient fractionation of a small number of cells into cytosol and 
cytosol/mitochondrial matrix fractions without the need for density 
centrifugation, as is commonly used to isolate mitochondria.
It is worth pointing out that most mitochondrial targeting studies have 
been carried out on isolated mitochondria in vitro, or in yeast. Only recently 
have transfection technologies allowed the routine introduction of foreign 
genes into mammalian cells. The work of Boutry et a l (1987) is most relevant 
to this work, where CAT was linked to a 90 amino acid N-terminal segment 
from the (3-subunit of the mitochondrial ATPase of Nicotiana plumbaginifolia. 
This construct was then introduced into and expressed in tobacco cells, where 
the chimaeric polypeptide was targeted to the mitochondrion. This 
demonstrates the suitability of CAT for mitochondrial targeting studies (at 
least in plants) and the ability of in vivo targeting studies to reveal the nature 
of presequences.
6.2 Fractionating COS-7 cells
For the transfection/fractionation experiments to proceed, it was 
necessary to optimise all the appropriate conditions for these procedures. A 
protocol for cell fractionation was initially devised, to ensure that the plasma 
membrane could be disrupted without rupturing the mitochondrial membranes. 
Following this, a suitable method for transfection of the plasmid was selected 
based on maximal expression. The three chosen methods were compared using
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optimal conditions for each protocol.
6.2.1 Culturing and harvesting cells
COS-7 cells were cultured (in 60 mm transfection dishes) as described in 
the methods section, until confluence was reached. Cells were harvested as 
described, washed with sterile ice-cold PBS and scraped off the dish to be 
resuspended in 1-1.5 ml ice-cold PBS. The cells were then centrifuged for 5 
min at 2500 rpm in 50 ml sterile plastic tubes, and resuspended to 10^  cells/ml 
in PBS.
6.2.2 Fractionating cells
Cells (at 10  ^cells/ml) were incubated for 1 min at 4°C in the presence of 
a range of digitonin concentrations before centrifuging at high speed in a 
benchtop centrifuge to pellet the membrane, whole cells and unruptured 
organelles. The supernate was carefully removed, leaving the pellet 
undisturbed. Both were then stored at -20°C.
6.2.3 Identifying fractions by enzyme assay
By assaying for enzymes specific for the fractions of interest, it is 
possible to identify which subcellular compartments are present in each lysate 
by the presence or absence of an enzmye. The marker enzymes chosen were 
lactate dehydrogenase (LDH), which is found solely in the cytosol, citrate 
synthase, which is found only in the mitochondrion, and malate 
dehydrogenase (MDH), which is found in both the cytosol and mitochondrion. 
As the plasma membrane is solubilised, so LDH and MDH are released into 
solution. When more digitonin is used, the mitochondria are ruptured along
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with the plasma membrane. In this case, mitochondrial MDH and citrate 
synthase are released along with the cytosolic MDH and LDH.
In Fig. 6.1 it can be seen that LDH and MDH are released at approx. 
0.05 mg digitonin/10*^  cells. Citrate synthase and mitochondrial MDH are 
released at approx. 0.5 mg/10  ^cells. From this it was decided to use a range of 
digitonin concentrations between 0 and 1.0 mg/10*" cells which ensured that 
the plasma membrane was completely solublised without any damage 
occurring to the mitochondrion (i.e. >0.05 mg/10*" cells, but <0.5 m g/10*" 
cells), and at least 1 fractionation carried out at a concentration of digitonin 
>0.5 mg/10  ^cells.
6.2.4 Identifying fractions by Western blots
i
Cell extracts (40 pi, 10*" cells/ml) were subjected to SDS-PAGE, and >
transferred onto nitrocelluose as described. LDH and citrate synthase were 
then detected by ECL (Fig. 6.2), using rabbit polyclonal antisera raised ‘in 
house’. The results confirmed the data generated by the enzyme assays, that 
cytosolic enzymes are released when digitonin concentrations exceed 0.05 (
m g/10  ^ cells, and that the mitochondrial membranes are disrupted at 0.5 mg J
digitonin/10  ^cells.
6.2.5 Optimising transfection
Three transfection protocols were tested, following optimised protocols 
described for each method. Plasmid (pBLSV CAT) was purified using the 
Qiagen midi prep kit, and transfected into cells growing in 4x60 mm 
transfection dishes, using one of the three protocols. Two negative controls 
were included; ‘plasmid only’ was to monitor for background uptake of the ^
plasmid by adding plasmid but no transfection reagent, and a negative control
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□ lactate dehydrogenase 
° malate dehydrogenase 
^citrate synthase
mg digitonin/miliion cells
Figure 6.1 Fractionation of cells and release of marker enzymes
Graph showing release of various enzymes with increasing digitonin 
concentration.
It can be seen from the graph that cytosolic enzymes are released when 
digitonin concentrations exceed 0.05 mg/10  ^cells. Citrate synthase, and the 
mitochondrial malate dehydrogenase are found in the supernate once the 
mitochondrial membranes are disrupted at 0.5 mg digitonin/10^ cells.
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M, (X 10-3)1 2 3 4 5 6 7 8
4 3  _  _ Citrate synthase
3 Q ' Lactate dehydrogenase
20 ;
14.4
The results of the Western blot confirm that at 0.05 mg digitonin/10
at 0.5 mg digitionin/10^ cells, mitochondrial disruption has also taken place.
■i-
Figure 6.2. Western blot of fractionated cells to detect released enzymes
Fractionated cell extracts were electrophoresed through a 10% (w/v) 
SDS-polyacrylamide gel, and then transferred to nitrocellulose for ECL 
detection of lactic dehydrogenase and citrate synthase.
Lanes 1-4; Fractionated cells tested for the presence of citrate synthase
1 and 3) Cytosolic fraction only (0.05 mg digitonin/10  ^cells)
2 and 4) Cytosol and mitochondrial matrix (0.5 mg digitonin/10  ^cells)
Lanes 5-8; Fractionated cells tested for presence of LDH
5 and 7) Cytosolic fraction only (0.05 mg digitonin/10^  cells)
6 and 8) Cytosol and mitochondrial matrix (0.5 mg digitonin/10^ cells)
cells, the plasma membrane is ruptured without mitochondria being lysed, but
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negative control with no plasmid and no reagent. Cells were harvested after 48 
h, and diluted to 10^  cells/ml. Cell extracts were then made by adding 1 mg/ml 
digitonin or 1% (w/v) Triton X-100.
The results are tabulated below (Table 6.1), and demonstrate that 
lipofection is the most efficient method for mammalian cell transfection.
Table 6.1
Transfection method used CAT activity (cpm/assay)
Lipofection 23,074 +/- 597
DEAE-Dextran 7,936+/-2117
Calcium chloride 2,955 +/- 732
Plasmid only 505 +/- 125
Negative control 889 +/- 220
Both detergents were found to cause some difficulties in obtaining a 
clear phase separation during the CAT assay, particularly when using Triton 
X-100. It was therefore decided to use an additional aliquot which was given a 
freeze-thaw treatment in later experiments to avoid such complications.
6.2.6 Developing a standard protocol for cell transfection and 
fractionation
The enzyme assays and Western blotting analysis revealed that COS-7 
cells could be fractionated into cytosol only and cytosol + mitochondrial 
matrix extracts. When digitonin was at a concentration of 0.05 mg/lO*  ^cells (in 
1 ml PBS), only the plasma membrane was solubilised, but when the 
concentration of digitonin was 1 mg/lO*" cells (in 1 ml PBS), both the plasma 
membrane and the mitochondrial membranes were broken, releasing their
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contents.
CAT assays demonstrated the efficiency of lipofection over calcium 
chloride and DEAE dextran treatments, using prescribed protocols for each 
method.
A standard protocol for transfection of cells, their harvesting and 
fractionation was therefore as follows: 5 pg pure DNA per dish transfected by 
lipofection and incubated with the lipofectin™/DNA overnight, after which 
time the medium is replaced and the cells left to incubate for 48 h. The cells 
are harvested in PBS, and fractionated with digitonin at 3 concentrations- to 
leave the cells intact, 0 mg/lO'" cells is used, to rupture the plasma membrane, 
0.1 m g/10  ^ cells guarantees full solubilisation without damage to the 
mitochondrion; and for full disruption, 1 mg/lO*'’ cells ensures complete 
solubilisation of both membranes. A fourth aliquot of cells was freeze-thaw 
treated to obtain detergent-free cell extracts for CAT assays.
thaw lysed cells demonstrated that CAT activity was unaffected by the 
mutation of 2 N-terminal amino acids in CAT expressed from pSoUP (Table 
6.2).
1
6,3 Testing pSoUP against original pBLSV CAT
Both plasmids were purified by Qiagen midi preps, and used to transfect 
cells using the above standard procedure. CAT assays performed on freeze-
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Table 6.2
Plasmid tested CAT activity (cpm/assay)
pBLSV CAT 166,299 +/- 3834
pSoUP 125,627+/-22372
negative control 572.5 +/- 28.5
Variability between pSoUP and pBLSY CAT activities is likely to be 
due to expression levels, caused by slight differences in quantity and quality of 
plasmid DNA transfected, or by random errors introduced by the experimental 
method.
A Western blot was then performed to discover if pSoUP also expressed 
a cytosolic CAT, as expected. Fig. 6.3 demonstrates that the location of CAT 
is also unaffected by the amino acid substitutions, with CAT released after 
plasma membrane lysis. Minimal CAT was detected associated with the
membrane pellet after lysis of cells (not shown). The identity of the fractions
was confirmed by the use of enzyme assays (section 6.2.3).
6.4 Testing the PDC E2 presequence/CAT gene constructs
The presequence-CAT gene constructs were then tested using the above 
protocols. The plasmids tested were pSoUP (CAT expression vector), pE2n 
SoUP (CAT expression vector with the DNA for the first 22 amino acids of 
the E2 presequence), pE2c SoUP (CAT expression vector with the DNA for 
the last 25 amino acids of the E2 presequence) and the full length E2 
presequence construct, pE2 SoUP.
Fig. 6.4 shows the Western blot of the fractionated samples taken from 
the cells transfected with pBLSV CAT and pE2n SoUP. pE2c SoUP did not 
express any CAT antigen, and is not shown in the figure. Results for pSoUP
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1 2 3 4 5 6 7 8
Fig 6.3 Fractionation of expressed CAT from pSoUP
Western blot of fractionated cells electrophoresed through a 10% (w/v) 
SDS-acrylamide gel.
1) 0 mg digitonin/10^ cells
2) 0.02 mg digitonin/10  ^cells
3) 0.04 mg digitonin/10  ^cells
4) 0.1 mg digitonin/10*^  cells
5) 0.2 mg digitonin/10^ cells
6) 0.4 mg digitonin/10  ^cells
7) 0.8 mg digitonin/10  ^cells
8) Purified CAT standard
The blot shows that CAT is detectable in the supernate once the 
digitonin concentration exeeds 0.02 mg/10  ^cells.
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Figure 6.4 Fractionation of expressed pE2n SoUP and pBLSV CAT
Western blot of fractionated cells electrophoresed through a 10% (w/v) 
SDS-polyacrylamide gel.
1 ) Purified CAT standard
Lanes 2-6, cells expressing pE2n SoUP
2) Freeze-thaw lysed cells
3) 0 mg digitonin/10^ cells
4) 0.1 mg digitonin/10^ cells
5) 0.25 mg digitonin/10^ cells
6) 1 mg digitonin/10^ cells
Lanes 7-11, cells expressing pBLSV CAT
7) Freeze-thaw lysed cells
8) 0 mg digitonin/10^ cells
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Figure 6.4 cont’d
9) 0.1 mg digitonin/10  ^cells
10) 0.25 mg digitonin/10  ^cells
11)1 mg digitonin/iO'" cells
This demonstrates that CAT expressed by pE2n SoUP is a cytosolic 
enzyme (released at 0.1 mg digitonin/10  ^cells), as is pBLSV CAT and pSoUP 
(Section 6.3). It can also be seen that the CAT expressed by pE2n SoUP is of a 
higher subunit Mj. value than that expressed by pBLSV CAT, as expected with 
the presence of the presequence on the CAT.
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were similar to pBLSV CAT (not shown). Further Western blot data on the 
behaviour of pE2 SoUP from Loïc Briand revealed a higher Mr CAT antigen 
present in the cytosolic fractions after fractionation of the cells. It appeared 
therefore that CAT expressed from all plasmids was cytosolic , except pE2c 
SoUP, which was not detected.
Shifts in mobility in CAT can be attributed to the presence of the 
presequence. CAT assays performed on freeze-thaw lysed cells demonstrated 
that CAT activity was unaffected by the presence of any of the presequences, 
except pE2c SoUP, which had no detectable activity. These results are 
tabulated below (Table 6.3).
Table 6.3
Plasmid tested CAT activity  (counts per
minute)
pE2 SoUP 
pE2n SoUP 
pE2c SoUP 
pSoUP 
pBLSV CAT 
negative control
22,728 +/- 2274
146,688 +/- 13976 
513 +/-21 
125,627 +/- 22372
166,299 +/- 3834 
572.5 +/- 28.5
Variability in expression levels, caused by slight differences in quantity 
and quality of plasmid DNA transfected, has again caused the differences seen 
here between those transfections which can be seen from ECL to be 
expressing CAT. It is worth noting that the low activity seen in the full length 
presequence-CAT construct (pE2 SoUP) was reflected in Western blots (not 
shown) where the levels of expressed CAT were low.
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Since pE2c SoUP had not expressed any CAT, it was decided to repeat 
the transfection of COS-7 with freshly prepared pE2c SoUP, made by 
W izard™  Maxipreps. This transfection also failed to express CAT, as 
detected by immunological and CAT activity assays. Since the plasmid was 
unable to express any CAT, it was considered that what had been regarded as 
a sequencing error in pE2c SoUP could have been a genuine base deletion in 
the region of the synthesised oligonucleotide. Sequence analysis was repeated 
on the plasmid. The results confirmed that a base was missing, and that any 
expressed polypeptide would terminate prematurely due to a frame shift 
mutation.
6.5 D iscussion
In this chapter, the presequence segments integrated into the plasmid 
pSoUP were expressed in COS-7 cells to test the ability of the presequences to 
halt folding and inti ate targeting of CAT to the mitochondrion.
It was found that the N-terminal section of the presequence was 
insufficient to prevent folding of CAT, or to trigger its translocation to the 
mitochondrion. Furthermore, it was found that a base deletion had occurred in 
the DNA for the C-terminal segment of the presequence, causing a frame shit 
in the rest of CAT, which invalidated that part of the experiment. This frame 
shift was confirmed by the absence of any activity in any cell extracts in a 
number of separate transfections.
The plasmid constructed by L. Briand, which contained the entire 
presequence in pSoUP, gave some surprising results. Expression of CAT was 
poor and was untargeted, a fact confirmed by the observation that the 
presequence was not cleaved from CAT when analysed by SDS-PAGE 
analysis (not shown). Table 6.3 confirms that there was low expression of 
active CAT from pE2 CAT. This observation also demonstrates that the
2 1 4
Chapter 6: Transfection o f COS-7 Cells with pSoUP Constructs
presequence did not prevent CAT from folding properly, since a significant 
level of CAT activity was present, despite the presequence being attached.
Of note are other experiments carried out in this laboratory which 
demonstrate the antifolding activity of the BCDC-E2 presequence. Expression 
of mature BCDC-E2 in E. coli produces folded, active cores. However, N- 
terminal segments of the BCDC-E2 presequence as short as 17 amino acids 
prevented assembly, and led to degredation of the polypeptide. This raises a 
number of issues; firstly, the difference in behaviour between the BCDC-E2 
expression studies and the PDC-E2/CAT targeting studies would suggest that 
CAT in mammalian systems is not an accurate model for E2, since folding is 
not prevented and import is not initiated. Secondly, it demonstrates that E2 
presequences have antifolding capabilities in heterologous systems, whether it 
be by directly preventing the rest of the polypeptide from reaching a native 
conformation, or by interacting with the chaperones of the host bacterium.
It is disappointing that the PDC-E2 presequence was unable to target 
CAT. A number of reasons why the sequence failed to target CAT exist. It is 
possible that the presequence interacts with the lipoyl domain in PDC-E2; 
since this is lacking from CAT, the behaviour of the presequence would not be 
the same. Alternatively, it may be that the assembly of CAT has prevented 
uptake. A polypeptide has been found which has both a peroxisomal targeting 
signal and a weak mitochondrial targeting signal. This polypeptide was 
translocated to peroxisomes when present as a dimer, but imported into the 
mitochondrion when a point mutation inhibited dimérisation (reviewed by 
Danpure, 1997). These discoveries highlight the importance of the assembly 
status of a polypeptide on its ablility to target to the mitochondrion.
Further work to elucidate the role of the presequence should be based 
around a repetition of the experiments with BCDC-E2 expression in E. coli, 
using instead PDC-E2. Investigation into the interaction of the presequence 
with the lipoyl domain may also aid understanding of this system.
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7.1 In troduction
PDC is a key enzyme in glucose homeostasis because it catalyses the 
committed step in carbohydrate metabolism linking glycolysis to the citric |
acid cycle, thus governing the flux of 2 carbon units into the cycle. Since PDC 
represents such a pivotal point in metabolism, it is regulated by a number of 
factors, including hormonal signals and the end products of the reaction.
Regulation is primarily achieved by four isoforms of a dedicated complex- i
bound kinase which inhibits the enzyme by phosphorylation; a specific 
phosphatase reactivates it. The kinase and phosphatase exert their control over
the E l component, which catalyses the first, irreversible, rate limiting step, so |
.5that by inhibiting this component the entire reaction sequence is prevented.
Kinase activity is controlled by a number of metabolites which act as
•i'i
positive or negative effectors; pyruvate, ADP, CoA and NAD+ inhibit |
phosphorylation while ATP, acetyl CoA and NADH are positive effectors. In 
response to activation, the kinase abolishes almost all PDC activity by 
phosphorylating up to 3 different serine residues on E la  (Fig. 7.1). Recent site 
directed mutagenesis studies (Nemerya et a l ,  1996) have shown that the 
phospho-serine residues generated by the kinase are likely to exert their effect 
by competing with pyruvate for the active site arginine residues. The 3 serines 
undergo phosphorylation at different rates, site 1 being phosphorylated more 
rapidly than site 2 and site 2 more rapidly than site 3. Each site is sufficient, |
when phosphorylated, to inactivate E l without the other 2 sites being
phosphorylated (Korotchkina et al., 1996). It has also been shown, through 
32p incorporation (Yeaman et a l,  1978 and Korotchkina et al., 1996), that 
only 1 phosphorylation event per E l tetramer needs to occur for inactivation 
of the entire tetramer, suggesting an element of positive cooperativity between
■1:subunits. Cooperativity between subunits in the tetramer has already been
■7.proposed for other aspects of the enzyme’s activity, such as the alternating site k
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Reaction of PDC with ATP
125
100
% activity
60 8040200
^  ATP treated intact PDC 
Control PDC
Time (min)
Figure 7.1 Effect of ATP on PDC activity
ATP (4 mM) was added to PDC in kinase buffer (1 mg/ml, methods 
section 2.7.6). PDC assays (methods section 2.7.1.4) at regular intervals show 
the loss of activity due to phosphorylation. After 20 min, only 10% activity is 
left, and minimal activity is left after 60 min.
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demonstrated by Khailova et al. (1989).
A number of related PDC kinase genes have been found (currently 4 in 
the human genome numbered PDCK 1-4, Rowles et al., 1996) which all have 
sequences similar to the prokaryotic protein histidine kinase family, and lack 
motifs usually associated with the eukaryotic serine/threonine protein kinases 
(Popov et al, 1993). The kinase isoenzymes possess varying characteristics, 
with differing specific activities and Ki values for synthetic analogues of its 
substrates (Bowker-Kinley et al, 1997). The isoenzymes are found in varying 
quantities in different tissues (e.g. PDCK3 is found exclusively in heart and 
skeletal muscle, Gudi et al., 1995), indicating that the subtle differences in the
"S'.
functions of each kinase are important to the metabolism of those tissues. 
Work by Harris et a l  (1997) has demonstrated that PDCK 4 levels increase in 
the heart of rats when starved, and is restored to normal levels when the rat is 
fed again, whereas PDCK 1 and 2 levels are unaffected by the treatments.
The prokaryotic protein histidine kinases are known to be dimers which 
correlates well with existing evidence suggesting that PDC kinase is also a 
dimer. This would explain how 3-5 kinase molecules can inactivate 60 E l 
subunits without leaving the complex. PDC kinase subunits are able to bind 
the inner lipoyl domain of PDC-E2, and Liu et al. (1995b) have demonstrated 
that the kinase repeatedly releases and binds lipoyl domains. The kinase dimer 
is therefore thought to move over the complex by swinging "hand over hand", 
alternating between states where the kinase is bound to 1 and 2 lipoyl 
domains. An active kinase molecule could therefore deactivate the entire 
complex very quickly, moving over the surface of the E2 core, gaining access 
to all the bound El.
The focus of this research was on the nature of the multiple 
phosphorylations. Whilst all 3 phosphorylations take place when both the El 
and the kinase are bound to the complex, this is not the case when both 
subunits are free in solution. When kinase and El are freed from the complex,
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only the first, most rapidly phosphorylated serine, is modified by the kinase. 
The question to be asked, therefore, is this: is attachment of the kinase, E l or 
both kinase and E l to the E2 core necessary for the multiple phosphorylation 
of E l?
To help in answering this question, it is possible to utilise a discovery 
made in this laboratory regarding the lipoyl domains. Digesting intact PDC 
with the enzyme collagenase leads to the cleavage of E2 at the linker region 
between the inner lipoyl domain and the E l binding domain (Fig. 7.2a,b), 
giving 2 lighter fragments termed E2p (the lipoyl domains) and E2i (the inner 
domains). Collagenase does this by cleaving a tetrapeptide (Pro Leu Gly Pro), 
unique in PDC-E2, a sequence which occurs frequently in the structural 
protein, collagen. The result of cleaving E2 at this point is a loss of PDC 
activity due to the loss of the E2 lipoyl groups (Fig. 7.2c). A residual activity 
of 10%~15% is retained by the complex since the lipoyl domains of protein X 
are unaffected, and are also able to participate in the reaction. This cleavage 
also releases the kinase molecules from the complex.
As a consequence of being in solution rather than being attached to the 
complex, the kinase inactivates PDC 10-20 times more slowly. In this 
research, it was intended to compare free with bound kinase, quantifying how 
many phosphorylations took place throughout the inactivation curve of PDC 
while E l remained bound. In this way, we could discover whether the multiple 
phosphorylations were promoted by the kinase being localised to the complex, 
or whether this pattern was solely due to the attachment of the El component 
to core of PDC.
To discover how many phosphorylation events have taken place in each 
experiment, a recently developed approach was adopted, using the power of 
electrospray mass spectrometry (ESMS) to distinguish between the species. 
Electrospray mass spectrometry permits the accurate determination of the 
mass of large polypeptides, which could not be determined using a more
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Site of collagenase digestion
outer inner E l binding Catalytic inner domain
Lipoyl domains domain
Figure 7 .2 a  Domain diagram  of E2 and site of collagenase digestion
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I
A diagramatic representation of E2 is shown, highlighting the domain 
structure. The catalytic, core forming domain is C-terminal, the outer lipoyl 
domain is N-terminal. The site where collagenase cleaves the lipoyl domains
’r. ,from the E2 core is shown by the arrow head.
Chapter 7: Determining the Behaviour o f PDC Kinase hy Electrospray Mass Spectroscopy
B
67
43
3 0 -
- ^ 3
M 0 30 60 90 120 150 180 0 30 60 90 120 150 180 M
Incubation time (min)
Figure 7.2b SDS-PAGE analysis of collagenase digested PDC
SD S-PAG E (10% (v/v)), shows the digestion of PDC by collagenase 
over time (A) compared to untreated control PDC (B). The collagenase digests 
E2, yielding lighter E2l (E2 lipoyl domains) and E2i (Inner core and E3 
binding domains) polypeptide fragments. It can be seen that digestion is 
almost complete by 60 min. It is worth pointing out that the bands in the 
undigested ‘B ’ lanes showing up as E2p are degredation products. Whilst E 2 l  
is cross-reactive with E2 antisera  in im m unoblots, these bands in the 
undigested material do not show up on coomassie stained gels (data not 
shown).
M=Mr markers C = collagenase bands.
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Effect of collagenase digestion on PDC activity
125"
100'
75"
% PDC 
activity 50"
1500 50 100
□ Collagenase 
treated PDC
O Control PDC
Time (min)
Figure 7.2c G raph showing effect of collagenase on PDC activity
PDC was incubated with collagenase as described, and PDC assays taken 
at intervals to reveal the loss of activity due to the loss of lipoyl domains. 
After full digestion, approx. 15% activity remains.
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conventional mass spectrometer. In brief, the ESMS generates small, ionised 
droplets of solute carrying the polypeptides. The solvent surrounding each 
polypeptide is rapidly dried off ( ‘desorption’), leaving the molecule in the gas 
phase, in a charged state. The ionised peptide then enters the mass 
spectrometer, where the mass to charge ratio of the molecule is measured (Fig. 
7.3). The measurement data generated are finally processed by computer to 
determine the mass of the polypeptide (for a review, see Mann and Wilm, 
1995). This technique is sensitive and precise enough to detect the small 
percentage change in mass that a single phosphorylation can produce in a large 
polypeptide and distinguish between multiple phosphorylated forms of 
subunits in a mixed sample (Nairn et a i,  1995).
In addition to this area of research, it was also hoped to confirm the 
results of Yeaman et aL (1978) and Korotchkina et al. (1995), demonstrating 
negative cooperativity between subunits using ESMS. If only 1 
phosphorylation was required per tetramer, then ESMS would reveal an equal 
number of phosphorylated and unphosphorylated E la  subunits in PDC which 
was completely inactivated.
7.2 Devising a protocol for ESMS analysis of PDC-El
Since PDC preparations were found to contain too many species on 
which to conduct ESMS analysis directly, a protocol had to be found to obtain 
purer E l preparations which would allow such analysis.
7.2.1 ESMS directly on PDC E1/E3 fraction
It was first decided to isolate the E1/E3 fraction of PDC, using a high 
salt treatment followed by purification of the separated enzymes using FPLC 
gel filtration, as described in the methods section (2.6.3). Absorbance readings
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Counter-current
Glass capillary
Sam ple
solution
High
Mass
spectrometer
# -1-^ +
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Vacuum
interface
Figure 7.3 The 3 steps in eiectrospray mass spectrometry
Diagram taken from Mann and Wilm, (1995). Firstly, the solution is 
passed through a needle which is kept at a high voltage. The solution is then 
dispersed from the glass capillary into a mist of highly charged droplets. The 
droplets are then dried using a hot counter-current of hot N] gas, which 
releases the protonated protein molecules into the gas phase. The change from 
a liquid to gas phase leaves the protein intact, with at least one solvation shell. 
The droplets then enter a vacuum in the mass spectrometer, and are separated 
and detected according to their mass/charge ratio.
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measured at 280 nm were used to identify those fractions containing E2 with 
protein X and El with E3 (Fig. 7.4). SDS-PAGE revealed which polypeptides 
were in each fraction (Fig. 7.5). During the salt treatment it was noted that a 
small amount of protein precipitated. From 7 mg PDC, approx. 2.5 mg of 
E1/E3 was obtained in a total volume of 13 ml (70% recovery of E1/E3 from 
the column).
The isolated E1/E3 fraction was injected directly into the ESMS to 
discover if further purification would be necessary, or whether the ESMS 
would be able to detect the various species in the mixture. Using 
recommended amounts of protein (approx. 100 p.g, enough to guarantee 
injecting 20 pg E la )  in 50%(v/v) acetonitrile, 0.1%(v/v) TEA, the sample was 
injected into the ESMS at 0.02 ml min'P It was discovered that a large number 
of species were present in the sample, and it was felt that the data could not be 
trusted to give accurate mass data for any polypeptides present within the 
sample. It is not known if the sample was contaminated heavily or if the El 
and E3 components had been precipitated and lost, reducing their 
concentrations to the level of the contaminants.
From SDS-PAGE analysis, it was noted that some contaminants were 
present in the preparation. Based on the premise that contaminants had caused 
the difficulties, it was decided individual species would have to be isolated 
before injection into the ESMS.
'f
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Figure 7.4 Separation of E2/X and E1/E3 by FPLC
The absorbance trace, taken at 280 nm, of the eluate from the Superose 
column (as described in methods chapter 2.6.3).
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Figure 7.5 SDS-PAGE analysis of fractions obtained from FPLC
Fractions obtained from FPLC gel filtration of dissociated PDC were 
analysed by SDS-PAGE (10% acrylamide), and stained with Coomassie blue.
1 ) Mr markers
2) Native PDC
3) E2/protein X pooled fractions.
4) E1/E3 pooled fractions.
The gel shows that the E1/E3 is free of contamination with E2 or X 
Only Sp-22 (an anti-oxidant protein), associated with PDC, contaminates the 
fraction.
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7.2.2 Isolation of E la  by HPLC
229
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Since it was apparent that E la  would have to be isolated from other 
components, it was decided to use ESMS analysis on polypeptide fractions as 
they were eluted from a reverse phase HPLC column; a technique suggested 
by Dr. Tino Krell. For this method approx. 200 p,g of E1/E3 would be 
required.
HPLC was assessed for its ability to separate the various polypeptides. 
After dissociating PDC as described above, the E1/E3 fraction was dialysed 
into HPLC grade dH2 Ü by ultrafiltration from buffer into dH20. Washing the 
sample 3 times with HPLC grade dH20 was considered sufficient to remove 
all traces of salt. During the cycles of washing and concentrating the E1/E3 
fraction, precipitation of the polypeptides was noticed.
An HPLC column was pre-equilibrated with buffer A (98:2 
dH20:acetonitrile, 0.1% (v/v) TEA), washed with 100% buffer B (10:90 
dH20:acetonitrile, 0.1% (v/v) TEA), and re-equilibrated in buffer A. The 
E1/E3 (200 |ig in 500|ig of dH20) was injected onto the column, and buffer 
(flowing through the column at 0.4 ml iniin^) was changed from 100% A to 
100% B over the period of 1 h. The absorbance of the eluate (at 215 nm) was 
measured over time to detect the elution of the various polypeptides (Eig. 7.6). 
The resolution between the absorbance peaks was deemed sufficient for 
isolation of each unknown species prior to ESMS analysis.
I
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Figure 7.6 Separation of E la , E l(5 and E3 by HPLC
The absorbance measurements read at 215 nm of the eluate coming from 
the reverse phase HPLC column. Peaks of absorbance were numbered 1-3, and 
later identified by ESMS, comparing the obtained data with mass data for 
human PDC equivalents. The identity of each peak is discussed in section 
7.2.3
„v’
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7.2.3 Analysis of E la , E l(3 and E3 by ESMS
Since the isolation of each protein species (and therefore E la )  from 
purified E1/E3 was apparently possible, the ability to resolve the various 
phosphorylated forms of PDC by ESMS was checked before proceeding with 
the collagenase experiments.
This presented an early opportunity to answer the latter question, 
whether or not 1 phosphorylation per tetramer was sufficient for complete 
inactivation of PDC, since phosphorylated PDC was required for this 
procedure anyway.
Phosphorylation of PDC was carried out; this was performed at a higher 
PDC concentration than normal for purification of sufficient E1/E3, to 
compensate for losses expected during their dissociation/purification and 
concentration, and because only a small volume could be injected onto the 
FPLC column. PDC at 14 mg/ml was diluted 1:1 with kinase buffer. ATP (0.4 
mM) was added to the PDC and the inactivation monitored over time using 
PDC assays, with 1 ml aliquots (7 mg) removed at various points during the 
inactivation (Fig. 7.7). Treatment was stopped in each aliquot by the addition 
of 5 mM EDTA; samples were then stored at -2QoC. Each aliquot of treated 
PDC (including an untreated negative control) was dissociated and the E1/E3 
fraction isolated by FPLC, as described. It was noted that slight precipitation 
of the protein occurred during salt dénaturation in each of the aliquots. Once 
the E1/E3 fractions from each aliquot had been isolated, they were washed and 
concentrated into 100 \x\ HPLC grade dH20, as previously. This procedure too 
caused precipitation of the polypeptides. The yeild of the E1/E3 isolated from 
each aliquot (as determined by BCA assay) was between 78 qg (time=0 
control PDC) to 190 qg (half inactivated PDC). As mentioned, 200 p.g was the 
recommended amount for HPLC/ESMS. This meant that 94-98% (for time=0
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Figure 7.7 Effect of ATP on PDC activity
PDC was treated as described, and PDC assays carried out to monitor 
loss of activity with time. At 4 points on the graph (indicated by the arrow 
heads) an aliquot of PDC was removed and the treatment halted by chelating 
Mg2+ with EDTA. The aliquot was then frozen for later analysis.
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and half inactivated PDC, respectively) of El and E3 had precipitated from the 
original 7 mg PDC, or was otherwise lost from the start of the PDC 
dissociation until the final isolation of the two components.
HPLC was performed on each of the samples as previously. The HPLC 
was connected to the ESMS, allowing the eluate from the HPLC to be injected 
directly into the ESMS for real-time analysis of the polypeptides eluted from 
the column. Unfortunately it was found that the flow rate used to elute the 
polypeptides from the HPLC was too high for the ESMS. With high flow 
rates, the ESMS is unable to dry off all the solvent before it enters the mass 
spectrometer. The result was that the mass spectrometer could not detect any 
polypeptides above the background noise generated by the solvent.
It was decided to separate the remaining samples on the HPLC as before, 
collecting peak fractions to be injected later into the ESMS at a lower flow 
rate. Fractions (100 pi) containing the peak concentrations of separated 
polypeptides were injected into the ESMS at 0.02 ml min" ^ , in contrast to the 
previous rate of 0.3 ml min i-
Such were the losses at each stage of protein purification that most 
fractions collected produced no ESMS data. However, the ATP treated PDC 
which was removed at the half point on the inactivation curve (Fig. 7.7) was in 
sufficient quantity for data to be collected. The data were processed by f
subtracting background noise and smoothing the graphed data, using the 
MassLynx software. The software could then be used to calculate approximate 
mass values for the ions detected (by manually detecting components after 
peak centering), before using the Maximum Entropy deconvolution procedure 
(stopped after 8 iterations) to obtain more accurate data on the same ions. The 
data obtained are shown in Fig. 7.8. From this data, identification of the ^
polypeptides could be made, based on the known masses for the human PDC >
components.
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Figure 7.8 Graphs generated by the Maximum Entropy programme
The data for the 3 fractions isolated in Fig. 7.8 were processed by the 
Maximum Entropy programme. The 3 graphs generated show the presence of 
ions with masses of:
Peak 1) 40348.5 and 40428 units, corresponding to E l a  and singly 
phosphorylated E la
Peak 2) 35822 and 50213.5 units, corresponding to E l(3 and E3 
peak 3) 35809 units, corresponding to E l (3
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By comparison with Fig 7.6 it can be seen that E la  elutes in peak (1), E3 
in peak (2), E ip  in peak (3). E ip  is also found in peak (2), possibly due to the 
presence of two allelic forms of E ip  which each elute in different peaks. 
Alternatively, the difference between the 2 E lps found could be caused by an 
event such as deamidation. The masses for bovine E la ,  E ip  and E3 are 
therefore E la  = 40348.5 and 40428.0 ; E ip  = 35809 and 35822.5 ; E3 = 
50213.5 mass units. These compare favourably with masses calculated from 
cloned human genes (E la  = 40183, E ip  -  35863 and E3 = 50216). In the 
peak (1) fraction, a peak at 40428 represents the singly phosphorylated E la  
(40348.5 + 79.5 units, the mass of phosphate being 78 units). The viability of 
the technique is therefore demonstrated, but no further conclusions can be 
drawn from the experiment since the E la  of interest, from the fully 
inactivated PDC, was not in sufficient quantity for mass spectrometery.
7.3 Using less PDC to avoid precipitation
It was clear that precipitation was caused by using PDC at such high 
concentrations. An attempt was made to carry out the purification at lower 
concentrations (3 mg/ml). Fractions (1.2 mg) were separated as before, using 
24 ml bed volume Superose 12 column (1x30 cm) instead, to minimise losses 
on the column. Fractions of E1/E3 were collected, washed in dH20 and 
concentrated as before. At this point a BCA assay was used to measure the 
amount of protein present. It was found that only 50 |Lig of protein was 
isolated, which was not enough to continue. Whilst using less protein was 
more efficient in terms of %yield, it did not yield enough protein on a single 
run; to make enough E1/E3 for HPLC using this method, 6 FPLC purifications 
would be performed for each time point on the inactivation curve.
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7.4 Optimising purification protocol for analysis of treated 
PDC
It was decided to continue adapting earlier procedures (section 7.2) for 
the analysis of collagenase treated PDC, and its response to ATP. Further 
research was designed to continue optimising yields of purified E1/E3 with the 
buffering system required for the collagenase treatment.
7.4.1 Optimising the buffering system
The procedure was initially carried out using the collagenase Tris buffer 
and the kinase phosphate buffer as described in methods. PDC was split into 4 
parts, to be treated with either ATP, collagenase, collagenase and then ATP, 
and an untreated control. All PDC was first diluted with 2 vol collagenase 
buffer (to 8 mg/ml), and incubated in the presence or absence of collagenase.
Following this, all PDC was diluted with 2 vol kinase buffer. However, 
some precipitation occurred upon addition of the buffer, and addition of ATP 
also caused a large amount of precipitation.
The protein remaining in solution was dissociated and purified by FPLC. 
After dialysing the E1/E3 fractions into HPLC grade dH20, only 100 p,g 
protein, on average, was obtained. This was below the recommended amount 
of protein required for HPLC/ESMS. The E1/E3 samples were processed by 
HPLC/ESMS to ensure the recommended limits were correct. No results were 
obtained, confirming the need for approx. 200 pg of EÎ/E3 fraction for this 
experiment.
Since the precipitation of PDC during the kinase treatment was thought 
to be due to Ca^+ in the collagenase buffer reacting with phosphate in the 
kinase buffer, protocols to eliminate the phosphate were devised.
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The previous experiment was repeated with an imidazole buffer (20 mM 
imidazole, pH 7.5, 2 mM M gC^, 2 mM DTT), in place of a kinase buffer, to 
avoid precipitation of the protein as before.
Upon addition of the buffer there was less precipitation of PDC. 
However, upon addition of ATP, the protein again precipitated. It was thought 
that this was due to the ATP complexing with the calcium, so a protocol to 
eliminate the calcium was devised.
To prevent calcium complexing with ATP when performing the kinase 
experiment, EOT A was added after the collagenase treatment. This would 
afford the collagenase the required calcium, but remove it subsequently. The 
previous experiment, with the modified kinase buffer, was repeated using a 5 
molar excess of EGTA to chelate all the calcium after collagenase treatment. 
This did not prevent precipitation of the protein, and the experiment was 
halted.
7.5 Discussion
It is already known that E l does not respond well to concentration when 
separated from the rest of the complex, probably due to its high 
hydrophobicity. It is expected, therefore, that after FPLC dissociation, 
precipitation of E l during successive concentration steps should occur to some 
extent. The degree of precipitation however was not expected; at least 50% of 
the polypeptides appear to have been lost at this stage. Slight precipitation of 
PDC when treated with ATP and the incompatibility of kinase treatment of 
PDC with the collagenase buffer system was also unexpected.
Previous experiments in this area (Anderson, 1995) had not noted any 
great difficulty with precipitation of ATP. This is certainly due to the 
differences between previous protocols with ones used here; previous
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investigators have used larger volumes of buffer to dilute the PDC, and 
dilution of the collagenase buffer 10 fold appears to avoid such precipitation, 
as does dilution of PDC with kinase buffers.
To repeat these experiments successfully, the 3 stages at which material 
is lost must be modified to minimise losses. Protein is lost through 
precipitation during the collagenase/kinase treatment, through gel filtration 
purification of the E1/E3 fraction, and through concentration of the E1/E3 into 
a small volume of dH20 ready for HPLC purification of E la . It is obviously 
the third stage which causes the greatest losses.
If the precipitation during this final stage is due to the hydrophobic 
nature of the polypeptides, this could be avoided by trypsin digesting the 
polypeptides. The smaller fragments should stay in solution during 
concentration, which would have to be performed by dialysis instead of 
ultrafiltration. However, there would be a very large number of fragments 
generated by this method. Whilst HPLC - ESMS has been used to show 
phosphorylation of polypeptides from their tryptic digest fragments (Krell, 
1997), the large number of fragments generated by digesting 3 different 
polypeptides may be too many to resolve. If this experiment was possible it 
would have the advantage of relaying information about which sites were 
phosphorylated, and the ratio of phosphorylated to unphosphorylated serine at 
each site.
The data found here gives accurate mass determinations for bovine E la  
E ip  and E3, which have not yet been cloned and sequenced. The viability of 
the technique for discovering the behaviour of the PDC kinase was evaluated, 
and improvements discussed.
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8.1 Role of extended presequences
Long presequences are common to all the E2 components of the 2- 
oxoacid dehydrogenase complexes, and protein X of mammalian PDC. Where 
standard mitochondrial matrix targeting signals are approx. 15-30 amino acids 
long in human, these presequences are between 61 and 73 amino acids in 
length. In mitochondrial polypeptides which have such presequences, 
additional information is usually included, such as those polypeptides targeted 
for the inner membrane, or the 66 amino acid presequence of the 81 amino 
acid ATPase subunit 6, required to hold this hydrophobic polypeptide in 
solution.
An additional feature of all 2-oxoacid dehydrogenase complex E2 
components is the ability to self assemble into large symmetrical multimeric 
stmctures, as demonstrated recently for the PDC-E2/X subcomplex where full 
activity could be regained from separated denatured components (Sanderson et 
al, 1996). It is this capacity to assemble spontaneously which may be 
regulated outside the mitochondrion by the extended presequences. This 
hypothesis is supported by research demonstrating that OGDC-E2 with a 
presequence cannot be recognised by antibodies raised against the mature 
form, and further studies carried out in this laboratory with BCDC-E2, where 
expressed BCDC-E2 in E. coli could only assemble when no presequence was 
present. Current research into protein folding has demonstrated this theme in 
other systems, where parts of a polypeptide may prevent or control the folding 
of other parts of the peptide. Such sequences within polypeptides are described >:
as Tntra-molecular chaperones’.
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8.2 Summary of research
In order to investigate the roles of the presequence, a plasmid was 
designed to aid research into this sequence, and presequences in general. The 
majority of presequence mutagenesis studies are performed using vectors 
where presequence DNA has been inserted in-frame and upstream of the 
reporter gene. Such methods lead to the expression of the promotor region 
within the construct, compromising the validity of the subsequent results. A 
vector was designed to eliminate this problem. The gene for CAT was utilised, 
based on the common usage of CAT as a reporter protein and the great 
similiarity of CAT with the core domain of PDC-E2. To advance targeting 
studies from the in-vitro work originally employed by Hurt et al. ( 1984) and to 
further improve the in-vivo methods used by workers such as Thomas et al.
(1994), it was decided to alter the CAT plasmid to allow insertion of DNA 
fragments into the CAT gene, behind the first codon of the coding sequence.
However, mutagenesis of the CAT plasmid was hampered by unusual PCR 
conditions and loss of low molecular weight PCR products during purification.
These complications were incurred due to the choice of restriction sites at 
which the replacement DNA was to be ligated, and by the decision to mutate 
all 8 bases simultaneously. This degree of mismatch lowered the annealing 
temperature considerably more than estimated. Despite these temporary 
difficulties, the plasmid was finally altered to provide the desired restriction 
sites, and the encoded CAT was demonstrated in chapter 5 to behave in 
precisely the same manner as the CAT expressed by the original plasmid.
Following creation of the plasmid, a number of attempts to amplify the 
DNA coding for the presequence of PDC-E2 were carried out. PCRs were 
performed on both a A.gtlO human foetal cDNA library and human genomic 
DNA. Difficulties were encountered in all cases. Reasons for this were
• a
dicussed in chapter 4, including the possiblity that the genomic DNA sequence
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8.3 Summary of findings
for PDC-E2 contained an intron near the end of the presequence. Other 
methods could be used in future endeavours to isolate the entire presequence, 
including new techniques such as 5’ RACE.
In place of a full clone of the entire presequence, segments of the 
presequence were selected for inital research within this work, which were 
made synthetically. The choice of segments was based on analysis of the 
presequence using variety of computer methods. From this close scrutiny of 
the amino acid sequence, the N and C terminals of the presequence were 
selected for further analysis by expression in pSoUP. These sections were 
synthesised as single stranded precursors, then made double stranded by a 
methodology based on a single PCR cycle. Each DNA fragment was then 
cloned into the new plasmid vector, ready for transfection into COS-7 cells. It 7
was fortunate that at this point a co-worker in the lab. Dr Loic Briand, 
managed to produce a full length PDC-E2 presequence. This too was 
incoi-porated into the vector pSoUP.
Finally, the presequence segments integrated into pSoUP were expressed 
in COS-7 cells to test the ability of the presequences to halt folding and intiate 
targeting of CAT to the mitochondrion.
Ï
Surprisingly, the N-terminal sequence could not target CAT to the 
mitochondrion, but allowed CAT to fold in the cytosol uninhibited; one could 
compare this in vivo experiment with a similar in vitro experiment where a 
reduced presequence was able to target a non-mitochondrial enzyme to the 
mitochondrion (Hurt et al, 1985).
The full presequence in pSoUP, made by L. Briand, was also unable to 
target CAT in vivo, or prevent folding in the cytosol. Although CAT activity |
was low, it did correspond to the level of expression of CAT as seen by gel
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analysis, indicating that the low activity was not due to any antifolding. It is 
not surprising that import of CAT was not detected since CAT had already 
folded in the cytosol in both cases. These results are in contrast to other 
experiments carried out by L. Briand, where the antifolding activity of the 
BCDC-E2 presequence was revealed; expression of mature BCDC in E. coli 
produces folded, active cores, but incorporation of segments of the BCDC-E2 
N-terminal presequence as short as 17 amino acids were able to prevent this 
folding.
These findings suggest that either the presequence is incorrect, unable to 
prevent folding, or, more likely, that CAT, as a prokaryotic cytosolic enzyme, 
does not form a good model for mammalian mitochondrial PDC-E2. It perhaps 
also illustrates the difference between in vitro and in vivo experiments, where 
inside the cell, under normal circumstances, the mitochondrion appears to be 
more discerning. In vitro targeting experiments often require the organelles to 
operate with a high concentration of precursors to mitochondria, favouring 
import. In vivo experiments are often carried out in yeast and there is not 
always direct correlation between mitochondrial behaviour in yeast and 
mammalian cells; hence the need to perform mitochondrial targeting studies in 
higher eukaryotes to complete the picture.
It is worth noting that not only was CAT not translocated into the 
mitochondrion by the N-terminal section of the presequence, but it also 
remained soluble within the cytoplasm. If the N-terminal and the full length 
presequences were simply incapable of keeping CAT unfolded, then it could 
still be targeted to the mitochondrion. In this event, CAT would be trapped, 
held to the mitochondrion in a translocation-incompetent state by the partially 
translocated N-terminal sequence, and would not appear in the cytosolic 
fraction. Instead, CAT activity would be present in the membrane pellet in all 
digitonin fractionations. Of interest, however, are the findings of Leiper and 
Danpure (1997, also reviewed in Danpure, 1997) where a polypeptide was
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targeted to the mitochondrion when monomeric, and not targeted when the 
polypeptide dimerized. It was noted that this polypeptide dimerized faster than 
it could be commited to mitochondrial import. It is possible that a similar
I
R
:È:
event takes place with CAT; trimérisation (as indicated by the presence of 
CAT activity) could also prevent both targeting and uptake.
In summary, the experiments show that this PDC-E2 presequence is 
insufficient alone for targeting CAT to the mitochondrion. It is possible some 
property is held by the rest of PDC-E2 which also aids mitochondrial uptake.
8.4 Further work
Further work to elucidate the role of the presequence will be based 
around an extension of the experiments of Dr L. Briand with BCDC-E2 
expression in E. coli, using instead PDC-E2. An alternative method to
■■
determine the behaviour of the presequence would be the use of ‘epitope 
tagging’. If a full length cDNA for PDC-E2 were available, the mature part of 
E2 could be labelled with an epitope from a non-eukaryotic source. The result 
should be a more accurate representation of what takes place in vivo, yet 
retaining the capacity to follow the targeting of the polypeptide by detecting 
the epitope tag.
To further investigate the suitability of the plasmid, a number of 
characterised presequences should be used to target CAT in vivo. One of these 
should be the BCDC-E2 presequence, already characterised in E. coli as 
described. It may be possible that CAT requires the lipoyl didomain to 
accurately simulate any E2 component. Since the lipoyl domains are the next 
to be synthesised from the ribosome after the presequence, it would make 
sense if the intra-molecular chaperone activity of the presequence acted upon 
this section of the polypeptide. Further work on the interaction of the 
presequence with the lipoyl domains of E2 is currently being undertaken
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within the laboratory. A more lateral approach would be to substitute the CAT 
gene with the DNA sequence for mature PDC-E2. The presence of PDC-E2 in 
the cytosol would demonstrate the inability of this presequence to target to the 
mitochondrion. Proof of targeting could only be demonstrated by epitope 
tagging, as described above.
8.5 Experiments with PDC Kinase
I '
The ability of PDC kinase to phosphorylate three sites on El was also 
investigated. Initially, a method for isolation and analysis of El samples was 
devised and tested prior to its application to phosphorylated E l. Once this 
method had been tested, it was applied to PDC treated with ATP. Although 
other workers in this area had not noted any problems caused by precipitation 
of PDC during or after phosphorylation, the differences between the new 
method and previous ones were sufficiently large to compromise the 
experiments. Additional loss of material at a number of other points usually 
rendered mass spectroscopy of the final sample worthless. Fortunately, 
however, some data was acquired which gave accurate mass determinations :
for bovine PDC-Ela, PDC- E ip  and PDC-E3, which have not yet been cloned 
or sequenced.
Despite the apparent unsuitability of these procedures to analyse the 
behaviour of the kinase, the ability of the technique to differentiate between 
phosphorylated and non-phosphorylated forms of E l a  was demonstrated.
Alternative methods for treatment and purification of El could be devised; 
some of these possiblities were discussed in chapter 7. For example, if a dilute 
sample of PDC could be processed on an affinity column instead of a 
chromatography column, it may be possible to purify and analyse E l, as in 
this thesis, but without repeated concentration and washing steps, or without 
the high starting concentration for PDC during the kinase/collagenase
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treatment.
8.6 Discussion of Research
In each results chapter the research has been described and alternative 
approaches discussed. We can now look at the work as a whole and other 
ways in which the research could have been carried out, using methods that 
are now available.
Initially, a plasmid (pSoUP) was designed for general presequence 
analysis, the construction of which took more time than was suitable for this 
portion of the experiment. On reflection, a more general vector could have 
been used, such as a P-galactosidase or luciferase vector with a cloning site 
near, but not necessarily at, the start of the gene. This would have increased 
the amount of time available to carry out the other parts of the research. A new 
reporter gene coding for a fluorescent polypeptide called ‘Green fluorescent 
pro tien’ (GFP) is becoming popular, and in addition to being a highly effective 
reporter, the use of GFP with immunfluorescence microscopy could replace 
digitonin fractionation as a means of discovering the position of the targeted 
polypeptide. Furthermore, the folding of GFP could be monitored more 
accurately than CAT, by the use of laser scanning confocal microscopy and 
associated software to pinpoint location and quantitate the folding of the 
polypeptide from a non-fluorescent species to a folded one.
Isolation of the PDC-E2 presequence proved difficult; other 
presequences could have been tested, such as the E2 presequences of BCDC 
and OGDC. PCR of the OGDC-E2 presequence based on published data was 
also attempted, but failed. Only recently has a previously published full length 
clone of the BCDC-E2 gene been made available to this laboratory, and 
presequence experiments upon it are currently being undertaken. A positive 
control presequence could also have been utilised. A plasmid containing one
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such sequence was expected, but like the BCDC-E2 gene, this was available 
only in the later stages of this research.
As mentioned previously, it could be that regions of the polypeptide after 
the presequence are needed for targeting, such as the lipoyl didomain. It is 
known that the presequence interacts with the mature part of the polypeptide 
to prevent folding. It is possible therefore that without this interaction the 
polypeptide cannot be transported, if, like BSCl, the presequence must fold 
into a hairpin loop before translocation. Experiments to show this could use 
either epitope tagged full length PDC-E2, or pSoUP modified with the DNA 
coding for the presequence-lipoyl didomain in the cloning site.
It may be more interesting now to investigate the presequence of Protein 
X, which has been postulated to be the dominant autoantigen in PBC. The 
obvious experiment to conclude the various studies discussed here would be 
the transfection of PBC epithelial cells with GFP constructs containing the 
various presequences discussed. This would demonstrate which presequence, 
if any, mistargets polypeptides to the plasma membrane during PBC.
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